Decoding Endometrial Transcriptome Dynamics: From Menstrual Cycle to Clinical Applications in Reproductive Health

Abstract

This comprehensive review explores the dynamic transcriptional landscape of the human endometrium throughout the menstrual cycle, integrating cutting-edge single-cell and spatial transcriptomic technologies. We examine the precise molecular reprogramming that governs endometrial receptivity, stromal decidualization, and epithelial remodeling during the critical window of implantation. The article details methodological advances from bulk RNA-seq to spatial transcriptomics and their application in diagnosing endometrial disorders like recurrent implantation failure and polycystic ovary syndrome. Through validation studies and comparative analyses, we establish clinical correlations between transcriptomic signatures and reproductive outcomes, providing researchers and drug development professionals with a framework for developing novel diagnostic tools and targeted therapies for endometrial-factor infertility.

Mapping the Molecular Landscape: Endometrial Transcriptome Remodeling Across the Menstrual Cycle

The endometrium, the inner lining of the uterus, undergoes remarkable cyclical changes in response to ovarian steroid hormones estrogen and progesterone to support embryo implantation and pregnancy. These dynamic transformations are governed by complex signaling networks that precisely regulate gene expression patterns throughout the menstrual cycle. Understanding the molecular mechanisms by which estrogen and progesterone coordinate endometrial receptivity provides crucial insights into reproductive success and the pathogenesis of various gynecological disorders. Within the context of broader research on endometrial transcriptome dynamics, this review synthesizes current knowledge of hormone signaling pathways, their interconnected networks, and the sophisticated experimental approaches used to decipher them. For researchers and drug development professionals, this comprehensive analysis aims to bridge fundamental receptor mechanisms with translational applications in reproductive medicine.

Estrogen and Progesterone Receptor Signaling Mechanisms

Estrogen Receptor Signaling Pathways

Estrogen exerts its biological effects primarily through two nuclear receptors, estrogen receptor α (ERα) and ERβ, which belong to the nuclear receptor superfamily. Both receptors consist of five domains: the N-terminal A/B domain containing activation function-1 (AF-1), the central C domain or DNA-binding domain (DBD), the D domain or hinge region, and the C-terminal E domain or ligand-binding domain (LBD) which contains activation function-2 (AF-2) [1]. A sixth F domain is present at the extreme C-terminus, with a more clearly defined function in ERα than ERβ. Despite structural similarities, ERα and ERβ exhibit distinct transcriptional activities, with ERβ demonstrating lower affinity for estrogen response elements (EREs) and reduced transcriptional capacity in E2-induced ERE-dependent genomic signaling, partly due to the absence of a functional AF-1 in its N-terminus [1].

Estrogen signaling occurs through multiple mechanisms:

• Classical Genomic Pathway: Ligand-bound ER dimers bind directly to EREs in promoter regions of target genes, recruiting co-activators and chromatin remodeling factors to initiate transcription [1].

• Non-Classical Pathway: ER regulates genes lacking canonical EREs by interacting with other transcription factors such as AP-1, SP-1, and NF-κB [1].

• Ligand-Independent Genomic Events: Growth factor signaling activates ER through phosphorylation of specific serine residues (Ser118/Ser167) [1].

• Non-Genomic Signaling: Membrane-associated ERs, particularly G protein-coupled estrogen receptor (GPER), rapidly activate intracellular signaling cascades including MAPK, PI3K/AKT, and calcium mobilization within seconds to minutes [1].

Table 1: Estrogen Receptor Isoforms and Their Characteristics

Receptor Isoform	Gene	Primary Localization	Major Functions in Endometrium	Key Domain Differences
ERα	ESR1	Nuclear, cytoplasmic, membrane	Epithelial proliferation, PR synthesis, stromal regulation	Functional AF-1, longer N-terminal domain
ERβ	ESR2	Nuclear, cytoplasmic	Modulates ERα activity, anti-proliferative effects	Limited AF-1 activity, shorter N-terminal domain
GPER	GPER1	Plasma membrane, endoplasmic reticulum	Rapid signaling, MAPK/PI3K activation, calcium mobilization	7-transmembrane structure, unrelated to nuclear ERs

Progesterone Receptor Signaling Pathways

Progesterone signaling is primarily mediated by its cognate receptor, the progesterone receptor (PGR), which exists as two main isoforms: PR-A and PR-B. These isoforms are transcribed from alternate promoters within the same gene, with PR-A lacking 164 amino acids at the N-terminus compared to PR-B [2]. The stoichiometry of these isoforms is critical for proper progesterone responsiveness, as demonstrated by studies showing that overexpression of PR-A leads to endometrial hyperproliferation and infertility [2].

Progesterone receptor signaling occurs through:

• Genomic Actions: Ligand-bound PGR translocates to the nucleus and binds to progesterone response elements (PREs) in target gene promoters, regulating transcriptional programs essential for endometrial differentiation [2] [3].

• Non-Genomic Actions: PGR rapidly activates kinase signaling pathways including ERK/MAPK and AKT through interaction with c-Src kinase, important for peri-implantation stromal proliferation [2].

The expression of PGR is dynamically regulated throughout the menstrual cycle. In humans, PGR peaks in the luminal and glandular epithelium during the late proliferative and early secretory phases, then sharply decreases during the mid-secretory phase to allow for embryo implantation [3]. Similarly, stromal PGR expression shows temporal dynamics critical for establishing uterine receptivity.

Diagram Title: Estrogen and Progesterone Receptor Signaling Pathways

Transcriptional Networks and Epithelial-Stromal Crosstalk

Progesterone-Regulated Gene Networks

Progesterone signaling initiates elaborate transcriptional cascades that mediate epithelial-stromal crosstalk essential for endometrial receptivity. Key PGR target genes and their functions include:

Indian Hedgehog (IHH): One of the primary PGR targets in the epithelium, IHH acts as a paracrine signaling molecule to the stroma [2]. Uterine ablation of IHH in mice results in phenotypes similar to PGR knockouts, demonstrating its critical role [2].

COUP-TFII: Induced by IHH signaling in the stroma, this transcription factor inhibits estrogen-induced epithelial proliferation and enables implantation by inducing bone morphogenetic protein 2 (BMP2) [2].

HAND2: A stromal-expressed PGR target that mediates progesterone's anti-proliferative effects on the epithelium by inhibiting fibroblast growth factor (FGF) signaling and its downstream ERK/MAPK and AKT pathways [2].

BMP2 and WNT4: Critical for decidualization, BMP2 is induced by COUP-TFII and subsequently activates WNT4, which functions through β-catenin signaling [2].

FOXO1: A transcription factor that exhibits extensive cross-talk with PGR, with over 75% overlap in genome binding occupancy during human endometrial stromal cell decidualization [2]. FOXO1 regulates Wnt signaling and insulin-like growth factor binding protein 1 (IGFBP1) [2].

Table 2: Key Progesterone-Regulated Genes in Endometrial Signaling

Gene Symbol	Full Name	Expression Pattern	Function in Endometrium	Regulatory Mechanism
IHH	Indian Hedgehog	Epithelial, PGR-induced	Paracrine stromal signaling, initiates implantation cascade	Direct PGR target
COUP-TFII	Chicken Ovalbumin Upstream Promoter-Transcription Factor II	Stromal, IHH-induced	Inhibits estrogen signaling, induces BMP2	IHH signaling activation
HAND2	Heart and Neural Crest Derivatives Expressed 2	Stromal, PGR-induced	Suppresses FGF signaling, anti-proliferative epithelial effects	Direct PGR target
BMP2	Bone Morphogenetic Protein 2	Stromal, COUP-TFII-induced	Decidualization initiation, WNT4 activation	COUP-TFII regulation
WNT4	Wnt Family Member 4	Stromal, BMP2-induced	Decidualization, β-catenin signaling	BMP2 induction
FOXO1	Forkhead Box O1	Stromal, epithelial	Transcriptional cross-talk with PGR, regulates epithelial integrity	Extensive PGR co-occupancy

Estrogen-Regulated Gene Networks

Estrogen signaling through ERα promotes epithelial proliferation during the proliferative phase and induces progesterone receptor synthesis to prepare the endometrium for the secretory phase [1]. The transcriptional networks activated by estrogen include:

Leukemia Inhibitory Factor (LIF): Induced by the nidatory estrogen surge during the implantation window, LIF alters cellular junctions between luminal epithelial cells to permit embryo invasion [3].

Integrins: Estrogen and progesterone coordinately regulate adhesion molecules like integrin αvβ3 in epithelial cells, which function as receptors for extracellular matrix molecules and facilitate embryo attachment [4].

E-Cadherin: Participates in initial adhesion and attachment of the blastocyst during implantation, expressed in both trophoblast and endometrium [4].

The balanced interaction between estrogen and progesterone signaling is crucial for endometrial homeostasis. Estrogen induces PR expression, while progesterone subsequently inhibits ESR1 expression, creating a fine-tuned feedback system [2]. Disruption of this balance leads to pathological conditions including progesterone resistance and estrogen dominance, as seen in endometriosis [2].

Diagram Title: Progesterone-Mediated Epithelial-Stromal Crosstalk

Methodological Approaches for Studying Endometrial Hormone Signaling

Single-Cell and Spatial Transcriptomics

Advanced genomic technologies have revolutionized our understanding of endometrial hormone signaling by enabling high-resolution characterization of cellular heterogeneity and spatial organization:

Single-Cell RNA Sequencing (scRNA-seq): This approach has identified rare cell populations and specific cellular responses to hormonal stimulation. A recent scRNA-seq study of 59,770 endometrial cells revealed 13 distinct clusters and identified perivascular CD9+SUSD2+ cells as putative progenitor stem cells with roles in endometrial regeneration [5]. Analysis of these datasets involves several key steps:

• Cell Filtering and Quality Control: Exclusion of cells with fewer than 1,000 detected genes and less than 10,000 transcripts using Seurat R package (version 5.0.1) [5].

• Normalization and Variable Feature Selection: Data normalization using the "LogNormalize" method with a scale factor of 10,000, followed by identification of highly variable genes (3,800-4,800 features) for principal component analysis [5].

• Clustering and Differential Expression: Cell clustering using shared nearest neighbor graph construction with resolution parameter 0.7, followed by differential expression analysis using the "FindAllMarkers" function [5].

• Trajectory Analysis: RNA velocity analysis using the scVelo package to visualize cellular state transitions and differentiation pathways [5].

Spatial Transcriptomics (ST): The 10x Visium platform has been applied to map gene expression within tissue architecture, identifying seven distinct cellular niches in human endometrium with specific characteristics [6]. Key methodology includes:

• Tissue Preparation: Fresh frozen endometrial tissues sectioned and placed on 6.5×6.5mm capture areas containing ~5,000 barcoded spots [6].

• Library Preparation and Sequencing: Tissue permeabilization to release mRNA, reverse transcription to cDNA, library construction, and sequencing on Illumina NovaSeq 6000 with PE150 configuration [6].

• Data Processing: Alignment using Space Ranger pipeline (version 2.0.0) with human reference genome GRCh38-2020-A, quality control filtering excluding spots with <500 genes or >20% mitochondrial genes [6].

• Integration with scRNA-seq Data: Cellular deconvolution using CARD package to estimate cell type proportions for each spot based on reference single-cell data [6].

Splicing Quantitative Trait Loci (sQTL) Analysis

Recent research has revealed the importance of transcript isoform-level regulation in endometrial hormone response. A large-scale transcriptomic study of 206 endometrial samples identified menstrual cycle phase-dependent alternative splicing events not detectable through gene-level analyses [7]. The experimental workflow includes:

• RNA Sequencing and Isoform Quantification: Total RNA sequencing with transcript-level quantification to identify isoform usage variations.

• sQTL Mapping: Integration with genotype data to identify genetic variants that regulate splicing patterns, detecting 3,296 sQTLs with the majority (67.5%) not discovered in gene-level eQTL analysis [7].

• GWAS Integration: Colocalization of sQTLs with endometriosis genome-wide association study signals identified GREB1 and WASHC3 as genes associated with endometriosis risk through genetically regulated splicing events [7].

Protein-Protein Interaction Mapping

Identification of hormone receptor interactomes has revealed novel regulatory mechanisms:

Rapid Immunoprecipitation Mass Spectrometry of Endogenous Proteins (RIME): This approach identified TRIM28 as a protein complexing with both ERα and PR in uterine cells [8]. Methodology includes:

• Cross-linking and Chromatin Preparation: Formaldehyde cross-linking of chromatin-bound proteins followed by cell lysis and chromatin shearing.

• Immunoprecipitation: Antibody-based pulldown of target protein complexes.

• Mass Spectrometry Analysis: Protein identification and quantification to determine high-confidence interaction partners.

Functional validation through siRNA-mediated knockdown demonstrated that TRIM28 deficiency impairs decidualization and alters PR and ERα chromatin binding, establishing its essential role in uterine function [8].

Research Reagent Solutions Toolkit

Table 3: Essential Research Reagents for Endometrial Hormone Signaling Studies

Reagent Category	Specific Examples	Research Application	Key Features/Considerations
Antibodies for Immunohistochemistry	ERα (Clone 4f11), PR-B (Clone 16+SAN27) [4]	Protein localization and quantification in endometrial tissue	Validate specificity in knockout controls; optimize for formalin-fixed paraffin-embedded tissue
Single-Cell RNA-seq Platforms	10x Genomics Chromium, Seurat R package (v5.0.1) [5]	Cellular heterogeneity analysis, rare cell population identification	Quality control critical: exclude cells with <1,000 genes or >20% mitochondrial genes
Spatial Transcriptomics Kits	10x Visium Spatial Tissue Optimization Slide [6]	Spatial mapping of gene expression in tissue context	Requires RNA Integrity Number (RIN) >7; optimal tissue permeabilization time essential
Cell Culture Models	Primary Human Endometrial Stromal Cells (HESCs) [8]	Decidualization studies, hormone response assays	Confirm responsiveness to estrogen/progesterone; use early passages (P3-P5)
Gene Silencing Tools	siRNA against TRIM28, PGR [8]	Functional validation of candidate genes	Include multiple siRNA sequences; confirm knockdown efficiency by Western blot
Animal Models	PgrCre mouse line [8], Cell-specific knockout models [2]	In vivo functional studies, implantation analysis	Consider temporal and cell-type specific deletion to avoid developmental compensation
Bioinformatics Tools	scVelo (RNA velocity) [5], CARD (deconvolution) [6], GeneMANIA [4]	Data analysis, network mapping, integration	Use appropriate statistical thresholds; validate predictions experimentally

Dysregulation in Endometrial Pathologies

Hormonal signaling disruptions underlie several common endometrial disorders:

Endometriosis: Characterized by progesterone resistance and estrogen dominance, with altered expression of PGR isoforms and downstream targets [2]. Endometriosis-specific splicing differences are most pronounced in the mid-secretory phase, with genetic regulation of splicing identified in over 2,000 endometrial genes [7].

Thin Endometrium (TE): scRNA-seq analyses reveal TE-associated shifts in cell function, including increased fibrosis and attenuated cell cycle progression in perivascular CD9+SUSD2+ progenitor cells [5]. Cell-cell communication networks show aberrant collagen deposition around perivascular cells, indicating disrupted endometrial repair mechanisms [5].

Repeated Implantation Failure (RIF): Spatial transcriptomics of RIF endometrium identified altered cellular niches and dysregulated gene expression patterns during the window of implantation [6]. Integration with public scRNA-seq data revealed dominant epithelial components with specific marker expression changes [6].

Therapeutic Implications: Understanding these molecular mechanisms enables development of targeted treatments. Selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and GPER-selective compounds (G-1 agonist, G-15 antagonist) show promise for precisely modulating estrogen signaling [1]. Similarly, targeting PR isoform balance or downstream effectors like HAND2 may overcome progesterone resistance in endometriosis [2].

Concluding Perspectives and Future Directions

The intricate signaling networks through which estrogen and progesterone regulate endometrial gene expression represent a paradigm of physiological hormonal coordination. Recent technological advances, particularly single-cell and spatial genomics, have revealed unprecedented resolution of the cellular heterogeneity and molecular dynamics underlying endometrial receptivity. The integration of multi-omics data—from transcriptome and cistrome analyses to splicing quantitative trait loci mapping—provides a comprehensive framework for understanding both normal endometrial function and pathological states.

Future research directions should focus on several key areas: (1) defining the three-dimensional chromatin architecture changes during hormone stimulation; (2) elucidating the role of non-coding RNAs in fine-tuning hormone receptor activity; (3) developing more sophisticated in vitro models including organoid-stromal co-culture systems that better recapitulate tissue-level signaling; and (4) advancing personalized therapeutic approaches based on individual endometrial molecular profiling. For drug development professionals, targeting specific nodes within these hormonal signaling networks—such as TRIM28-mediated regulation of PR and ERα chromatin binding or specific splicing variants associated with disease risk—represents promising avenues for innovative treatments for endometrial disorders and infertility.

As these technologies and mechanistic insights continue to evolve, they will undoubtedly transform our approach to diagnosing and treating endometrial conditions, ultimately improving reproductive outcomes and women's health.

The human endometrium undergoes extensive remodeling throughout the menstrual cycle, driven by coordinated changes in its cellular composition and transcriptional states. This in-depth technical guide synthesizes findings from single-cell RNA sequencing (scRNA-seq) studies to present a comprehensive atlas of endometrial cellular heterogeneity. We detail the distinct epithelial, stromal, and immune cell populations that constitute the endometrium and characterize their transcriptomic dynamics across the menstrual cycle phases. The document provides detailed methodologies for reproducing key experiments, standardized tables of quantitative data for cross-comparison, and visualizations of critical signaling pathways and cellular relationships. This resource aims to equip researchers with the technical framework for investigating endometrial biology in both physiological and pathological contexts, ultimately supporting advancements in reproductive medicine and drug development.

The endometrium represents a uniquely dynamic tissue system that undergoes cyclic phases of proliferation, differentiation, shedding, and regeneration under the influence of ovarian sex steroids [9]. This remarkable regenerative capacity and transcriptional plasticity make it an ideal model for studying tissue homeostasis and cell state transitions. Single-cell transcriptomic technologies have revolutionized our understanding of this system by enabling the deconvolution of its cellular heterogeneity at unprecedented resolution [10] [9]. The application of scRNA-seq to endometrial tissue has revealed previously uncharacterized cell types and states, including a distinct ciliated epithelial population and subtle transitional states within the stromal compartment [10].

Understanding the coordinated interactions between the diverse cellular components of the endometrium provides critical insights into the essential physiological process of embryo implantation, and further serves as a baseline for identifying pathological deviations in conditions such as endometriosis, endometrial cancer, and Asherman's syndrome [9]. This technical guide synthesizes the current single-cell atlas of the human endometrium, with particular emphasis on methodological standardization and quantitative data presentation to facilitate reproducibility and cross-study comparison.

Comprehensive Cellular Composition of the Endometrium

Single-cell transcriptomic profiling has systematically characterized the cellular hierarchy of the human endometrium across the natural menstrual cycle. The following tables summarize the quantitative and qualitative features of the major cellular compartments.

Table 1: Major Cell Types in the Human Endometrium and Their Characteristics

Cell Type	Key Marker Genes	Proportion Range*	Primary Functional Role
Epithelial Cells	KRT8, KRT18, EPCAM	15-40%	Barrier formation, receptivity, glandular secretion
Stromal Fibroblasts	COL3A1, COL6A2, DCN	20-50%	Decidualization, tissue remodeling, structural support
Endothelial Cells	CDH5, VWF, ENG	5-15%	Vasculature formation, nutrient transport
T Cells	CD2, CD3D, CD3E	10-30%	Immune surveillance, cytokine signaling
B Cells	CD79A, CD79B, CD19	3-10%	Humoral immunity, antibody production
Myeloid Cells	CD14, CD68, LILRB4	5-25%	Phagocytosis, antigen presentation
Ciliated Cells	FOXJ1, CCDC78	1-5%	Fluid movement, particle clearance

Proportion ranges are approximate and vary significantly across menstrual cycle phases and individual samples [10] [11] [12].

Table 2: Endometrial Immune Cell Subpopulations and Their Features

Immune Subtype	Specific Markers	Tumor vs. Paratumor Enrichment	Functional State
CD8+ T Cells(exhausted)	PD-1, LAG3, TIM-3	Tumor-enriched [12]	Cytotoxic dysfunction
Macrophages	CD68, CD163, MRC1	Tumor-enriched [12]	M2-like polarization
Monocytes	CD14, FCGR3A	Paratumor-enriched [12]	Precursor population
Dendritic Cells	CD1C, CLEC9A	Paratumor-enriched [12]	Antigen presentation
Mast Cells	TPSAB1, CPA3	Variable	Inflammatory mediation

Quantitative Dynamics Across the Menstrual Cycle

Substantial redistribution of cellular proportions occurs across the menstrual cycle phases. Stromal fibroblasts demonstrate the most dramatic functional shift during the secretory phase, acquiring a decidualization phenotype characterized by specific transcriptomic signatures [10]. Immune cell populations, particularly uterine natural killer (uNK) cells and macrophages, increase significantly during the mid-secretory phase, coinciding with the window of implantation. Recent scRNA-seq data from 19 healthy fertile females across cycle days 4-27 has provided unprecedented resolution of these temporal dynamics, revealing abrupt and discontinuous transcriptomic activation in the epithelial compartment as the window of implantation opens [10] [11].

Experimental Methodologies and Workflows

Single-Cell RNA Sequencing Protocol

The generation of a high-quality single-cell atlas requires meticulous experimental execution from sample acquisition through computational analysis. The following workflow represents the standardized approach used in foundational endometrial studies:

Key Technical Considerations:

• Sample Acquisition: Endometrial biopsies should be obtained from well-characterized donors with documented cycle timing. Both C1 and 10x Chromium platforms have been successfully utilized, with anchor biopsies recommended for cross-platform comparison [11].

• Tissue Dissociation: Optimal enzymatic dissociation protocols must balance cell yield with preservation of transcriptomic integrity. Stromal fibroblasts and endothelial cells exhibit lower dissociation efficiency due to extracellular matrix embedding, potentially leading to under-representation [12].

• Quality Control: Rigorous quality filtering is essential using parameters such as unique molecular identifiers (UMIs), detected genes per cell, and mitochondrial percentage. The Seurat package provides standardized workflows for this purpose [12].

• Batch Correction: When integrating multiple datasets or samples, batch effect correction methods such as Harmony, Seurat's CCA, or scVI should be applied to minimize technical variation [13].

Computational Analysis Pipeline

The transformation of raw sequencing data into biological insights requires a multi-step computational approach:

Table 3: Key Computational Tools for scRNA-seq Analysis of Endometrium

Analysis Step	Recommended Tools	Critical Parameters
Quality Control	Seurat, Scanpy	Minimum genes/cell: 200-500Maximum mitochondrial %: 10-20%
Normalization	SCTransform, Scran	Method selected based onlibrary size characteristics
Dimensionality Reduction	PCA, UMAP, t-SNE	Dimensions: 10-30Resolution: 0.4-1.2
Batch Correction	Harmony, fastMNN, scVI	Integration features: 2000-3000appropriate for dataset size
Cluster Identification	Louvain, Leiden	Resolution parameter tuningbased on biological knowledge
Differential Expression	Wilcoxon rank-sum test, MAST	Minimum log fold-change: 0.25Adjusted p-value: < 0.05
Trajectory Inference	Monocle3, PAGA, Slingshot	Root node definitionbased on marker expression

Advanced visualization approaches have been developed specifically to address the challenges of single-cell data. Methods like Deep Visualization (DV) employ deep neural networks to create structure-preserving visualizations that can handle batch effects and maintain both local and global data geometry [13]. For dynamic processes like the menstrual cycle, hyperbolic embeddings (e.g., Poincaré maps) may better represent hierarchical developmental trajectories than traditional Euclidean approaches [13].

Transcriptomic Dynamics Across the Menstrual Cycle

Phase-Specific Cellular Transitions

The menstrual cycle encompasses profound transcriptomic reprogramming across all major endometrial cell types. scRNA-seq temporal mapping has revealed that the transition from proliferative to secretory phase involves coordinated gene expression changes in epithelial, stromal, and immune compartments [10].

Epithelial Compartment: The window of implantation opens with an abrupt and discontinuous transcriptomic activation in epithelial cells [10]. This is characterized by upregulation of receptivity markers (e.g., LIF, GPX3) and downregulation of cell adhesion inhibitors. A previously uncharacterized ciliated cell population shows distinct phase-specific gene expression patterns [10].

Stromal Compartment: Stromal fibroblasts undergo widespread decidualization during the secretory phase, characterized by increased expression of PRL, IGFBP1, and extracellular matrix remodeling factors. Pseudotime analysis reveals a continuous differentiation trajectory rather than discrete state transitions [10].

Immune Compartment: Immune cell populations demonstrate both proportional and transcriptional shifts across the cycle. uNK cells accumulate during the secretory phase and exhibit altered cytokine secretion profiles. Macrophages transition toward an immunomodulatory phenotype during the implantation window [9] [12].

Cell Type-Specific Marker Gene Expression

Table 4: Phase-Specific Marker Gene Expression Across Endometrial Cell Types

Cell Type	Proliferative Phase Markers	Secretory Phase Markers	Regulatory Transcription Factors
Epithelial Cells	MKI67, CCNB1, EGFR	LIF, GPX3, SPP1	PAX8, FOXA2, GATA6
Stromal Fibroblasts	VIM, COLLA1, TAGLN	PRL, IGFBP1, DIO2	FOXO1, CEBPB, HOXA10
Ciliated Cells	FOXJ1, CCDC78, DNAI1	PGRMC1, SPDEF	FOXJ1, RFX2, MCIDAS
Endothelial Cells	VWF, PECAM1, CD34	ENG, NOS3, EDN1	ERG, FLI1, SOX17
uNK Cells	XCL1, XCL2, GNLY	CD56, KLRB1, LILRB1	EOMES, TBX21, ZEB2
Macrophages	CD68, CD14, IL1B	CD163, MRC1, VSIG4	MAFB, MITF, IRF8

The Scientist's Toolkit: Essential Research Reagents and Materials

Reproducible investigation of endometrial cellular heterogeneity requires standardized reagents and platforms. The following table details essential solutions referenced in foundational studies:

Table 5: Key Research Reagent Solutions for Endometrial scRNA-seq Studies

Reagent/Category	Specific Examples	Function and Application Notes
Tissue Dissociation Kits	Human Tissue Dissociation Kits (Miltenyi)Collagenase IV/Hyaluronidase Mix	Generation of single-cell suspensionswith viability preservation
Cell Viability Assays	Trypan Blue ExclusionPropidium Iodide/Calcein-AM Staining	Assessment of cell integritypost-dissociation
Single-Cell Platforms	10x Genomics ChromiumFluidigm C1	Single-cell partitioningand barcoding
Library Prep Kits	10x Genomics Library KitSMART-Seq v4	cDNA amplification andlibrary construction
Sequencing Reagents	Illumina sequencing kits(NovaSeq, HiSeq)	High-throughput mRNAsequencing
Antibody Panels	CD45, CD31, EPCAM, CD90for cell sorting	Immune, endothelial, epithelial,and stromal cell isolation
Bioinformatics Tools	Seurat, Scanpy, Monocle3	Data processing, normalization,and cluster analysis
Batch Correction Tools	Harmony, scVI, fastMNN	Technical variation removalin multi-sample studies

Clinical and Therapeutic Implications

The single-cell atlas of endometrial cellular heterogeneity provides a foundational framework for understanding both physiological processes and pathological deviations. In endometrial carcinoma, scRNA-seq has revealed distinct epithelial cell identities including stem-like cells, secretory glandular cells, and ciliated cells, alongside profound alterations in the tumor immune microenvironment [12]. Exhausted CD8+ T cells and specific macrophage subpopulations are preferentially enriched in tumor tissues, presenting potential targets for immunotherapeutic strategies [12].

The characterization of cellular states across the menstrual cycle enables the identification of disrupted molecular signatures in conditions such as endometriosis and recurrent implantation failure. Furthermore, the comprehensive cataloging of cell type-specific markers facilitates the development of targeted therapeutic approaches with enhanced specificity and reduced off-target effects. Drug development professionals can leverage these datasets to identify cell type-specific pathway vulnerabilities and design more precise intervention strategies for endometrial disorders.

The single-cell atlas of the human endometrium represents a transformative resource for reproductive biology and medicine. By resolving cellular heterogeneity across the menstrual cycle at transcriptomic resolution, this framework enables a sophisticated understanding of endometrial function that was previously inaccessible. The methodological standards and quantitative references provided in this technical guide will support the research community in building upon these foundational findings.

Future directions in this field include the integration of multi-omic approaches (epigenomics, proteomics) to achieve deeper mechanistic insights, the application of spatial transcriptomics to preserve architectural context, and the establishment of comprehensive in vitro models that recapitulate endometrial cellular dynamics. As single-cell technologies continue to evolve, so too will our capacity to decipher the complex cellular conversations that underpin both endometrial health and disease, ultimately enabling more effective diagnostic and therapeutic strategies.

The acquisition of endometrial receptivity is a critical determinant of successful embryo implantation, a process governed by precise transcriptomic reprogramming during the limited window of implantation (WOI). Displacement of this window is responsible for approximately two-thirds of implantation failures, with aberrant molecular receptivity present in one of four patients experiencing recurrent implantation failure (RIF) [14]. This whitepaper synthesizes current research on endometrial transcriptome dynamics, highlighting the transition from a non-receptive to a receptive state through large-scale gene expression changes. Advances in RNA-sequencing (RNA-Seq) technologies have enabled the identification of specific biomarker panels, such as the 175-gene RNA-Seq-based Endometrial Receptivity Test (rsERT) and the 238-gene Endometrial Receptivity Array (ERA), which demonstrate high accuracy in predicting the WOI [14] [15]. Furthermore, emerging non-invasive approaches utilizing uterine fluid extracellular vesicles (UF-EVs) and innovative patient-derived models like endometrium-on-a-chip are refining our molecular understanding. This review details the key transcriptomic markers, their regulated biological pathways, and the experimental frameworks essential for investigating endometrial receptivity, providing a foundational resource for researchers and drug development professionals in reproductive medicine.

The human endometrium is a highly dynamic tissue that undergoes cyclic remodeling under the regulation of ovarian steroid hormones, estradiol (E2) and progesterone (P4) [16]. The window of implantation (WOI) is a transient period, typically occurring on days 19–24 of a regular menstrual cycle, during which the endometrium acquires a receptive phenotype capable of supporting blastocyst adhesion, attachment, and subsequent implantation [14] [17]. This transition involves major molecular and cellular changes, including the decidualization of stromal cells and the functional differentiation of epithelial cells [18]. The precise timing of the WOI varies among individuals, and its displacement—whether advanced, delayed, or pathologically disrupted—is a significant cause of recurrent implantation failure (RIF) in assisted reproductive technology (ART) [14].

The application of high-throughput transcriptomic technologies has revolutionized the study of endometrial receptivity, moving beyond classical histological dating (Noyes criteria) to a molecular definition of the WOI [14] [15]. Transcriptomic analyses across species have consistently revealed that the receptive endometrium possesses a vastly different gene expression profile compared to its pre-receptive or post-receptive states [19]. Studies utilizing RNA-Seq, which offers advantages in sensitivity, dynamic range, and whole-transcriptome coverage over microarrays, have identified critical genes and pathways involved in immune modulation, vascular remodeling, and cell-cell communication that are essential for receptivity [14] [19]. This molecular profiling provides not only deeper insights into the mechanisms of implantation but also the basis for developing diagnostic tools and targeted therapies for conditions of impaired receptivity such as RIF.

Key Transcriptomic Biomarkers and Functional Pathways

The transition to a receptive endometrial state is characterized by the differential expression of hundreds of genes that coordinate complex biological processes. Understanding these biomarkers and their functional networks is crucial for deciphering the mechanisms of receptivity.

Established and Emerging Biomarker Panels

Several biomarker signatures have been developed to classify the receptive endometrium. The established Endometrial Receptivity Array (ERA) is based on a 238-gene transcriptomic signature [18] [15]. More recently, an RNA-Seq-based Endometrial Receptivity Test (rsERT) was developed, comprising 175 biomarker genes, and demonstrated an average accuracy of 98.4% in predicting the WOI using tenfold cross-validation [14]. When this test was used to guide personalized embryo transfer (pET) in RIF patients, it significantly improved the intrauterine pregnancy rate from 23.7% to 50.0% in cycles transferring day-3 embryos [14].

Beyond tissue biopsies, transcriptomic analysis of extracellular vesicles from uterine fluid (UF-EVs) offers a non-invasive approach. One study identified 966 differentially expressed genes between women who achieved pregnancy and those who did not after a single euploid blastocyst transfer. A Bayesian model integrating these gene expression modules with clinical variables achieved a predictive accuracy of 0.83 for pregnancy outcome [20].

Table 1: Key Transcriptomic Biomarker Panels for Endometrial Receptivity

Biomarker Panel / Signature	Technology	Number of Genes	Reported Accuracy / Key Finding
rsERT [14]	RNA-Seq	175	Average accuracy of 98.4% (10-fold cross-validation)
ERA [18] [15]	Microarray	238	Clinical tool for personalized embryo transfer timing
UF-EV Signature [20]	RNA-Seq	966	Predictive model accuracy of 0.83 for pregnancy
Mouse Model Signature [19]	RNA-Seq	388 (312 protein-coding)	Defines receptive (D3.5 pc) vs. non-receptive (estrus) state

Critical Biological Pathways and Upstream Regulators

The differentially expressed genes converge on several key biological pathways that are hallmarks of the receptive endometrium.

• Immune and Vascular Remodeling: In mouse models, the pre-implantation endometrium shows significant enrichment for functional terms like Angiogenesis, Chemotaxis, and Lymphangiogenesis [19]. This involves the coordinated recruitment of immune cells such as uterine Natural Killer (uNK) cells, macrophages, and dendritic cells, which secrete factors like VEGF and matrix metalloproteinases (MMPs) to facilitate tissue remodeling and vascular changes [19].
• Stromal-Epithelial Crosstalk: The communication between stromal and epithelial cells is paramount. The HAND2-FGFs-FGFR axis is a critical pathway where stromal HAND2, induced by progesterone, suppresses the expression of fibroblast growth factors (FGFs) to inhibit epithelial proliferation [18]. Dysregulation of this pathway, for instance through Menin deficiency, impairs epithelial differentiation [18].
• WNT Signaling Regulation: The WNT signaling pathway must be tightly controlled for proper decidualization. Menin, a histone methyltransferase subunit, promotes the expression of WNT negative regulators like SFRP2 and DKK1 through H3K4me3 modification. Menin deficiency in RIF patients leads to aberrant activation of the WNT pathway, impairing decidualization and receptivity [18].
• Ion Channels and Transport: Gene set enrichment analysis of UF-EVs from receptive endometria highlights significant involvement of inorganic cation transmembrane transport and ATPase-coupled transmembrane transporter activity, suggesting a role for ion homeostasis in supporting the implantation environment [20].

Diagram 1: Key transcriptional pathways governing endometrial receptivity, highlighting stromal-epithelial crosstalk and Menin's role.

Experimental Models and Methodologies

Investigating the endometrial transcriptome requires robust experimental models and precise methodological protocols. The following section details established and emerging approaches.

Key Experimental Workflows

Endometrial Tissue Biopsy and RNA-Seq Analysis for rsERT

The development of the rsERT is a representative example of a rigorous transcriptomic profiling workflow [14].

• Patient Recruitment and Biopsy Collection: Recruit IVF patients with confirmed normal WOI timing (successful intrauterine pregnancy after first ET). Inclusion criteria: age 20-39, BMI 18-25, regular menstrual cycle, normal ovarian reserve, and tubal or male factor infertility only. Perform an endometrial biopsy using a pipelle during the mid-secretory phase (LH+7 in a natural cycle or P+5 in a hormone replacement therapy cycle).
• RNA Extraction and Sequencing: Homogenize the endometrial tissue. Extract total RNA using a commercial kit (e.g., Qiagen RNeasy Mini Kit) with DNase I treatment to remove genomic DNA. Assess RNA integrity (RIN > 8.0 recommended). Prepare RNA-Seq libraries (e.g., using Illumina TruSeq Stranded mRNA kit) and sequence on a platform such as Illumina NovaSeq to generate 150 bp paired-end reads.
• Bioinformatic Analysis and Model Building: Quality control of raw reads (FastQC), adapter trimming (Trimmomatic), and alignment to a reference genome (e.g., GRCh38 using STAR). Quantify gene-level counts (featureCounts). Identify differentially expressed genes (DEGs) between prereceptive, receptive, and postreceptive phases using packages like edgeR or DESeq2. Use a machine learning algorithm (e.g., support vector machine) on the DEG set (e.g., 175 genes) to build a classifier. Validate the model's accuracy via tenfold cross-validation [14].

Diagram 2: Workflow for developing an RNA-Seq-based endometrial receptivity test.

Non-Invasive Transcriptomic Profiling via Uterine Fluid Extracellular Vesicles (UF-EVs)

This protocol offers an alternative to invasive biopsies [20].

• UF-EV Collection and RNA-Seq: Collect uterine fluid during the WOI via a non-invasive catheter. Isolate EVs from the fluid by sequential centrifugation: first at low speed (e.g., 2,000 × g for 10 min) to remove cells and debris, followed by ultracentrifugation at 100,000 × g for 70 min to pellet EVs. Extract total RNA from the EV pellet. Construct RNA-Seq libraries, prioritizing small RNAs if needed, and sequence.
• Data Integration and Predictive Modeling: Identify differentially expressed genes between pregnant and non-pregnant groups. Perform Weighted Gene Co-expression Network Analysis (WGCNA) to cluster correlated genes into modules. Integrate the module eigengenes (representing the expression profile of each module) with key clinical variables (e.g., vesicle size, history of previous miscarriages) into a Bayesian logistic regression model to predict pregnancy outcome [20].

Advanced Research Models

• Endometrial Organoids: These 3D in vitro cultures closely replicate the cellular, transcriptomic, and functional characteristics of the native endometrial epithelium, including hormonal responses and secretory activity. They are valuable for studying receptivity mechanisms and epithelial-embryo interactions [16].
• Patient-derived Endometrium-on-a-Chip (EoC): This microfluidic model incorporates patient-derived epithelial organoids, stromal cells, and endothelial cells (HUVECs) in a 3D matrix to recapitulate the multi-layered and vascular features of the endometrium. It allows for real-time analysis of receptivity markers (e.g., integrin αvβ3, osteopontin) and angiogenic phenotypes, enabling the development of personalized receptivity scoring systems [17].

The Scientist's Toolkit: Essential Research Reagents and Materials

Table 2: Key Reagents and Materials for Endometrial Receptivity Research

Item	Specific Example / Type	Application in Research
Endometrial Biopsy Tool	Pipelle de Cornier	Minimally invasive collection of endometrial tissue for primary cell culture, RNA/DNA extraction, and histology [14].
RNA Stabilization Reagent	RNAlater	Preserves RNA integrity in tissue samples immediately after biopsy, preventing degradation prior to nucleic acid extraction [14].
Total RNA Extraction Kit	Qiagen RNeasy Mini Kit	Isolation of high-quality, DNA-free total RNA from tissue homogenates or cell lysates for downstream transcriptomic analysis [14].
RNA-Seq Library Prep Kit	Illumina TruSeq Stranded mRNA Kit	Preparation of cDNA libraries from purified mRNA for next-generation sequencing on Illumina platforms [14] [20].
Decidualization Induction Cocktail	Medroxyprogesterone Acetate (MPA) + cAMP	In vitro induction of decidualization in primary human endometrial stromal cells (hESCs) to model the stromal component of receptivity [18].
3D Cell Culture Matrix	Basement membrane extract (BME, e.g., Matrigel)	Support for the growth and differentiation of primary endometrial cells into organoids, maintaining physiological structure and function [16] [17].
Microfluidic Chip System	Endometrium-on-a-Chip (EoC) device	Recreation of the dynamic, multi-layered endometrial microenvironment for real-time, patient-specific study of receptivity and angiogenesis [17].

The comprehensive profiling of the endometrial transcriptome has fundamentally advanced our understanding of receptivity, moving from morphological descriptions to a detailed molecular definition of the WOI. The identification of specific biomarker genes and the critical pathways they regulate—including immune modulation, stromal-epithelial communication, and controlled WNT signaling—provides a solid foundation for both diagnostic and therapeutic innovation.

Future research directions will likely focus on the integration of multi-omics data (transcriptomics, proteomics, metabolomics) to build more holistic models of receptivity [15]. The application of single-cell and spatial RNA-sequencing will further resolve cellular heterogeneity and localized molecular interactions within the endometrium [16]. Artificially intelligent-driven analysis of these complex datasets is poised to enhance predictive accuracy and uncover novel regulatory networks [21]. Furthermore, the validation of non-invasive biomarkers from UF-EVs and the refinement of patient-specific in vitro models like the EoC hold immense promise for translating transcriptomic discoveries into personalized clinical interventions, ultimately improving pregnancy outcomes for individuals suffering from infertility and RIF.

The human endometrium is a uniquely dynamic mucosal tissue that undergoes approximately 400-500 cycles of proliferation, differentiation, shedding, and scarless regeneration throughout a woman's reproductive lifespan [22] [23]. This remarkable regenerative capacity, driven by rhythmic hormonal changes and resident stem cell populations, enables the endometrium to rapidly transform from a proliferative state to a secretory tissue capable of supporting embryo implantation, followed by menstrual shedding when implantation does not occur [24]. The endometrial cycle is traditionally divided into three main phases: the menstrual phase (days 1-4), characterized by tissue breakdown and shedding; the proliferative phase (days 5-14), marked by estrogen-driven regeneration; and the secretory phase (days 15-28), distinguished by progesterone-mediated differentiation [23]. Understanding the molecular mechanisms governing these transitions is crucial for elucidating the basis of endometrial disorders such as abnormal uterine bleeding, endometriosis, thin endometrium, and recurrent implantation failure [6] [5] [24]. This technical review examines the temporal dynamics of endometrial remodeling through the lens of recent transcriptomic, single-cell, and spatial profiling studies, providing researchers with a comprehensive framework of the molecular signatures and experimental approaches defining this field.

Cellular Hierarchy and Stem/Progenitor Cell Niches

The exceptional regenerative capacity of the endometrium is attributed to tissue-resident stem/progenitor cells located primarily in the basalis layer, which remains intact during menstruation and serves as the reservoir for regenerating the functionalis layer each cycle [22] [23]. Two major populations of endometrial stem/progenitor cells have been characterized: endometrial epithelial progenitors (eEPCs) and endometrial mesenchymal stem cells (eMSCs), each occupying distinct niches and exhibiting unique marker profiles.

Endometrial Epithelial Progenitors (eEPCs)

Endometrial epithelial progenitors are rare clonogenic cells comprising approximately 0.22% of the epithelial cell population [22]. These cells demonstrate key stem cell properties including self-renewal, high proliferative potential, and differentiation into gland-like structures in 3D cultures [22]. Multiple markers have been identified that enrich for epithelial progenitors, each with distinct spatial localization patterns suggesting a differentiation hierarchy along the glandular axis:

Table 1: Markers of Endometrial Epithelial Progenitor Cells

Marker	Localization	Function	Reference
N-cadherin (CDH2)	Bases of glands in basalis adjacent to myometrium	First specific surface marker enriching for clonogenic cells	[22]
SSEA-1 & nSOX9	Basalis epithelium and luminal epithelium	Co-expression suggests progenitor function; role in post-menstrual repair	[22]
AXIN2	Nuclear in basalis epithelial cells	Wnt pathway component; marks putative stem cells	[22] [23]
ALDH1A1	Co-localizes with 78% of N-cadherin+ cells	Aldehyde dehydrogenase isoform; role in retinoic acid signaling	[22]
LGR5	Identified in single-cell studies	Stemness marker in epithelial populations	[23]

This hierarchical organization spans from the base of epithelial glands in the basalis to the luminal epithelium, with cells expressing different marker combinations as they differentiate and migrate upward into the functionalis [22]. Notably, epithelial progenitor cells have been identified in menstrual fluid, indicating their shedding during menstruation, while populations persist in atrophic post-menopausal endometrium, demonstrating their hormone-independent persistence [22].

Endometrial Mesenchymal Stem Cells (eMSCs)

The stromal compartment contains perivascular mesenchymal stem cells identifiable by co-expression of PDGFRβ and CD146 or by SUSD2 alone [22]. These cells comprise approximately 1.5% of endometrial stromal cells and are enriched eightfold for colony-forming units compared to unsorted stromal cells [25]. Recent research has identified a subpopulation of perivascular CD9+ SUSD2+ cells that function as putative progenitor cells based on pseudotime trajectory analysis and enriched functions in ossification, stem cell development, and wound healing [5]. These eMSCs demonstrate typical MSC properties including differentiation into adipogenic, chondrogenic, myogenic, and osteogenic lineages, and fulfill International Society for Cellular Therapy (ISCT) criteria for MSC characterization [25].

Table 2: Markers of Endometrial Mesenchymal Stem Cells

Marker Profile	Localization	Frequency	Functional Characteristics
CD140b+CD146+	Perivascular in both basalis and functionalis	1.5% of stromal cells	8-fold enrichment for CFU-F; multipotent differentiation	[25]
SUSD2+	Perivascular niche	~1.3% of stromal cells	Clonogenic; self-renewal capacity	[22] [25]
CD9+SUSD2+	Perivascular	Subpopulation of SUSD2+ cells	Enhanced response during proliferative phase; progenitor functions	[5]

The coordinated activity of both epithelial and mesenchymal stem/progenitor populations enables the rapid tissue regeneration and remodeling that characterizes the endometrial cycle, with dysregulation of these populations implicated in various endometrial disorders [5] [23].

Phase-Specific Molecular Signatures

Advanced transcriptomic analyses have revealed intricate gene expression patterns across the menstrual cycle, with significant transitions occurring between the late proliferative and mid-secretory phases [26]. A recent proliferative phase-centered transcriptome analysis examining five time points (mid-proliferative, late proliferative, early secretory, mid-secretory, and late secretory) identified 5,082 differentially expressed genes (DEGs) across the cycle compared to the mid-proliferative reference point [26].

Proliferative Phase Dynamics

The proliferative phase, traditionally viewed simply as estrogen-driven growth, actually demonstrates complex transcriptomic programming that prepares the endometrium for potential implantation. The late proliferative phase serves as a critical transition point with 804 upregulated and 391 downregulated specific DEGs [26]. Key features include:

• Histone Gene Activation: Expression of histone-encoding genes within the HIST cluster on chromosome 6 shows increased activity during the late proliferative phase, supporting chromatin remodeling and preparation for rapid transcriptional changes [26].
• Early Upregulation of Secretory Markers: Genes including STEAP4, SCGB1D2, and PLA2G4F show significant expression increases as early as the late proliferative phase (log2FC of 4.3, 5, and 5.8 respectively), peaking during the mid-secretory phase [26].
• Cell Cycle Progression: Genes regulating cell proliferation and DNA replication are prominently upregulated during the proliferative phase, followed by coordinated downregulation as the tissue transitions to the secretory phase [26].

Secretory Phase Transition

The transition to the secretory phase initiates profound transcriptomic reprogramming directed by progesterone signaling, with the highest number of phase-specific DEGs observed in the mid-secretory phase (945 downregulated, 594 upregulated) [26]. Critical molecular events include:

• Window of Implantation Signatures: The mid-secretory phase demonstrates unique expression patterns associated with endometrial receptivity, including upregulation of genes involved in embryonic attachment, immunomodulation, and vascular remodeling [26].
• Chromatin Remodeling: Single-cell assays for transposase-accessible chromatin with sequencing (scATAC-seq) have identified temporal patterns of coordinated chromatin remodeling in epithelial and stromal cells, with uniquely accessible regions emerging during the secretory phase [27].
• Transposable Element Activation: The implantation window coincides with pervasive cooption of transposable elements into the regulatory chromatin landscape of decidualizing cells, with TE-derived transcripts expressed in a spatially defined manner [27].

Menstrual Preparation and Initiation

The late secretory phase, in the absence of implantation, is characterized by progesterone withdrawal that triggers inflammatory and apoptotic pathways culminating in menstruation [24] [23]. Key processes include:

• Inflammatory Cascade: Immune cell infiltration (particularly uterine NK cells, macrophages, and T cells) and upregulation of pro-inflammatory mediators [24] [23].
• Vasoconstriction and Hypoxia: Prostaglandin-mediated constriction of spiral arterioles creates tissue hypoxia, activating matrix metalloproteinases and apoptosis [24].
• Tissue Breakdown: Coordinated expression of matrix metalloproteinases (MMPs) and other proteolytic enzymes degrades the extracellular matrix, facilitating tissue shedding [24].

Figure 1: Transcriptomic Transitions Across the Menstrual Cycle. Key molecular events during phase transitions include histone gene activation during the late proliferative phase and transposable element cooption during the mid-secretory window of implantation [27] [26].

Experimental Models and Methodologies

Single-Cell and Spatial Transcriptomic Profiling

Recent advances in single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics have revolutionized our understanding of endometrial remodeling by resolving cellular heterogeneity and spatial organization [6] [5] [28]. Standardized protocols have emerged for these applications:

Single-Cell RNA Sequencing Workflow:

• Tissue Processing: Fresh endometrial biopsies are dissociated into single-cell suspensions using enzymatic digestion (collagenase/hyaluronidase) and mechanical disruption [5].
• Cell Quality Control: Cells are filtered to exclude those with <500 detected genes or >20% mitochondrial gene content to remove low-quality cells [6] [5].
• Library Preparation: Using 10x Genomics Chromium system for droplet-based encapsulation and barcoding [6] [5].
• Bioinformatic Analysis: Seurat R package (v4.3.0+) for normalization, clustering, and differential expression analysis; harmony algorithm for batch effect correction [6] [5].

Spatial Transcriptomics Protocol:

• Tissue Preparation: Fresh frozen tissues sectioned at optimal thickness; RNA integrity number (RIN) >7 required to minimize degradation [6].
• Visium Spatial Technology: Tissues placed on 6.5×6.5mm capture areas with ~5,000 barcoded spots; H&E staining for histological reference [6].
• Data Processing: Space Ranger pipeline for alignment to reference genome (GRCh38); Seurat for spatial data analysis and integration with scRNA-seq datasets [6].
• Cellular Deconvolution: CARD package or similar tools to estimate cell type proportions within each spot using single-cell data as reference [6].

Organoid and 3D Culture Systems

3D organoid models have emerged as powerful tools for studying endometrial biology and disease, maintaining native tissue architecture and functionality [23]. Key methodologies include:

• Epithelial Organoid Derivation: Isolation of epithelial cells from endometrial biopsies followed by embedding in Matrigel with specialized media containing Wnt agonists, R-spondin, Noggin, and growth factors [23].
• Stromal-Epithelial Assembloids: Coculture systems combining epithelial organoids with primary stromal cells to model tissue-level interactions [23].
• Hormonal Response Modeling: Controlled administration of estradiol and progesterone to mimic cyclical changes and study phase-specific responses [23].

Figure 2: Experimental Workflow for Endometrial Transcriptomics. Integrated approaches combining single-cell and spatial technologies with 3D modeling enable comprehensive analysis of endometrial dynamics [6] [5] [23].

Research Reagent Solutions

Table 3: Essential Research Reagents for Endometrial Biology Studies

Reagent/Category	Specific Examples	Application	Key Considerations
Dissociation Enzymes	Collagenase, Hyaluronidase, Trypsin	Single-cell suspension preparation	Optimization required for tissue viability; avoid over-digestion	[6] [5]
Cell Culture Matrices	Matrigel, Cultrex BME	3D organoid culture	Lot-to-lot variability; concentration optimization critical	[23]
Stem Cell Media Supplements	R-spondin, Noggin, Wnt agonists	Epithelial organoid growth	Essential for stem cell maintenance and proliferation	[23]
Hormonal Treatments	17β-estradiol, Progesterone, MPA	Cycle phase modeling	Concentration and timing critical for physiological relevance	[23]
Antibodies for FACS	Anti-SUSD2, Anti-CD140b, Anti-CD146, Anti-CD9	Stem cell isolation	Validation required for endometrial tissue specificity	[5] [25]
Spatial Transcriptomics	10x Visium slides, Space Ranger software	Spatial gene expression analysis	RNA quality critical (RIN>7); optimization of permeabilization time	[6]
scRNA-seq Platforms	10x Chromium, Smart-seq2	Single-cell transcriptomics	Cell viability >80% recommended; target cell recovery 5,000-10,000 cells	[6] [5]
Bioinformatics Tools	Seurat (v4.3.0+), Harmony, scVelo	Data analysis and integration	Computational resources required for large datasets	[6] [5]

Clinical Implications and Therapeutic Applications

Dysregulation of the molecular mechanisms governing endometrial remodeling contributes to various reproductive disorders, with recent research identifying specific pathological signatures:

Endometriosis and Aberrant Stem Cell Function

Single-cell and spatial transcriptomic profiling of endometriotic lesions has revealed retained menstrual cycle gene expression patterns in ectopic endometrial stromal cells, with distinct ovarian stromal cell populations contributing to fibrosis and inflammation [28]. Key findings include:

• WNT5A Signaling: Upregulation and aberrant activation of non-canonical WNT signaling in endometrial stromal cells contributes to lesion establishment, offering novel therapeutic targets [28].
• Stem Cell Dysregulation: Stem/progenitor cells normally involved in physiological repair are hijacked in endometriosis, establishing pro-inflammatory and pro-fibrotic microenvironments that sustain lesions [23] [28].
• Immune Microenvironment: Altered immune cell populations including macrophages (particularly M2 subsets), T cells, and impaired NK cell activity contribute to disease persistence [23].

Thin Endometrium and Regenerative Failure

Thin endometrium (TE) characterized by inadequate endometrial growth (<7mm) presents significant clinical challenges for implantation. scRNA-seq analyses comparing TE with normal endometrium have identified:

• CD9+ SUSD2+ Cell Dysfunction: TE-associated shifts in perivascular CD9+ SUSD2+ cell function manifest as increased fibrosis and attenuated cell cycle progression and adipogenic differentiation [5].
• Aberrant Cell Communication: Disrupted crosstalk between cell types, particularly excessive collagen deposition around perivascular CD9+ SUSD2+ cells, indicates compromised endometrial repair capacity [5].
• Extracellular Matrix Remodeling Defects: Impaired response to endometrial repair in TE, particularly in extracellular matrix reorganization pathways [5].

Recurrent Implantation Failure (RIF)

Spatial transcriptomics of endometrial tissues from RIF patients has identified seven distinct cellular niches with specific characteristics, revealing:

• Epithelial Dominance: Uncilated epithelial cells are the dominant components in RIF endometrium, with altered spatial organization compared to controls [6].
• Dysregulated Immune Factors: Abnormal gene expression patterns related to immune response, immune infiltration, and immune cell type imbalances contribute to implantation failure [6].
• Novel Biomarkers: Spatial transcriptomics has identified potential biomarkers for RIF that could improve diagnosis and targeted interventions [6].

The integration of single-cell technologies, spatial transcriptomics, and advanced 3D modeling has revolutionized our understanding of endometrial temporal dynamics, revealing unprecedented resolution of the molecular programs driving cyclical remodeling. The proliferative phase, particularly the late proliferative transition, emerges as a critical period establishing the foundation for subsequent secretory transformation and receptivity establishment [26]. The identification of specific stem/progenitor cell hierarchies and their niche interactions provides mechanistic insights into both physiological regeneration and pathological states [22] [5] [23].

Future research directions should focus on:

• Advanced Multi-omics Integration: Combining transcriptomic, epigenomic, and proteomic datasets to build comprehensive regulatory networks.
• Microenvironment Mapping: Higher-resolution spatial profiling to delineate cell-cell communication networks and niche signaling.
• Patient-Derived Models: Development of personalized organoid systems for precision medicine applications in endometrial disorders.
• Non-Hormonal Therapeutics: Targeting identified pathway dysregulations (e.g., WNT5A signaling in endometriosis) for novel treatment strategies [28].

These approaches will continue to unravel the complexity of endometrial biology, providing new diagnostic and therapeutic avenues for the myriad disorders affecting this uniquely dynamic tissue.

The human endometrium is a highly dynamic mucosal tissue that undergoes approximately 400-500 cycles of regeneration, differentiation, and shedding throughout a woman's reproductive life [29]. The spatial organization of its epithelial compartments—the luminal epithelium (LE) and glandular epithelium (GE)—creates distinct functional niches that are essential for embryo implantation and pregnancy establishment [30] [31]. The LE forms the uterine cavity's surface and directly interacts with the implanting embryo, while the GE constitutes tubular glands that extend into the endometrial stroma, providing crucial secretions for embryonic development [32]. Emerging research demonstrates that these compartments exhibit profound differences in their transcriptomic profiles, signaling pathway activation, and response to ovarian hormones [33] [30] [31]. Within the context of endometrial transcriptome dynamics across the menstrual cycle, understanding this spatial architecture is fundamental to unraveling the mechanisms of endometrial receptivity, implantation failure, and related disorders.

Spatial Mapping of Endometrial Compartments: Techniques and Workflows

Advanced spatial transcriptomic technologies have revolutionized our ability to map gene expression patterns to their precise histological locations within the endometrium, moving beyond the limitations of bulk tissue analysis.

Laser Capture Microdissection (LCM) and RNA-seq

Laser Capture Microdissection enables the precise isolation of specific endometrial cell types from tissue sections for subsequent transcriptomic analysis.

Table 1: Key Steps in LCM and RNA-seq Workflow for Endometrial Compartments

Step	Procedure	Technical Specifications	Application in Endometrium
Tissue Preparation	Fresh-frozen endometrial tissue sections (e.g., 8-10 µm thickness)	OCT embedding, cryosectioning	Preservation of RNA integrity [33]
Staining	Rapid hematoxylin and eosin or immunofluorescence staining	Short protocols to minimize RNA degradation	Identification of LE, GE, stroma, blood vessels [33]
Microdissection	Isolation of LE, GE, and other compartments using laser	PALM or Arcturus systems; ~500-1000 cells per sample	Cell-type specific RNA collection [33]
RNA Extraction	Picopure RNA isolation or similar kits	Including DNase treatment; RNA integrity number (RIN) >7.5	Ensure quality for sequencing [33] [30]
Library Prep & Sequencing	Low-input RNA-seq protocols (e.g., Smart-seq2)	Illumina platforms; ~20 million reads per sample	Detection of ~11,000-12,000 genes per compartment [33]

Figure 1: Experimental workflow for laser capture microdissection and RNA sequencing of endometrial compartments.

Single-Cell and Spatial Transcriptomic Integration

Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) provide complementary approaches for resolving cellular heterogeneity and spatial organization.

Table 2: Spatial Transcriptomics Platforms for Endometrial Research

Technology	Resolution	Key Advantage	Representative Application
10x Visium	55 µm spots (1-10 cells)	Whole transcriptome coverage with morphological context	Mapping seven distinct cellular niches in normal and RIF endometrium [6]
Single-Cell RNA-seq	Single-cell	Reveals cellular heterogeneity and rare populations	Identified SOX9+ epithelial progenitors and distinct perivascular cells [5] [31]
Integration with scRNA-seq	Single-cell (inferred)	Deconvolutes spatial spots to estimate cell type proportions	CARD algorithm integration revealed epithelial dominance in RIF niches [6]

The integration of scRNA-seq with spatial data using computational tools like Cell2location and CARD has enabled the reconstruction of high-resolution spatial maps of the human endometrium, identifying specific locations for SOX9+ epithelial progenitors in both surface epithelium and basal glands [31] [6].

Molecular Signatures of Luminal and Glandular Epithelium

Comprehensive transcriptomic analyses reveal that LE and GE exhibit distinct gene expression profiles that underpin their specialized functions throughout the menstrual cycle.

Compartment-Specific Gene Expression Patterns

Differential expression analysis between pregnant and cyclic endometrium in porcine models demonstrated that the LE showed the highest number of differentially expressed genes (1410 DEGs), compared to 800 DEGs in GE [33]. In the proliferative phase, human endometrial mapping has identified SOX9+LGR5+ cells enriched in the surface epithelium, while SOX9+LGR5- cells localized to basal glands, suggesting compartment-specific progenitor populations [31].

Table 3: Distinct Molecular Signatures of Endometrial Epithelial Compartments

Feature	Luminal Epithelium (LE)	Glandular Epithelium (GE)
Marker Genes	LGR5, WNT7A, KRT17 [31]	SCGB2A2, PAEP, CXCL8 [31]
Key DEG Categories	Biosynthetic processes, ion transport, apoptotic processes [33]	Cell migration, growth, signaling, metabolic processes [33]
Cycle Dynamics	SOX9+ populations dominant in proliferative phase [31]	PAEP+ secretory cells dominant in secretory phase [31]
Mouse Model Findings	JAK-STAT, MAPK, PI3K-Akt pathways [30]	Retinol metabolism, sphingolipid metabolism, Notch signaling [30]
Adhesion Molecules	Integrins, SPP1 (Osteopontin) [33]	MUC1, glycoproteins [30]

Signaling Pathways Regulating Epithelial Compartmentalization

The divergence in LE and GE gene expression profiles is governed by activation of distinct signaling pathways that regulate their specialized functions.

Figure 2: Key signaling pathways differentially activated in luminal versus glandular epithelium.

In mouse models, LE predominantly regulates embryo attachment through activation of JAK-STAT, MAPK, and PI3K-Akt signaling pathways, whereas GE modulates retinol metabolism, sphingolipid metabolism, and Notch signaling to support embryonic development and maintain the uterine microenvironment [30]. In humans, WNT and NOTCH pathways play complementary roles in regulating differentiation toward secretory (GE) and ciliated (LE) lineages, with WNT downregulation increasing secretory differentiation and NOTCH downregulation promoting ciliated differentiation [31].

Functional Divergence in Reproductive Processes

The molecular signatures of LE and GE directly translate to their specialized roles in embryo implantation and endometrial regeneration.

Embryo-Maternal Interaction and Implantation

The LE serves as the primary interface for embryo attachment and invasion. In porcine models, LE demonstrates upregulation of adhesion molecules including integrin family members and osteopontin (SPP1), which facilitate trophectoderm adhesion through mechanical forces generated by elongating conceptuses [33]. In humans, the LE undergoes morphological transformation from tall columnar to cuboidal morphology and loses polarity during the receptive phase, enabling direct interaction with the trophoblast [30].

The GE functions as a "logistical hub" for embryonic nutrition and signaling. GE cells secrete leukemia inhibitory factor (LIF) and glycoproteins including MUC1, which regulate implantation and support embryonic nutrient supply [30]. These secretions are essential for maintaining endometrial receptivity and are dysregulated in conditions such as repeated implantation failure (RIF) [6].

Stem Cell Populations and Regenerative Niches

Both epithelial compartments harbor distinct stem/progenitor cells that drive cyclical regeneration. Putative epithelial stem cells marked by SSEA-1, AXIN2, and LGR5 are primarily located in the basal glands but also populate the surface epithelium [29]. Single-cell transcriptomics has identified SOX9+ epithelial populations with progenitor characteristics in both luminal and glandular microenvironments [31].

Perivascular CD9+SUSD2+ cells have been identified as putative mesenchymal stem cells that contribute to endometrial regeneration [5]. These cells exhibit enriched functions in ossification, stem cell development, and wound healing, with their dysfunction implicated in thin endometrium pathogenesis [5].

Research Toolkit: Methodologies and Reagent Solutions

Experimental Models for Studying Endometrial Compartments

Table 4: Research Models for Investigating Endometrial Compartmentalization

Model System	Key Application	Technical Considerations
Air-Liquid Interface (ALI) Culture	Separate cultivation of primary LE and GE cells [32]	Maintains differentiated state and polarization; requires filter supports
3D Endometrial Organoids	Modeling epithelial physiology and hormone response [31] [29]	Retains tissue morphology and function; suitable for drug screening
Delayed Implantation Mouse Model	Studying temporal dynamics of embryo implantation [30]	Allows precise activation of implantation with estradiol-17β injection
Spatial Transcriptomics (Visium)	Mapping gene expression in tissue architecture [6]	Requires fresh-frozen tissue with RIN >7; 55 µm resolution

Essential Research Reagents and Solutions

Table 5: Key Research Reagent Solutions for Endometrial Compartment Studies

Reagent/Category	Specific Examples	Function in Research
Cell Isolation Enzymes	Trypsin (0.2%), Collagenase (0.1%), Dispase II (0.06%) [30] [32]	Sequential digestion for separation of LE and GE cells
Cell Culture Media	Proliferation Medium (P), Differentiation Medium (SF/NU) [32]	Support growth and maintenance of compartment-specific phenotypes
Spatial Transcriptomics	10x Visium Spatial Tissue Optimization Slides [6]	Capture location-specific gene expression patterns
Key Antibodies for Validation	Calb1 (LE marker), Vimentin (stromal marker) [30]	Immunofluorescence validation of compartment identity
Hormonal Regulators	Estradiol-17β, Progesterone [30] [31]	Mimic menstrual cycle phases in experimental models

The spatial organization of endometrial niches into distinct luminal and glandular epithelial compartments is fundamental to endometrial function and reproductive success. The integration of single-cell and spatial transcriptomic technologies has revealed unprecedented resolution of the molecular signatures that define these compartments across the menstrual cycle. Future research directions should focus on:

• High-resolution spatial mapping of human endometrium across all menstrual cycle phases to establish a comprehensive reference atlas.
• Functional validation of identified signaling pathways using advanced in vitro models including ALI cultures and organoids.
• Investigation of compartment-specific dysregulation in endometrial disorders such as recurrent implantation failure, endometriosis, and thin endometrium.

Understanding the spatial organization of endometrial niches will continue to provide critical insights for developing targeted therapies for infertility and other reproductive disorders, ultimately improving outcomes in assisted reproduction and women's health.

Advanced Transcriptomic Technologies: From Single-Cell Resolution to Spatial Mapping in Endometrial Research

The human endometrium is a complex, dynamic tissue that undergoes cyclic regeneration throughout a woman's reproductive life. Understanding its cellular composition and molecular regulation is crucial for elucidating the mechanisms behind successful reproduction and the pathogenesis of various endometrial disorders. Traditional bulk transcriptomic approaches have provided valuable insights but obscure cell-to-cell variation by averaging gene expression across diverse cell types. Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative technology that enables the systematic characterization of cellular heterogeneity at unprecedented resolution. Within the broader context of endometrial transcriptome dynamics across the menstrual cycle, scRNA-seq provides a powerful lens through which to examine the intricate cellular relationships and state transitions that underlie both normal endometrial function and disease states. This technical guide explores how scRNA-seq is revolutionizing our understanding of endometrial cellular heterogeneity, from defining novel subpopulations to uncovering pathological mechanisms in conditions such as endometriosis, thin endometrium, and endometrial cancer.

Fundamental Principles of scRNA-seq in Endometrial Research

Single-cell RNA sequencing enables the profiling of gene expression in individual cells, revealing cellular heterogeneity, identifying rare cell populations, and reconstructing developmental trajectories. The typical workflow begins with the preparation of single-cell suspensions from endometrial tissue biopsies, followed by cell capture, reverse transcription, cDNA amplification, library preparation, and sequencing. The 10X Genomics Chromium system has been widely adopted in endometrial studies for its high-throughput capabilities [34] [35].

A critical advantage of scRNA-seq in endometrial research is its ability to resolve the complex cellular ecosystem of the endometrium, which includes epithelial, stromal, endothelial, immune, and perivascular cells, each with distinct functions and transcriptional programs. By capturing transcriptomes from thousands of individual cells, researchers can identify novel cell subtypes, characterize transitional cell states, and understand how different cell populations contribute to endometrial regeneration across the menstrual cycle and in pathological conditions.

Integration with Menstrual Cycle Dynamics

The endometrium undergoes profound structural and functional changes throughout the menstrual cycle in response to ovarian hormones. scRNA-seq studies have been strategically applied to different cycle phases to capture these dynamic transformations. Research has focused on the proliferative phase, when the endometrium regenerates after menstruation [34], the secretory phase when implantation occurs, and the window of receptivity when the endometrium is prepared for embryo attachment [26]. This phase-specific application of scRNA-seq has been instrumental in revealing how different cell types respond to hormonal cues and coordinate their functions to support endometrial transformation.

Key Experimental Protocols and Methodologies

Endometrial Tissue Processing and Single-Cell Isolation

The quality of scRNA-seq data heavily depends on the initial tissue processing and cell isolation procedures. For endometrial tissues, the following protocol has been widely employed [34] [36]:

• Tissue Collection and Storage: Endometrial biopsies are obtained using a Pipelle aspirator during specific menstrual cycle phases, confirmed by histological dating. Samples are immediately placed in MACS Tissue Storage Solution at 4°C until processing.

• Tissue Dissociation:

  • Wash tissue with phosphate-buffered saline (PBS) and mince into 2 mm³ pieces
  • Digest in filter-sterilized Dispase II solution (0.5 U/mL) in complete media (DMEM-F12 with 10% FCS) at 4°C overnight
  • Manually disaggregate tissue solution, wash with complete media, and centrifuge at 200× g for 5 minutes
  • Further digest with filter-sterilized Collagenase III (150 U/mL) and DNAse (139 U/mL) in complete media with agitation for 45 minutes at 37°C

• Cell Purification:

  • Wash dissociated cells and treat with Red Blood Cell Lysis Buffer for 5 minutes at room temperature
  • Stop reaction with complete media, wash cells, and centrifuge
  • Assess viability and count cells using an automated cell counter
  • Resuspend in PBS with bovine serum albumin (400 µg/mL) at 1000 cells/µL concentration

scRNA-seq Library Preparation and Sequencing

For library preparation and sequencing, the following methodology has been successfully applied to endometrial cells [34]:

• Single-Cell Capture and Barcoding: Load cell suspensions on a 10X Genomics Chromium Controller instrument for single-cell gel bead-in-emulsion (GEM) formation and barcoding using the Chromium Single Cell 3' Gel Beak Kit v2.

• cDNA Synthesis and Amplification: Perform GEM reverse transcription, followed by cDNA amplification via PCR.

• Library Construction: Prepare sequencing libraries according to manufacturer's instructions using the Chromium Single Cell 3' Library Kit v2.

• Sequencing: Sequence libraries on an Illumina platform (e.g., Illumina 2500) with a target of approximately 3,000 cells per sample and an average sequencing depth of 50,000 reads per cell.

Computational Analysis Pipeline

The computational analysis of endometrial scRNA-seq data typically involves the following steps [34] [5]:

• Data Processing: Process raw sequencing data using Cell Ranger 2.1.1, aligning reads to the reference genome (hg19) using STAR mapper and quantifying counts.

• Quality Control: Filter cells expressing 200-5,000 genes with less than 10% mitochondrial genes. Remove ribosomal genes and regress out cell cycle effects using sctransform.

• Integration and Clustering: Integrate multiple samples using canonical correlation analysis (CCA) in Seurat to remove batch effects. Perform dimensionality reduction via principal component analysis (PCA), followed by graph-based clustering (Louvain algorithm).

• Cell Type Identification: Annotate cell clusters using reference-based annotation tools (SingleR) with Human Primary Cell Atlas and Blueprint ENCODE references, combined with manual assessment using known marker genes.

• Differential Expression and Trajectory Analysis: Identify differentially expressed genes using Model-based Analysis of Single-Cell Transcriptomics (MAST) test. Reconstruct cell lineages and dynamics using RNA velocity (Velocyto) and pseudotime analysis (Monocle2).

Major Research Findings on Endometrial Cellular Heterogeneity

Stromal Cell Diversity and Perivascular Niches

scRNA-seq has revealed unprecedented heterogeneity within the endometrial stromal compartment, which was previously considered a relatively uniform population. Studies have identified ten distinct stromal cell subtypes and two pericyte subsets in the proliferative phase endometrium [34]. These stromal subpopulations appear to represent specific functional niches with specialized roles in regulating inflammation and extracellular matrix composition.

Perivascular cells have emerged as particularly important players in endometrial biology. Researchers have identified CD140b+CD146+ perivascular cells as putative endometrial mesenchymal stem/stromal cells (eMSCs) with regenerative potential [36]. More recently, a subpopulation of CD9+SUSD2+ perivascular cells has been characterized as putative progenitor cells based on pseudotime trajectory analysis and enriched functions in ossification, stem cell development, and wound healing [5]. These cells demonstrate a distinctive perivascular expression pattern that varies across menstrual cycle phases, suggesting regulated involvement in tissue regeneration.

Table 1: Key Stromal and Perivascular Cell Subpopulations Identified by scRNA-seq in Human Endometrium

Cell Population	Key Markers	Proposed Function	Menstrual Cycle Dynamics
Stromal subset 1	Not specified	ECM organization	Predominant in proliferative phase
Stromal subset 2	Not specified	Inflammatory regulation	Present across cycle
Perivascular pericytes	MCAM/CD146, PDGFRB, RGS5	Vascular support, progenitor niche	Maintained across cycle
CD140b+CD146+ eMSCs	PDGFRB, MCAM	Regenerative capacity	Culture alters characteristics
CD9+SUSD2+ progenitors	CD9, SUSD2	Progenitor function, wound healing	Higher in proliferative phase

Epithelial Cell Heterogeneity and Specialization

The endometrial epithelium consists of distinct subpopulations with specialized functions. scRNA-seq has confirmed the presence of two major epithelial lineages: ciliated epithelium (marked by EPCAM, CDHR4, and FOXJ1) and unciliated glandular epithelium (marked by EPCAM but lacking ciliated markers) [35]. Importantly, lineage tracing analyses have provided evidence that endometrioid endometrial cancer (EEC) originates specifically from unciliated glandular epithelium rather than ciliated epithelium or stromal components [35].

Research has also identified LCN2+/SAA1/2+ cells as a featured subpopulation in endometrial tumorigenesis, highlighting how scRNA-seq can reveal rare but biologically significant cell states that may drive pathological processes [35]. The proportional dynamics of epithelial cells change dramatically during endometrial carcinogenesis, with epithelial expansion being a hallmark of progression from normal endometrium to atypical endometrial hyperplasia and finally to endometrioid endometrial cancer.

Metabolic Reprogramming During Decidualization

scRNA-seq analyses have illuminated the metabolic transitions that occur during endometrial stromal cell decidualization—the process by which stromal fibroblasts differentiate into specialized decidual cells in preparation for pregnancy. Studies have revealed that the differentiation of stromal cells into decidual cells is accompanied by increased amino acid and sphingolipid metabolism [37]. Furthermore, there exists significant metabolic heterogeneity among decidual cells themselves, with subpopulations exhibiting different metabolic activities and cellular states [37].

This metabolic reprogramming appears to be conserved across species, with significant metabolic changes in amino acids and lipids observed during the transition from non-pregnancy to pregnancy states in pigs, cattle, and mice [37]. These findings highlight how scRNA-seq can capture not just cellular identities but also functional metabolic states that are critical for endometrial function.

Table 2: scRNA-seq Applications in Endometrial Pathologies

Pathological Condition	Key Cellular Alterations	Technical Approaches	References
Thin endometrium (TE)	Decreased CD9+SUSD2+ progenitors, increased fibrosis, attenuated cell cycle	scRNA-seq, CellChat, pseudotime	[5]
Endometrioid endometrial cancer	Epithelial expansion, LCN2+/SAA1/2+ subpopulation, altered TME	scRNA-seq, CNV inference, RNA velocity	[35]
Repeated implantation failure	Altered epithelial populations, disrupted cellular communication	Spatial transcriptomics, scRNA-seq integration	[6]
Decidualization defects	Metabolic heterogeneity, altered amino acid and sphingolipid metabolism	scRNA-seq, metabolic pathway analysis	[37]

Technical Considerations and Experimental Design

Integration with Spatial Transcriptomics

While scRNA-seq provides unparalleled resolution of cellular heterogeneity, it traditionally loses spatial context—a critical limitation for understanding tissue organization. Recent studies have addressed this by integrating scRNA-seq with spatial transcriptomics (ST), which preserves locational information [6]. For example, researchers have applied 10x Visium Spatial Transcriptome sequencing to endometrial tissues from patients with repeated implantation failure (RIF) and normal controls, identifying seven distinct cellular niches with specific characteristics [6].

The integration of these technologies enables more comprehensive tissue mapping, allowing researchers to not only identify cell types but also understand their spatial organization and neighborhood relationships. Computational methods like CARD (conditional autoregressive-based deconvolution) can be used to infer cell type proportions within each spatial spot based on scRNA-seq reference data [6].

Addressing Technical Variability and Batch Effects

Endometrial scRNA-seq studies face particular challenges related to biological and technical variability. Biological variability stems from differences in menstrual cycle timing, age, parity, and individual genetic backgrounds. Technical variability can arise from sample processing, cell viability, sequencing depth, and batch effects. Successful experimental design must account for these factors through:

• Careful participant selection and cycle phase confirmation
• Processing samples in parallel when possible
• Implementing batch correction algorithms (e.g., Harmony, CCA)
• Including sufficient biological replicates (typically n≥3 per group)
• Validating findings with orthogonal methods (e.g., immunofluorescence, flow cytometry)

Research Reagent Solutions for Endometrial scRNA-seq

Table 3: Essential Research Reagents for Endometrial scRNA-seq Studies

Reagent/Catalog	Application	Function	Example References
Collagenase III	Tissue dissociation	Enzymatic digestion of endometrial tissue	[34] [36]
Dispase II	Tissue dissociation	Epithelial cell separation	[34]
DNase I	Tissue dissociation	Reduce cell clumping	[36]
Ficoll-Paque	Cell purification	Density gradient separation	[36]
CD45 microbeads	Immune cell depletion	Negative selection of leukocytes	[36]
CD140b/CD146 antibodies	Perivascular cell isolation	Positive selection of eMSCs	[36]
10X Chromium Kit	Library preparation	Single-cell barcoding	[34] [35]
MACS Tissue Storage Solution	Sample preservation	Maintain cell viability post-biopsy	[34]

Signaling Pathways and Cellular Communication Networks

scRNA-seq data enables the reconstruction of cell-cell communication networks by analyzing ligand-receptor interactions. In endometrial studies, tools like CellChat, iTALK, and NicheNet have been applied to infer communication pathways between different cell types [5] [37]. For example, in thin endometrium, cell-cell communication analysis has revealed aberrant crosstalk among specific cell types, particularly highlighting dysregulated collagen deposition pathways around perivascular CD9+SUSD2+ cells [5].

In the context of early pregnancy, communication analysis between decidual cells and trophoblasts has identified important metabolic interactions mediated by specific ligands and receptors [37]. These analyses provide insights into how different endometrial cell populations coordinate their functions to support implantation and maintain pregnancy.

Visualization of scRNA-seq Workflow and Cellular Heterogeneity

scRNA-seq Workflow for Endometrial Tissue

Endometrial Cellular Hierarchy Revealed by scRNA-seq

Future Perspectives and Applications

The application of scRNA-seq in endometrial research continues to evolve, with several promising directions emerging. Multi-omic approaches that combine scRNA-seq with epigenomic, proteomic, and spatial technologies will provide more comprehensive views of endometrial regulation. Longitudinal studies tracking the same individuals across multiple cycle phases could reveal personal patterns of endometrial dynamics and how they relate to reproductive outcomes.

From a clinical perspective, scRNA-seq signatures hold potential for developing diagnostic classifiers for endometrial conditions like thin endometrium, recurrent implantation failure, and early endometrial cancer. The identification of specific cellular subpopulations driving pathology may reveal new therapeutic targets for conditions that currently lack effective treatments.

Furthermore, the integration of scRNA-seq data with genetic association studies could help unravel the cellular context of genetic risk factors for endometrial disorders, advancing our understanding of how genetic variants influence cellular function in a tissue-specific manner.

Single-cell RNA sequencing has fundamentally transformed our understanding of endometrial biology by resolving its cellular heterogeneity at unprecedented resolution. Through the applications and methodologies detailed in this technical guide, researchers can leverage scRNA-seq to uncover the complex cellular dynamics that underlie endometrial function across the menstrual cycle and in pathological states. As the technology continues to advance and integrate with complementary spatial and multi-omic approaches, it promises to further illuminate the intricate cellular conversations that enable endometrial regeneration, receptivity, and repair, ultimately advancing both basic reproductive science and clinical care for endometrial disorders.

Spatial transcriptomics (ST) is a transformative set of technologies that enables researchers to measure gene expression directly within tissue sections, preserving the precise spatial location of each measurement. Unlike conventional RNA sequencing methods that analyze homogenized samples, ST maintains the native architecture of the tissue, allowing the study of cellular neighborhoods, tissue organization, and microenvironmental gradients [38]. This spatial context is particularly critical for understanding complex biological systems like the human endometrium, which undergoes dramatic, cyclic remodeling throughout the menstrual cycle. The dynamic nature of endometrial tissue, involving coordinated interactions between epithelial, stromal, immune, and vascular components, makes it an ideal candidate for spatial transcriptomic analysis. By mapping gene expression patterns to tissue architecture, researchers can unravel the intricate molecular mechanisms governing endometrial receptivity, regeneration, and pathologies such as thin endometrium and endometriosis [5] [28].

The 10x Genomics Visium platform has emerged as a powerful tool for spatial transcriptomic profiling, effectively bridging the gap between traditional histology and comprehensive transcriptomics. This guide details the core technology, experimental workflow, and practical application of the Visium platform within the specific context of endometrial research, providing scientists with the technical foundation needed to implement this cutting-edge methodology in reproductive biology studies.

Core Technology of the 10x Visium Platform

Fundamental Principles and Workflows

The 10x Visium platform operates on the principle of capturing mRNA transcripts from a tissue section on a spatially barcoded glass slide. The core technology relies on RNA-binding probes attached to the slide surface within designated capture areas. These probes contain several key domains: (1) a spatial barcode unique to each spot on the slide, which records the spatial location of the mRNA; (2) a unique molecular identifier (UMI) that tags individual mRNA molecules to enable accurate quantification and correct for amplification bias; and (3) an oligo-dT sequence that binds to the poly-A tail of mRNA molecules [39].

10x Genomics offers two primary versions of the Visium workflow, each optimized for different sample types. The table below summarizes the workflows for fresh frozen and FFPE tissues.

Table: Comparison of 10x Visium Workflows for Fresh Frozen and FFPE Tissues

Parameter	Visium for Fresh Frozen (FF) Tissue	Visium for Formalin-Fixed Paraffin-Embedded (FFPE) Tissue
Sample Preservation	Rapid freezing, optimal for high RNA integrity	Formalinfixed and paraffin-embedded, suitable for degraded RNA
mRNA Capture Mechanism	Direct binding to poly(dT) probes	Probe hybridization and ligation (requires gene-specific probes)
Key Instrument	Standard workflow	CytAssist instrument for probe transfer
Tissue Section Thickness	10-20 μm	5-10 μm
Key Advantage	Full transcriptome coverage	Compatible with clinical archives

For fresh frozen (FF) tissues, the workflow involves placing a tissue section onto the Visium slide, followed by tissue permeabilization to release mRNA. The released mRNA molecules bind directly to the adjacent poly(dT) probes on the slide. Subsequently, on-slide reverse transcription generates cDNA that incorporates the spatial barcode and UMI, and this cDNA is then collected for library preparation and sequencing [39].

For formalin-fixed paraffin-embedded (FFPE) tissues, which are common in clinical research, the process uses the Visium CytAssist instrument. This workflow employs a pair of gene-specific probes that hybridize to the target mRNA. The probes are then ligated together, and the resulting product is captured by the poly(dT) sequence on the Visium slide. This method is specifically optimized for handling partially degraded RNA typically extracted from FFPE samples, making it invaluable for studies utilizing historical clinical specimens [39] [38].

Technical Specifications and Evolution

The standard 10x Visium platform features a capture area of 6.5 mm × 6.5 mm containing approximately 5,000 spots, each with a diameter of 55 μm and a center-to-center distance of 100 μm. This configuration results in a resolution that typically captures data from 1-10 cells per spot, providing a tissue-level overview of gene expression [39] [40].

The recent introduction of Visium HD represents a significant advancement in resolution. It utilizes a much smaller feature size of 2 μm, enabling single-cell resolution or even subcellular analysis. Visium HD employs the same underlying chemistry as the Visium FFPE workflow but uses a continuous lawn of barcoded oligos on the capture slide, which allows for a more precise mapping of gene expression [39]. The following diagram illustrates the core workflow and technological evolution of the Visium platform.

Experimental Protocol for Endometrial Research

Tissue Preparation and Quality Control

Successful spatial transcriptomics begins with optimal tissue collection and preparation. For endometrial research, this typically involves pipelle biopsies or hysteroscopic samples collected during specific phases of the menstrual cycle, precisely timed using luteinizing hormone (LH) surge detection (e.g., LH+7 for the mid-luteal phase) [6].

• Preservation Strategy: The choice between fresh frozen (FF) and FFPE preservation is critical. FF tissue generally provides higher RNA integrity and is preferred for whole-transcriptome discovery research. FFPE preservation is essential when working with archival clinical samples but requires the CytAssist workflow and yields more fragmented RNA [38].
• Quality Control: Rigorous RNA quality assessment is mandatory. For FF samples, an RNA Integrity Number (RIN) > 7 is ideal. For FFPE samples, a DV200 value (percentage of RNA fragments > 200 nucleotides) above 50-70% is recommended. Recent evidence suggests that even samples below these thresholds can yield biologically meaningful data, but success rates may be lower [38].
• Sectioning and Staining: Tissue sections must be cut to the prescribed thickness (10-20 μm for FF, 5-10 μm for FFPE) and placed within the capture area of the Visium slide. Subsequent hematoxylin and eosin (H&E) staining and high-resolution brightfield imaging are performed to correlate histological features with gene expression data [6] [38].

Visium Assay Execution and Sequencing

The following table details the key reagents and their functions in the Visium workflow, forming an essential toolkit for researchers.

Table: Research Reagent Solutions for 10x Visium Experiments

Reagent / Material	Function	Considerations for Endometrial Tissue
Visium Spatial Slide	Contains spatially barcoded oligos for mRNA capture	One capture area per slide; plan for replicates
Visium Tissue Optimization Slide	Determines optimal permeabilization time	Critical for heterogeneous tissues like endometrium
Permeabilization Enzyme	Releases mRNA from cells for capture	Optimization time is tissue-type and thickness dependent
CytAssist Instrument	Enables FFPE and custom panel workflows	Required for archival clinical endometrial samples
H&E Staining Kit	Provides histological context	Allows pathologist annotation of endometrial zones
Sequencing Libraries	Prepared for Illumina platforms	FFPE libraries often require deeper sequencing

After library preparation, sequencing depth is a crucial consideration. While manufacturer guidelines often suggest 25,000-50,000 reads per spot, recent practical experience from over 1,000 samples indicates that FFPE Visium experiments often benefit from 100,000-120,000 reads per spot to achieve sufficient transcript coverage, especially given the inherent RNA degradation in such samples [38].

Data Processing and Analysis Pipeline

The computational analysis of Visium data requires specialized tools to integrate spatial and molecular information. The standard workflow begins with the Space Ranger pipeline, which aligns sequencing reads to a reference genome, assigns them to spatial barcodes, and generates a feature-spot matrix containing gene counts for each spot [6].

Subsequent analysis typically leverages the Seurat package in R, which has integrated functionalities for spatial data. Key steps include [5] [6]:

• Quality Control: Filtering out spots with low gene counts (< 500 genes) or high mitochondrial gene percentage (>20%), which may represent damaged tissue areas.
• Normalization and Scaling: Using methods like SCTransform to normalize counts and remove technical variation.
• Dimensionality Reduction and Clustering: Principal Component Analysis (PCA) followed by graph-based clustering (e.g., Louvain algorithm) to group spots with similar expression profiles.
• Spatial Visualization: Overlaying cluster identities or gene expression levels onto the tissue image to identify spatially restricted patterns.

For a deeper understanding of cellular communication, tools like CellChat can be applied to infer ligand-receptor interactions between spatially defined cell populations, revealing how different niches in the endometrium communicate [5]. Furthermore, integration with paired single-cell RNA sequencing (scRNA-seq) data through deconvolution methods (e.g., CARD) can help estimate the proportion of different cell types within each Visium spot, refining the resolution beyond spot-level analysis [6].

Application in Endometrial Transcriptome Dynamics

Spatial transcriptomics has provided groundbreaking insights into endometrial biology and pathology by preserving the architectural context of gene expression events.

In the study of thin endometrium (TE), a condition leading to infertility, spatial and single-cell analyses revealed a critical role for perivascular CD9+ SUSD2+ cells acting as putative progenitor stem cells. The CellChat analysis uncovered aberrant communication networks in TE, particularly highlighting over-deposition of collagen around these perivascular cells, indicating a disrupted response to endometrial repair and remodeling [5]. This finding, which would be impossible without spatial context, suggests a potential molecular mechanism for failed endometrial regeneration in TE.

In endometriosis, spatial transcriptomic profiling of ectopic lesions has identified distinct stromal cell niches that sustain lesion growth. The research identified WNT5A upregulation and aberrant activation of non-canonical WNT signaling in endometrial stromal cells, revealing a potential novel therapeutic target for this condition [28]. The spatial data allowed researchers to pinpoint the precise cellular neighborhoods where these pathogenic interactions occur.

For conditions like repeated implantation failure (RIF), spatial transcriptomics has been used to map the endometrial landscape during the window of implantation. One study identified seven distinct cellular niches in the mid-luteal phase endometrium, with deconvolution analysis showing that unciliated epithelial cells were the dominant component. This spatial atlas provides a valuable resource for understanding the complex cellular ecosystem required for successful embryo implantation [6]. The following diagram summarizes how ST reveals key endometrial processes.

Spatial transcriptomics with the 10x Visium platform has fundamentally enhanced our ability to study the endometrial transcriptome within its native structural context. By bridging histology and molecular biology, it has uncovered novel mechanisms in endometrial regeneration, receptivity, and disease pathogenesis. As the technology continues to evolve, with improvements in resolution, cost-effectiveness, and computational integration, its role in advancing reproductive medicine is set to expand dramatically. Future directions include the integration of spatial transcriptomics with other omics modalities, such as proteomics and epigenomics, and the development of more sophisticated computational tools to model the dynamic, cell-cell interactions that define the cyclic transformation of the human endometrium.

The endometrial transcriptome undergoes precise, dynamic changes throughout the menstrual cycle to prepare the uterus for embryo implantation. Understanding these complex changes requires moving beyond single-layer analysis to an integrated approach. Multi-omics data integration—the simultaneous consideration of transcriptomic, proteomic, and epigenetic datasets—provides a powerful framework for uncovering the coordinated molecular mechanisms that govern endometrial receptivity. This integrated approach is transforming women's health research, offering unprecedented insights into both normal endometrial function and pathological states such as endometrial cancer and endometriosis-associated infertility [41] [15] [42].

The molecular landscape of the endometrium is shaped by the intricate interplay between different biological layers. Epigenetic modifications, including DNA methylation and histone alterations, dynamically regulate gene expression patterns without changing the underlying DNA sequence [43]. These transcriptomic changes then direct the synthesis of proteins that execute cellular functions, though this relationship is not always straightforward due to post-transcriptional and post-translational regulation [44]. By integrating these complementary data types, researchers can construct more comprehensive models of endometrial biology, revealing regulatory networks and biomarkers that remain invisible when examining each data type in isolation [45] [46].

Methodological Approaches for Multi-omics Integration

Computational Integration Strategies

Effective integration of multi-omics data requires sophisticated computational methods that can handle the high-dimensionality and heterogeneity of these datasets. Several strategic approaches have been developed, each with distinct advantages for specific research contexts.

Early Integration methods combine raw datasets from multiple omics layers before analysis. This approach employs algorithms like autoencoders to create a unified representation, allowing the model to learn from all data types simultaneously. However, this method may obscure omics-specific patterns and requires careful normalization to address technical variations between platforms [45].

Late Integration involves analyzing each omics dataset separately and combining the results at the final stage. Methods like MOGONET use omics-specific graph convolutional networks (GCNs) to learn intra-omics representations before integration through correlation networks. This approach preserves modality-specific signals but may miss important cross-omics interactions [45].

Intermediate Integration strategies, such as the novel SynOmics framework, represent the most advanced approach by modeling both within-omics and cross-omics dependencies simultaneously. SynOmics constructs feature-level networks and employs bipartite graph convolution to capture regulatory interactions between different omics types, such as miRNA-mRNA targeting relationships. This method operates in the feature space rather than sample space, enabling more biologically meaningful integration of molecular interactions [45].

Directional Integration Methods

Biological systems often exhibit directional relationships between omics layers, such as the generally positive correlation between mRNA expression and protein abundance. The Directional P-value Merging (DPM) method incorporates these expected directional associations as constraints during data integration [46].

DPM uses a user-defined constraints vector (CV) to specify how different omics datasets are expected to interact. For example, a CV of [+1, +1] would prioritize genes showing consistent up-regulation or down-regulation across both transcriptomic and proteomic datasets, while [+1, -1] would identify genes with inverse relationships, such as those potentially regulated by negative feedback mechanisms. The method computes a directionally weighted score (X_DPM) that rewards consistent directional changes and penalizes inconsistent patterns, leading to more biologically relevant gene prioritization [46].

The general DPM workflow includes: (1) processing upstream omics datasets into matrices of gene P-values and directional changes; (2) merging P-values and directions into a single gene list using directional constraints; (3) pathway enrichment analysis of the merged gene list; and (4) visualization of resulting pathways as enrichment maps highlighting directional evidence [46].

Table 1: Comparison of Multi-omics Integration Methods

Method	Integration Strategy	Key Features	Best Suited Applications
Early Integration	Combines raw data before analysis	Learns joint representations, may obscure omics-specific patterns	Discovery of unified molecular signatures
Late Integration	Analyzes datasets separately, combines results	Preserves modality-specific signals, may miss cross-omics interactions	Validation of findings across omics layers
Intermediate Integration (SynOmics)	Models within- and cross-omics dependencies simultaneously	Feature-level networks, bipartite graph convolution	Mapping regulatory networks, biomarker discovery
Directional P-value Merging (DPM)	Incorporates directional constraints during integration	User-defined constraints vector, rewards consistent patterns	Pathway analysis with expected directional relationships

Experimental Protocols and Workflows

Data Generation Techniques

Generating high-quality multi-omics data requires specialized experimental techniques for each molecular layer, with careful consideration of platform selection and experimental design.

Transcriptomic Profiling can be performed using DNA microarrays or RNA sequencing (RNA-Seq). RNA-Seq has become the preferred method due to its broader dynamic range, ability to detect novel transcripts, and higher accuracy in quantifying gene expression levels. For endometrial studies, RNA-Seq can reveal key receptivity genes (e.g., LIF, HOXA10, ITGB3) and non-coding RNAs (e.g., lncRNA H19, miR-let-7) that regulate embryo adhesion and immune tolerance [44] [15]. The standard workflow includes: (1) RNA extraction from endometrial tissue biopsies; (2) library preparation with poly-A selection or ribosomal RNA depletion; (3) sequencing on platforms such as Illumina; and (4) quality control including RIN score assessment.

Proteomic Analysis commonly utilizes liquid chromatography-tandem mass spectrometry (LC-MS/MS). Advanced methods like isobaric tags for relative and absolute quantitation (iTRAQ) enable multiplexed protein quantification across multiple samples. For endometrial receptivity studies, this approach has identified key proteins including HMGB1 and ACSL4 [15]. The standard protocol involves: (1) protein extraction from tissue or uterine fluid; (2) tryptic digestion; (3) peptide labeling with isobaric tags; (4) LC-MS/MS analysis; and (5) database searching against human protein databases.

Epigenomic Profiling encompasses several complementary techniques. DNA methylation analysis employs whole-genome bisulfite sequencing (WGBS) or reduced representation bisulfite sequencing (RRBS) to map methylated cytosines at single-base resolution. Chromatin accessibility is typically assessed by ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing), which has largely replaced earlier methods like DNase-seq. Histone modifications and transcription factor binding are profiled using ChIP-seq (Chromatin Immunoprecipitation followed by sequencing) or newer alternatives such as CUT&Tag that offer higher sensitivity with lower input requirements [43] [47].

Single-cell and Spatial Multi-omics

Emerging technologies enable multi-omics profiling at single-cell resolution, revealing cellular heterogeneity within endometrial tissues that is masked in bulk analyses. Single-cell RNA sequencing (scRNA-seq) can identify distinct endometrial cell subpopulations and their gene expression dynamics throughout the menstrual cycle [47].

Multimodal single-cell technologies now allow simultaneous measurement of multiple omics layers from the same cell. For example, scATAC-seq can profile chromatin accessibility alongside gene expression in individual cells, enabling the mapping of gene regulatory networks across different endometrial cell types. These approaches have revealed distinct paracrine signaling circuits in endometrial cancer, such as midkine (MDK) produced by carcinoma cells engaging nucleolin (NCL) receptors on adjacent stromal cells [41].

Spatial transcriptomics and proteomics techniques preserve the architectural context of endometrial tissues, allowing researchers to correlate molecular profiles with specific tissue compartments (e.g., luminal epithelium, glandular epithelium, stroma). This is particularly valuable for understanding localized molecular interactions during the window of implantation [41] [15].

Diagram 1: Multi-omics experimental workflow

Analytical Frameworks and Bioinformatics Tools

Quality Control and Preprocessing

Robust quality control is essential for each omics data type to ensure reliable integration. For RNA-Seq data, this includes assessment of sequencing depth, gene body coverage, 3' bias, and contamination. Tools such as FastQC and MultiQC provide comprehensive quality reports. For proteomics data, quality metrics include peptide identification rates, mass accuracy, and intensity distributions. Epigenomics data requires evaluation of enrichment quality (for ChIP-seq), bisulfite conversion rates (for WGBS), and fragment size distribution (for ATAC-seq) [43].

Data normalization addresses technical variations between samples and platforms. RNA-Seq data typically uses normalization methods such as TPM (Transcripts Per Million) or DESeq2's median-of-ratios. Proteomics data often employs variance-stabilizing normalization or quantile normalization. Epigenomics data requires specialized approaches like GC-content normalization for ATAC-seq and bias correction for ChIP-seq [44] [43].

Batch effects, arising from processing samples in different batches or using different technicians, can introduce significant artifacts. Combat, limma, or Harmony algorithms effectively remove batch effects while preserving biological signals. For longitudinal endometrial studies, where samples may be collected across multiple cycles, specialized methods accounting for both batch effects and temporal correlations are recommended [43].

Integration and Pathway Analysis

After preprocessing, several specialized tools enable integrated analysis. SynOmics employs graph convolutional networks on feature-level networks, using both intra-omics networks (e.g., protein-protein interactions) and cross-omics bipartite networks (e.g., transcription factor-gene regulatory relationships) [45].

Directional P-value Merging (DPM) integrates significance estimates across datasets while incorporating directional constraints based on biological relationships. For endometrial research, this might involve specifying expected positive correlations between estrogen receptor activation and downstream target gene expression [46].

Pathway enrichment analysis places integrated gene lists in biological context using databases such as Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome. The ActivePathways method extends this by determining which input omics datasets contribute most to individual pathway detections, highlighting consistent pathway alterations across molecular layers [46].

Table 2: Key Bioinformatics Tools for Multi-omics Integration

Tool	Primary Function	Input Data Types	Output
SynOmics	Feature-level integration using GCNs	Any omics data with feature networks	Integrated features, predictions
DPM	Directional integration of P-values	P-values with directional changes	Prioritized gene lists
ActivePathways	Multi-omics pathway enrichment	Gene lists from multiple omics	Significantly enriched pathways
MOFA	Factor analysis for multi-omics	Multiple omics matrices	Latent factors, feature weights
MOGONET	GCN-based integration	Multiple omics data types	Sample classifications, biomarkers

Applications in Endometrial Biology

Endometrial Receptivity and Implantation

Multi-omics approaches have revolutionized our understanding of endometrial receptivity—the transient period when the endometrium is receptive to embryo implantation. Transcriptomic analyses have identified receptivity-associated genes including LIF, HOXA10, ITGB3, and various non-coding RNAs (lncRNA H19, miR-let-7). The clinically implemented Endometrial Receptivity Array (ERA) test, based on 238 coding genes, exemplifies successful translation of transcriptomic findings to clinical practice, though it overlooks contributions from non-coding RNAs [15].

Proteomic studies of uterine fluid have identified receptivity biomarkers including HMGB1 and ACSL4, offering potential for non-invasive assessment. Metabolomic analyses have revealed secretory-phase shifts in arachidonic acid pathways and amino acid availability, suggesting metabolic reprogramming to support implantation [15].

Integration of these datasets through machine learning models has achieved impressive predictive accuracy (AUC > 0.9) for receptivity status, outperforming single-omics approaches. Single-cell and spatial multi-omics further resolve the cellular heterogeneity of endometrial tissues, identifying distinct stromal and epithelial subpopulations with specialized roles during the window of implantation [15].

Endometrial Cancer Molecular Subclassification

The Cancer Genome Atlas (TCGA) research network established the foundational molecular classification of endometrial cancer through integrated multi-omics analysis. This work identified four distinct subtypes: (1) POLE ultramutated, (2) microsatellite instability hypermutated, (3) copy-number low, and (4) copy-number high [41].

This molecular taxonomy has profound clinical implications, surpassing the limitations of traditional histopathological classification. For instance, POLE-mutant endometrial cancers exhibit excellent prognosis despite high-grade histology, while copy-number high tumors (frequently corresponding to serous histology) have poor outcomes [41] [48].

Multi-omics approaches have further revealed the tumor microenvironment's role in endometrial cancer progression, including cancer-associated fibroblasts (CAFs) that remodel extracellular matrix and tumor-associated macrophages (TAMs) that promote immune evasion through M2 polarization and immunosuppressive cytokine secretion [41].

Integrated analyses have identified potential biomarkers and therapeutic targets such as CDKN2A, which shows elevated expression in endometrial cancer and correlates with altered p53/Rb and NRF2 pathways. CDKN2A expression negatively correlates with CD8+ T cell activity, suggesting immune evasion mechanisms [48].

Diagram 2: Multi-omics view of endometrial receptivity

Endometriosis-associated Infertility

Multi-omics approaches have elucidated the complex pathophysiology of endometriosis-associated infertility, revealing interconnected hormonal, immune, and epigenetic disturbances. Transcriptomic and proteomic analyses have demonstrated estrogen dominance coupled with progesterone resistance in endometriotic lesions, characterized by upregulated aromatase (CYP19A1) and downregulated progesterone receptors [42].

Integrated analyses have identified pervasive immune dysregulation, including altered macrophage polarization (M1/M2 imbalance), impaired natural killer cell cytotoxicity, and T-cell subset dysregulation. These changes create a pro-inflammatory microenvironment that impairs oocyte quality, endometrial receptivity, and embryo implantation [42].

Epigenomic studies have revealed disease-associated DNA methylation patterns and histone modifications that sustain the inflammatory phenotype and progesterone resistance. Metabolomic profiling has identified oxidative stress signatures and altered energy metabolism in endometriosis, suggesting potential targets for therapeutic intervention [42].

Research Reagent Solutions

Table 3: Essential Research Reagents for Endometrial Multi-omics Studies

Reagent Category	Specific Examples	Application in Endometrial Research
RNA Sequencing Kits	Illumina TruSeq, SMARTer Stranded Total RNA	Transcriptome profiling of endometrial biopsies, identification of receptivity signatures
Bisulfite Conversion Kits	EZ DNA Methylation Gold Kit, Premium Bisulfite Kit	DNA methylation analysis of endometrial tissues, epigenetic clock studies
Chromatin Analysis Kits	Illumina ATAC-seq Kit, CUT&Tag Assay Kit	Chromatin accessibility profiling, histone modification mapping in endometrial cells
Protein Digestion Kits	FASP Protein Digestion Kit, S-Trap Micro Columns	Sample preparation for LC-MS/MS proteomic analysis of endometrial tissues
Single-cell Platforms	10X Genomics Chromium, Parse Biosciences	Single-cell multi-omics of heterogeneous endometrial cell populations
Immunoassay Kits	Luminex Multiplex Assays, Olink Proteomics	Validation of candidate protein biomarkers in uterine fluid or serum
Pathway Analysis Software	GSEA, g:Profiler, Enrichr	Functional interpretation of multi-omics datasets in endometrial context

The integration of transcriptomic, proteomic, and epigenetic data represents a paradigm shift in endometrial research, moving from isolated observations to comprehensive network-level understanding. As multi-omics technologies continue to advance, particularly in single-cell and spatial resolution, they promise to unravel the remarkable dynamism of the endometrial transcriptome across the menstrual cycle with unprecedented precision.

For clinical translation, future efforts must focus on standardizing protocols, validating biomarkers across diverse populations, and developing accessible computational tools that can be implemented in diagnostic settings. The integration of multi-omics data with clinical metadata through artificial intelligence approaches will be particularly important for developing personalized diagnostic and therapeutic strategies for endometrial disorders.

The journey from correlation to causation will require tight integration between multi-omics discovery and functional validation, potentially through organoid models and genome engineering. As these technologies mature, multi-omics integration will undoubtedly become a cornerstone of both basic endometrial biology and clinical practice in reproductive medicine.

The human endometrium is a highly dynamic tissue that undergoes cyclical regeneration, differentiation, and shedding throughout the menstrual cycle. Understanding these temporal dynamics is crucial for elucidating the molecular basis of endometrial receptivity, fertility, and associated disorders. Single-cell RNA sequencing (scRNA-seq) has revolutionized our ability to profile gene expression at cellular resolution; however, it traditionally provides only static snapshots of these dynamic processes. Computational methods for temporal modeling, particularly RNA velocity and trajectory inference, have emerged as powerful approaches to reconstruct cellular dynamics from snapshot data, enabling researchers to infer the past and future states of individual cells along developmental continua.

Within endometrial research, these approaches are particularly valuable for mapping the complex cellular transitions that occur during the window of implantation (WOI) and for identifying pathological deviations in conditions such as recurrent implantation failure (RIF) and intrauterine adhesions (IUA). By reconstructing temporal dynamics, these methods help uncover the molecular drivers of stromal decidualization, epithelial differentiation, and immune cell recruitment throughout the menstrual cycle. This technical guide provides an in-depth examination of core computational methods for temporal modeling, their applications in endometrial biology, and practical considerations for implementation in reproductive research.

Biological Foundations of Endometrial Dynamics

The endometrial tissue exhibits remarkable cellular plasticity across the menstrual cycle, with coordinated changes in epithelial, stromal, and immune populations. Time-series scRNA-seq studies have revealed that the establishment of endometrial receptivity involves a two-stage stromal decidualization process and a gradual transitional process of luminal epithelial cells across the WOI [49]. These processes are tightly regulated by ovarian hormone signaling and involve complex cell-cell communication networks.

In pathological states, these temporal programs become disrupted. For instance, in intrauterine adhesions (IUA), single-cell analyses have uncovered a profibrotic shift in macrophage states and increased immune cell infiltration, with macrophage-derived factors CCL5 and SPP1 promoting fibroblast-to-myofibroblast transition—a key driver of endometrial fibrosis [50]. Similarly, recurrent implantation failure (RIF) endometria exhibit displaced WOI timing and a hyper-inflammatory microenvironment characterized by dysfunctional epithelial cells [49]. These findings highlight the critical importance of temporal modeling for understanding both physiological and pathophysiological endometrial processes.

Table 1: Key Temporal Processes in Endometrial Biology

Process	Cellular Participants	Key Regulators	Pathological Disruptions
Stromal Decidualization	Endometrial stromal cells, Natural Killer cells	Progesterone, BMP2, IL-15	Shallow decidualization, Impaired embryo biosensing
Epithelial Receptivity	Luminal, Glandular epithelial cells	LIF, STAT3, HOXA10	Displaced WOI, Adhesion deficiencies
Immune Recruitment	Macrophages, uNK cells, T cells	CCL2, CCL5, SPP1	Hyper-inflammatory microenvironment, Fibrosis
Vascular Remodeling	Endothelial cells, Pericytes	VEGF, ANGPT1/2	Poor perfusion, Hypoxia

Computational Methodologies for Temporal Modeling

Core Concepts and Definitions

Temporal modeling of single-cell data encompasses several interrelated approaches:

• RNA Velocity: Computational method that estimates the instantaneous rate of gene expression change by quantifying the ratio of unspliced (nascent) to spliced (mature) mRNA for each gene, predicting future cellular states [51] [52].
• Trajectory Inference (Pseudotime Analysis): Methods that order cells along a hypothetical developmental timeline based on transcriptomic similarity, reconstructing differentiation pathways without requiring time-series data [52].
• Metabolic Labeling: Experimental approaches that incorporate nucleotide analogs (e.g., 4-thiouridine) to distinguish newly synthesized transcripts, providing ground truth for validating computational predictions [52].

Theoretical Foundations of RNA Velocity

RNA velocity models are built upon ordinary differential equations (ODEs) that describe transcription, splicing, and degradation processes:

Where U and S represent unspliced and spliced mRNA abundance, α denotes the transcription rate, β the splicing rate, and γ the degradation rate. Traditional velocity methods assume constant transcriptional rates, but newer approaches like InterVelo allow transcription rates to vary with cellular state, better capturing biological reality [51].

Diagram 1: RNA Velocity Kinetic Model (55 characters)

Advanced Methodologies: From Static Snapshots to Dynamic Models

Recent methodological advances have addressed key limitations in early temporal modeling approaches:

InterVelo represents a significant advancement by simultaneously learning cellular pseudotime and RNA velocity through a mutually enhancing framework. This deep learning approach employs a variational autoencoder (VAE) with neural ODEs to model latent state dynamics, using pseudotime to guide velocity estimation while using velocity to refine pseudotime direction [51]. This eliminates the need for prior knowledge of developmental direction or root cells, which is particularly valuable in endometrial studies where the origin of cellular lineages may be unknown.

Multi-omic integration extends temporal modeling beyond transcriptomics. Methods like MultiVelo incorporate chromatin accessibility data (e.g., from scATAC-seq) to provide a more comprehensive view of regulatory dynamics [51]. This is especially relevant for studying hormone-responsive tissues like the endometrium, where epigenetic reprogramming plays a crucial role in cellular differentiation.

Table 2: Comparison of Temporal Modeling Methods

Method	Core Algorithm	Data Requirements	Key Advantages	Limitations
Steady-State Velocity [52]	Least squares regression	Unspliced/Spliced counts	Computational efficiency, Interpretability	Constant rate assumption, Gene-specific times
Dynamical Modeling [52]	Expectation-maximization	Unspliced/Spliced counts	Accounts for stochasticity	Computationally intensive, Complex implementation
VeloVI [51]	Variational inference	Unspliced/Spliced counts	Uncertainty quantification, Information sharing across genes	Complex implementation, Steep learning curve
DeepVelo/cellDancer [51]	Neural networks	Unspliced/Spliced counts	Cell-specific kinetics, No constant rate assumption	Large data requirements, Potential overfitting
InterVelo [51]	VAE + Neural ODE	Unspliced/Spliced counts	Simultaneous pseudotime/velocity, No prior direction needed	Complex architecture, Computational demands
MultiVelo [51]	Extended ODE models	RNA + Chromatin access.	Multi-omic integration, Regulatory insights	Requires matched modalities, Data sparsity issues

Experimental Design and Protocol Implementation

Sample Collection and Single-Cell Preparation for Endometrial Studies

Optimal temporal modeling requires careful experimental design and sample processing:

Timing and Cohort Selection: For menstrual cycle studies, precise timing relative to LH surge is critical. Studies should include multiple time points (e.g., LH+3, LH+7, LH+11) with sufficient biological replicates (minimum n=3 per time point) to account for inter-individual variation [49]. Both fertile controls and pathological cohorts (e.g., RIF, IUA patients) should be included for comparative analyses.

Single-Cell Library Preparation: The 10X Chromium system is widely used for droplet-based scRNA-seq. For velocity analyses, protocols must preserve intronic reads to distinguish unspliced and spliced transcripts. Standard cell viability thresholds (>80%) and minimum gene detection thresholds (1,500-3,000 genes/cell) should be applied, with doublet removal using tools like Scrublet [50] [49].

Quality Control Metrics: Recent endometrial scRNA-seq studies have successfully utilized datasets with median values of 8,481 unique transcripts and 2,983 genes per cell across >220,000 cells [49]. Stringent quality control is essential to remove low-quality cells while retaining biological heterogeneity.

Computational Workflow for Temporal Analysis

Diagram 2: Temporal Analysis Computational Workflow (52 characters)

Integrative Analysis of Time-Series scRNA-seq Data

For studies incorporating multiple time points, several computational strategies enable robust temporal reconstruction:

Metabolic Labeling Integration: Methods like scNT-seq incorporate 4-thiouridine labeling to distinguish newly synthesized transcripts, providing direct evidence of transcriptional dynamics that can validate velocity predictions [52]. Although primarily demonstrated in cell culture, adaptation to endometrial organoids represents a promising validation approach.

Cell State Matching: Across sequential time points, cells can be linked based on transcriptomic similarity using methods like StemVAE, which models transition probabilities between states and predicts temporal gene expression patterns [49].

Multi-omic Registration: For datasets with paired transcriptomic and epigenomic profiles, methods like MultiVelo align RNA velocity and chromatin velocity to identify key regulatory transitions during endometrial differentiation [51].

Applications in Endometrial Research

Characterizing the Window of Implantation

Time-series scRNA-seq analysis of human endometrium across the WOI has revealed previously unappreciated dynamics in epithelial and stromal compartments. A recent study profiling over 220,000 endometrial cells from LH+3 to LH+11 identified:

• A two-stage decidualization process in stromal cells, with distinct early and late molecular signatures [49]
• A gradual transitional process in luminal epithelial cells, characterized by sequential activation of receptivity genes
• Time-varying gene sets regulating epithelial receptivity, with different molecular programs active at LH+7 versus LH+9 [49]

RNA velocity analysis demonstrated that luminal epithelial cells exhibit high differentiation potential, with trajectory streams indicating differentiation toward glandular cell fates [49]. These findings provide a refined molecular definition of the WOI with clinical implications for precisely timing embryo transfer in fertility treatments.

Uncovering Pathological Mechanisms in Endometrial Disorders

In intrauterine adhesions (IUA), scRNA-seq of 139,395 cells from nine individuals revealed profound alterations in stromal-immune crosstalk. Trajectory and ligand-receptor analyses highlighted:

• Profibrotic macrophage lineages and TGF-β signaling as key drivers of fibrosis [50]
• Increased proportions of specific stromal subclusters (Cluster 3) in IUA tissues, with functional enrichment in chromosome segregation pathways [50]
• Macrophage-derived CCL5 and SPP1 as promoters of fibroblast-to-myofibroblast transition in vitro [50]

In recurrent implantation failure, temporal modeling has identified:

• Displaced WOI timing and dysregulated epithelium in a hyper-inflammatory microenvironment [49]
• Two distinct classes of epithelial deficiency based on time-varying receptivity gene expression [49]
• Altered stromal cell biosensing capabilities potentially contributing to impaired embryo-endometrium dialogue

Table 3: Key Research Reagent Solutions for Endometrial Temporal Modeling

Reagent/Resource	Application	Function	Implementation Considerations
10X Chromium	scRNA-seq library prep	Partitioning cells into droplets with barcoded beads	Preserve intronic reads for velocity analysis
Colcemid	Metaphase arrest (flow cytogenetics)	Microtubule disruption for chromosome analysis	Concentration optimization required (0.01-0.1 μg/ml) [53]
4-thiouridine (s4U)	Metabolic labeling	Incorporation into nascent RNA for age determination	Currently limited to in vitro systems [52]
Chromomycin A3	Chromosome staining (flow cytogenetics)	GC-specific DNA binding for karyotyping	Requires 457nm laser (less common) [54]
Hoechst 33258/33342	Chromosome staining (flow cytogenetics)	AT-specific DNA binding for karyotyping	Compatible with 355nm laser (more common) [54]
InterVelo Python Package	RNA velocity estimation	Simultaneous pseudotime and velocity learning	GitHub: github.com/yurouwang-rosie/InterVelo [51]

Technical Validation and Interpretation

Methodological Benchmarking and Performance Metrics

Rigorous validation is essential when applying temporal modeling approaches. Benchmarking studies should assess:

• Consistency with known biology: Trajectories should align with established endometrial differentiation pathways (e.g., stromal→decidual, luminal→glandular)
• Concordance across methods: Key findings should be robust across multiple velocity (InterVelo, VeloVI) and pseudotime (PAGA, Slingshot) methods
• Experimental validation: Where possible, findings should be confirmed using orthogonal approaches such as immunofluorescence for predicted protein markers or in vitro functional assays

For RNA velocity methods, key performance metrics include:

• Latent time consistency: Whether pseudotemporal ordering aligns with known developmental sequences
• Velocity coherence: The extent to which velocity vectors point toward biologically plausible future states
• Robustness: Consistency of results across subsamples and parameter settings

Pitfalls and Limitations in Endometrial Applications

Several challenges are particularly relevant to endometrial temporal modeling:

• Cellular continuousness: The endometrium contains cell states with continuous rather than discrete transitions, complicating cluster-based analyses
• Cycle phase mixing: Subtle differences in individual cycle timing can introduce apparent heterogeneity that may be misinterpreted as distinct cell states
• Hormonal responsiveness: Rapid transcriptional responses to hormonal fluctuations can create velocity patterns that reflect acute signaling responses rather than differentiation
• Sparse sampling: Limited availability of human endometrial samples, particularly at precise time points, can limit statistical power

Future Directions and Clinical Translation

The integration of temporal modeling with emerging technologies promises to further advance endometrial research:

• Spatiotemporal mapping: Combining RNA velocity with spatial transcriptomics will enable reconstruction of both temporal and spatial dynamics of endometrial remodeling
• Multi-omic dynamics: Joint modeling of transcriptomic, epigenomic, and proteomic changes across the menstrual cycle will provide more comprehensive regulatory insights
• Clinical predictive models: Machine learning approaches applied to temporal models may enable prediction of individual WOI timing or personalized risk assessment for endometrial disorders
• Intervention modeling: Temporal models could potentially simulate the effects of hormonal manipulations or therapeutic interventions on endometrial differentiation trajectories

As these methods mature, temporal modeling approaches are poised to transition from basic research tools to clinically applicable methodologies for diagnosing and treating endometrial-factor infertility and other reproductive disorders. The continued refinement of computational methods, coupled with carefully designed endometrial studies, will deepen our understanding of this remarkably dynamic tissue and its critical role in reproductive health.

The human endometrium, the mucosal lining of the uterus, undergoes dynamic, cyclical changes of shedding, regeneration, and differentiation throughout reproductive life, processes tightly coordinated by the hypothalamic-pituitary-ovarian axis [16] [31]. Endometrial dysfunction underpins many common disorders, including abnormal uterine bleeding, infertility, miscarriage, endometriosis, and endometrial carcinoma, representing a significant healthcare burden worldwide [31] [55]. Traditional two-dimensional (2D) cell cultures fail to capture the structural and functional complexity of the native endometrium, while animal models are limited by significant physiological differences from human reproductive biology [56] [57].

Endometrial organoids (EOs) have emerged as revolutionary three-dimensional (3D) in vitro models that offer a physiologically relevant system to study the endometrium [16] [57]. These self-organizing structures are generated from primary tissue or menstrual fluid and recapitulate the cellular composition, transcriptomic profile, hormonal responsiveness, and functional characteristics of the native endometrium [16] [58] [31]. This technical guide explores how these innovative models recapitulate endometrial physiology, with particular focus on their application for validating transcriptomic dynamics across the menstrual cycle.

Endometrial Physiology and Transcriptomic Dynamics

Architectural and Functional Foundations

The endometrium comprises two main layers: the lamina basalis (basal layer), which remains relatively constant, and the lamina functionalis (upper layer), which undergoes dramatic cyclic changes [16]. At the cellular level, the endometrium contains four major populations: epithelial, stromal, endothelial, and immune cells, which collectively form a complex structural and functional network [16].

The menstrual cycle is traditionally divided into three histological phases—menstrual, proliferative, and secretory—driven by oscillating levels of estradiol (E2) and progesterone (P4) [16]. However, recent single-cell RNA-sequencing (scRNA-seq) studies have redefined four major transcriptomic phases (Phase 1-4) that correlate with, but provide greater resolution than, traditional histological staging [16]. The table below summarizes key transcriptomic changes during these phases.

Table 1: Transcriptomic Dynamics of Endometrial Epithelium Across the Menstrual Cycle

Phase	Correlating Menstrual Phase	Key Transcriptomic Features	Regulatory Hormones
Phase 1	Menstruation & Early Proliferative	Upregulation of MMP7, MMP10, MMP11 (ECM degradation); Initiation of ESR1 and PGR expression [16]	Low P4, rising E2
Phase 2	Late Proliferative	Upregulation of TIMP1, CADM1; High THBS1 expression (angiogenesis, tissue remodeling) [16]	High E2
Phase 3	Early-Mid Secretory	Expression of PAEP, CXCL8; Preparation for receptivity [16] [31]	Rising P4
Phase 4	Late Secretory	Decidualization markers (PRL, IGFBP1); Inflammatory mediators if no implantation [16] [55]	Declining P4 and E2

Challenges in Cycle Staging and Molecular Validation

A significant challenge in endometrial research is the natural variability in menstrual cycle length among women, coupled with rapid changes in gene expression [59]. To address this, molecular staging models have been developed that use global gene expression patterns to assign cycle stage with greater precision than histological dating alone [59]. These models have revealed significant and remarkably synchronized daily changes in expression for over 3,400 endometrial genes throughout the cycle, with the most dramatic changes occurring during the secretory phase [59]. Endometrial organoids provide a validated platform to study these precise transcriptomic dynamics in a controlled in vitro environment.

Generation and Validation of Endometrial Organoids

Source Materials and Isolation Protocols

Endometrial organoids can be established from various tissue sources, each with distinct advantages:

• Tissue Biopsies/Hysterectomies: The traditional source, providing basal and functionalis epithelial cells [58] [57].
• Menstrual Fluid (MF): A non-invasive source containing tissue fragments with regenerative capacity. Menstrual fluid-derived organoids (MFO) show similar characteristics to biopsy-derived organoids [58].
• Hormone-Treated Endometrium: Enables study of endometrial biology in the context of exogenous hormones, relevant for a large proportion of the reproductive-age population [58].

Table 2: Standard Protocol for Generating Endometrial Organoids from Tissue

Step	Procedure	Key Reagents	Purpose
1. Tissue Processing	Mince tissue into 1 mm³ pieces using sterile scissors	DMEM/F12 medium with HEPES	Mechanical dissociation
2. Enzymatic Digestion	Digest tissue fragments with collagenase (I, II, or IV) with periodic shaking	Worthington Collagenase, DNase, Dispase [58] [56]	Liberate epithelial gland fragments and single cells
3. Cell Separation	Filter digestate; separate epithelial clusters from stromal cells via filtration or EpCAM magnetic beading [58]	40 μm cell strainer, CELLection Epithelial Enrichment kit	Enrich for epithelial organoid-forming cells
4. 3D Culture	Suspend cell clusters in Matrigel; plate; overlay with specialized medium	Matrigel, Advanced DMEM/F12, growth factors [56] [57]	Support 3D self-organization and growth
5. Maintenance	Change media every 2-3 days; passage every 7-10 days	TrypLE Express for passaging [56]	Long-term culture and expansion

Figure 1: Workflow for Generating Endometrial Organoids

Essential Culture Components

The long-term success of endometrial organoid cultures depends on a carefully formulated medium that activates key signaling pathways for self-renewal and differentiation.

Table 3: Essential Research Reagents for Endometrial Organoid Culture

Reagent Category	Specific Examples	Function	Target Pathway
Base Medium	Advanced DMEM/F12 [58] [56]	Nutrient foundation	-
Growth Factors	EGF, FGF-10, R-Spondin-1, Noggin, Wnt3a, HGF [56] [57]	Promote proliferation and self-renewal	WNT, MAPK
Pathway Inhibitors	A83-01 (TGF-β inhibitor), CHIR-99021 (GSK3 inhibitor) [56]	Inhibit differentiation and promote stemness	TGF-β, WNT/β-catenin
Supplements	B27, N2, N-acetylcysteine, Nicotinamide [56]	Provide essential nutrients and antioxidants	Metabolic support
Matrix	Matrigel [58] [56]	3D scaffold for growth	Extracellular matrix
Hormones (for differentiation)	Estradiol (E2), Medroxyprogesterone Acetate (MPA), cAMP [60]	Induce secretory differentiation and receptivity	Estrogen/Progesterone signaling

Functional Validation: Recapitulating Physiological Processes

Benchmarking Against Native Tissue Transcriptomics

Comprehensive validation studies using scRNA-seq have demonstrated that endometrial organoids closely mirror the in vivo endometrial epithelium at the transcriptomic level [16] [31]. Key findings include:

• Cellular Heterogeneity: Organoids contain progenitor cells (SOX9+, LRIG1), secretory cells (PAEP+), and ciliated cells (FOXJ1+), reflecting the diversity of the native epithelium [31] [57].
• Hormonal Responsiveness: Organoids express estrogen (ER) and progesterone (PR) receptors and respond to hormonal treatment by differentially expressing thousands of genes, mimicking the in vivo secretory transition [16] [60].
• Spatial Cues: Integrated spatial transcriptomics reveals that specific epithelial subsets in organoids correspond to distinct in vivo populations, such as SOX9+/LGR5+ cells from the surface epithelium and SOX9+/LGR5- cells from basal glands [31].

Modeling the Window of Implantation (WOI)

Specialized WOI organoid systems have been developed to mimic the receptive endometrium. These models exhibit critical features of the implantation window, including:

• Secretory Function: Production of essential factors like glycogens and pro-implantation molecules (LIF, PAEP, HB-EGF) into the organoid lumen [16] [60].
• Morphological Changes: Formation of pinopodes and cilia generation, structural markers of receptivity [60].
• Decidualization and ECM Remodeling: Upregulation of decidual markers (PRL, IGFBP1) and extracellular matrix remodeling enzymes, crucial for embryo invasion [16] [60].

Figure 2: Signaling Pathways Governing Epithelial Lineage Differentiation in Organoids. In vitro modulation of WNT and NOTCH pathways directs progenitor cell fate toward secretory or ciliated lineages, respectively, with progesterone being critical for secretory differentiation [31].

Advanced Model Systems

To address the limitation of conventional epithelial-only organoids, advanced co-culture systems have been developed:

• Floating Organoid Models: Retain both epithelial and stromal cell components, enabling the study of critical epithelial-stromal interactions necessary for decidualization [61].
• Disease-Specific Organoids: Successfully generated from eutopic and ectopic lesions of endometriosis patients, providing models to study disease mechanisms and drug responses [56].

Applications and Future Perspectives

Endometrial organoids have become indispensable tools for both basic and translational research. Key applications include:

• Drug Screening and Toxicology: Testing contraceptive efficacy or the impact of environmental toxins like Bisphenol A on endometrial function [57].
• Disease Modeling: Studying the pathophysiology of endometriosis, adenomyosis, and endometrial cancer in a patient-specific context [56] [57].
• Regenerative Medicine: Exploring organoid transplantation for treating endometrial dysfunction-related infertility, such Asherman's syndrome [57].

Future development of endometrial organoid technology will focus on enhancing physiological relevance through the incorporation of vascular networks, immune cell populations, and sophisticated microfluidic systems to better mimic the dynamic in vivo microenvironment [57]. These advancements will solidify the role of organoids as the premier platform for deciphering human endometrial biology and pathology.

Clinical Translation: Diagnosing and Treating Endometrial Disorders Through Transcriptomic Signatures

Recurrent implantation failure (RIF) represents a significant challenge in reproductive medicine, affecting approximately 5-15% of couples undergoing in vitro fertilization (IVF) [6] [62]. Defined as the failure to achieve a clinical pregnancy after multiple transfers of good-quality embryos, RIF stems from a complex interplay of embryonic and maternal factors, with endometrial dysfunction emerging as a critical determinant [63] [64]. The establishment of endometrial receptivity during the window of implantation (WOI) requires precisely orchestrated molecular and cellular events, and growing evidence indicates that dysregulation of these processes underlies many cases of RIF [64] [49].

The endometrial transcriptome undergoes dynamic changes throughout the menstrual cycle, culminating in a brief period of receptivity that enables embryo attachment and invasion [49]. Disruptions to these transcriptomic programs—whether in timing or function—can compromise receptivity and lead to implantation failure. This technical review synthesizes recent advances in our understanding of dysregulated molecular pathways and altered cellular niches in RIF, with particular emphasis on high-resolution transcriptomic profiling approaches that are reshaping both diagnostic capabilities and therapeutic targeting.

Molecular Taxonomy of RIF: Transcriptomic Subtyping

Distinct Molecular Subtypes

Comprehensive computational analyses integrating multiple endometrial transcriptomic datasets have revealed that RIF comprises biologically distinct molecular subtypes with characteristic pathway dysregulations:

Table 1: Molecular Subtypes of Recurrent Implantation Failure

Subtype	Key Characteristics	Dysregulated Pathways	Potential Therapeutic Candidates
Immune-Driven (RIF-I)	Enriched immune and inflammatory signatures; Increased effector immune cell infiltration; Higher T-bet/GATA3 expression ratio	IL-17 signaling (p < 0.01); TNF signaling; Altered immune cell populations	Sirolimus (rapamycin); Immunomodulatory approaches
Metabolic-Driven (RIF-M)	Metabolic pathway dysregulation; Altered circadian rhythm genes	Oxidative phosphorylation; Fatty acid metabolism; Steroid hormone biosynthesis; PER1 circadian clock gene	Prostaglandins; Metabolic modulators

These subtypes were identified through unsupervised clustering of endometrial transcriptomes from RIF patients, with the MetaRIF classifier achieving high accuracy (AUC: 0.94 and 0.85) in distinguishing them across validation cohorts [63]. This molecular taxonomy explains previous inconsistencies in treatment responses and provides a framework for personalized therapeutic interventions.

Window of Implantation Displacement

Transcriptome profiling has revealed that approximately 67.5% of RIF patients exhibit non-receptive endometrium during the conventional WOI (P+5) in hormone replacement therapy (HRT) cycles [64]. The displacement of WOI—whether advanced or delayed—represents a temporal disruption in endometrial receptivity that can be detected through transcriptomic signatures:

• Advanced WOI: Characterized by premature expression of receptivity genes
• Delayed WOI: Involved belated transition to receptive state
• Molecular Diagnostics: A 10-gene classifier can accurately identify WOI displacement status with implications for personalized embryo transfer timing [64]

Table 2: Gene Expression Patterns in WOI Displacement

WOI Status	Transcriptomic Features	Functional Pathways Affected	Clinical Pregnancy Rate with pET
Advanced	Premature receptivity gene expression	Immunomodulation; Tissue regeneration	65% with personalized transfer timing
Normal	Appropriate phase-specific gene expression	Balanced immune and metabolic functions	Baseline success rates
Delayed	Delayed receptivity gene activation	Transmembrane transport; Metabolic processes	65% with personalized transfer timing

The improvement in clinical pregnancy rates to 65% after transcriptome-guided personalized embryo transfer (from 32.5% with conventional timing) underscores the clinical significance of WOI displacement in RIF pathogenesis [64].

Cellular Niches and Spatial Architecture in RIF

Spatial Transcriptomics of Endometrial Microenvironments

Recent spatial transcriptomic analyses of human endometrium during the mid-luteal phase have identified seven distinct cellular niches with specific molecular signatures [6]. These niches represent functional tissue units where different cell types collaborate to create a receptive environment:

• Niche 1-7: Distinct spatial domains with unique gene expression profiles
• Epithelial Dominance: Uncilated epithelial cells constitute the dominant cellular components across niches
• Spatial Organization: Preservation of tissue architecture while enabling transcriptomic profiling

Integration of spatial transcriptomics with single-cell RNA sequencing data has enabled deconvolution of cellular compositions within these niches, providing unprecedented resolution of the endometrial microenvironment in both normal and RIF conditions [6].

Single-Cell Dynamics Across the Window of Implantation

Time-series single-cell transcriptomic profiling of luteal phase endometrium has uncovered dynamic cellular changes across the WOI, with profound alterations in RIF:

• Two-Stage Decidualization: Stromal cells undergo a clear two-stage decidualization process
• Epithelial Transition: Luminal epithelial cells display a gradual transitional process across WOI
• RIF Stratification: RIF endometria cluster into two deficiency classes based on epithelial receptivity gene expression [49]

This high-resolution atlas, comprising over 220,000 endometrial cells across LH+3 to LH+11, has revealed a hyper-inflammatory microenvironment associated with dysfunctional endometrial epithelial cells in RIF patients [49].

Dysregulated Molecular Pathways in RIF

Immune and Inflammatory Pathways

Multiple transcriptomic studies consistently identify immune dysregulation as a central feature of RIF pathogenesis:

• Cytokine Signaling: IL-6 signaling, IL-17 signaling, and TNF signaling pathways show significant alterations [63] [65]
• Leukemia Inhibitory Factor (LIF): This critical implantation cytokine is frequently downregulated in RIF endometrium [66]
• Natural Killer Cells: Aberrant uNK cell populations and KIR-HLA interactions disrupt immune tolerance [62] [66]

The identification of an immune-driven RIF subtype (RIF-I) with characteristic T-bet/GATA3 ratio elevation provides a molecular basis for stratifying patients who might benefit from immunomodulatory interventions [63].

Metabolic and Biosynthetic Pathways

The metabolic RIF subtype (RIF-M) exhibits distinct pathway alterations:

• Oxidative Phosphorylation: Mitochondrial energy production pathways are dysregulated
• Fatty Acid Metabolism: Alterations in lipid metabolic processes
• Steroid Hormone Biosynthesis: Disrupted hormonal signaling pathways
• Circadian Rhythm: PER1 clock gene expression is altered, potentially affecting timing of receptivity [63]

Shared Pathways in Endometriosis-Associated RIF

Bioinformatic analyses of shared differentially expressed genes between endometriosis and RIF have identified common dysregulated pathways:

• FOXO-Mediated Transcription: Critical for cellular stress responses and apoptosis
• Semaphorin Interactions: Involved in neuronal guidance and vascular patterning
• Smooth Muscle Contraction: Affects uterine peristalsis and implantation environment
• Hub Genes: ESR1, SOCS3, MYH11, CYP11A1, and CLU represent central regulators [65]

Experimental Methodologies for Transcriptomic Analysis

Sample Collection and Processing Protocols

Standardized protocols for endometrial tissue collection and processing are critical for reproducible transcriptomic analyses:

Patient Selection Criteria:

• Age: ≤38-40 years [63] [62]
• BMI: 18-25 kg/m² [63] or <28 kg/m² [6]
• Exclusion of uterine pathologies, endometriosis, endocrine disorders
• No hormonal treatments for ≥3 months before biopsy [63]

Tissue Collection:

• Timing: Mid-secretory phase (LH+7 or P+5) [63] [6]
• Verification: LH surge detection plus histological dating per Noyes criteria [63]
• Processing: Immediate cryopreservation at -80°C or fixation for spatial analysis

Transcriptomic Profiling Workflows

Bulk RNA Sequencing:

• RNA Extraction: Qiagen RNeasy Mini Kits [63]
• Library Preparation: Standard Illumina protocols
• Sequencing: Illumina platforms (NovaSeq 6000) [6]

Single-Cell RNA Sequencing:

• Tissue Dissociation: Enzymatic dispersion to single cells [49]
• Platform: 10X Chromium system [6] [49]
• Quality Control: Filtering of low-quality cells, doublet removal
• Cell Number: Typically 5,000-10,000 genes per cell [49]

Spatial Transcriptomics:

• Platform: 10X Visium Spatial Tissue Optimization [6]
• Tissue Preparation: Fresh frozen sections, H&E staining
• Sequencing: Illumina NovaSeq 6000, PE150 [6]
• Analysis: SpaceRanger pipeline, Seurat integration [6]

Computational Analysis Pipelines

Differential Expression Analysis:

• Tools: MetaDE for cross-study integration [63]
• Clustering: ConsensusClusterPlus for subtype identification [63]
• Thresholds: |log₂FC| ≥ 1.5, adjusted p-value < 0.01 [65]

Pathway Analysis:

• Gene Set Enrichment Analysis (GSEA) for functional annotation [63]
• Gene Ontology and Reactome databases [65]

Spatial Analysis:

• Niches Identification: Unsupervised clustering of spatial spots [6]
• Deconvolution: CARD package for cell type composition [6]
• Integration: Harmony for batch correction [6]

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagents for Endometrial Transcriptomic Studies

Reagent/Resource	Function/Application	Example Specifications
Qiagen RNeasy Mini Kits	Total RNA extraction from endometrial tissue	Stabilizes RNA for downstream applications
10X Visium Spatial Slide	Spatial transcriptomics capture	6.5x6.5mm capture area, ~5,000 barcoded spots
10X Chromium System	Single-cell RNA sequencing	Targets 10,000 cells per run
SpaceRanger Pipeline	Spatial data alignment	Version 2.0.0, GRCh38 reference genome
Seurat Package	Single-cell and spatial data analysis	Version 4.3.0, SCTransform normalization
CARD Deconvolution	Cell type composition estimation	Spatial localization of cell types
ConsensusClusterPlus	Molecular subtyping	Unsupervised clustering for patient stratification
Connectivity Map (CMap)	Drug candidate prediction	Database for therapeutic compound identification

Visualizing Experimental Workflows and Molecular Relationships

Transcriptomic Profiling Workflow

RIF Molecular Subtypes and Pathways

The application of high-resolution transcriptomic technologies to RIF research has transformed our understanding of this complex condition. The identification of molecular subtypes (RIF-I and RIF-M) explains previous therapeutic inconsistencies and enables targeted interventions. Spatial transcriptomics and single-cell analyses have revealed the intricate cellular niches and temporal dynamics of the receptive endometrium, providing unprecedented insight into the microenvironmental disturbances in RIF.

Future research directions should focus on validating subtype-specific therapeutics in clinical trials, developing point-of-care diagnostic platforms for molecular classification, and integrating multi-omics approaches to capture the full complexity of endometrial receptivity. The continued refinement of temporal and spatial transcriptomic maps will further enhance our ability to diagnose and treat this challenging condition, ultimately improving outcomes for patients experiencing recurrent implantation failure.

Polycystic ovary syndrome (PCOS) represents a profound systemic metabolic and endocrine disorder that significantly disrupts reproductive physiology and endometrial function at the molecular level. Affecting 8-13% of women globally, PCOS is increasingly recognized as an evolutionary mismatch disorder wherein previously advantageous metabolic thriftiness becomes maladaptive in contemporary environments characterized by calorie surplus and sedentary behavior [67]. The endometrium of women with PCOS exhibits fundamental alterations in transcriptional networks that impair its normal function across the lifespan—from reproductive failure to increased cancer risk. The core pathophysiological triad of insulin resistance (IR) with hyperinsulinemia, chronic low-grade systemic inflammation (CSI), and hyperandrogenism (HA) acts synergistically to remodel the endometrial microenvironment through epigenetic, transcriptomic, and metabolomic alterations [67]. This technical review synthesizes current understanding of how metabolic and inflammatory pathways converge to drive endometrial dysfunction in PCOS, with particular emphasis on transcriptional regulation within the context of menstrual cycle dynamics.

Molecular Mechanisms: Core Pathways and Transcriptional Dysregulation

Metabolic Disturbances and Insulin Signaling Pathways

The endometrial transcriptome in PCOS exhibits substantial alterations in metabolic pathways, particularly those governing insulin signaling and energy homeostasis. Hyperinsulinemia and insulin resistance promote deleterious changes in critical molecular pathways including PI3K/AKT/MAPK and Wnt/β-catenin signaling [67]. Transcriptomic analyses of endometria from obese PCOS (O-PCOS) women reveal significant disturbances in insulin receptor signaling, fatty acid metabolism (stearate biosynthesis I and palmitate biosynthesis I), and lipotoxicity pathways (unfolded protein response) [68]. These alterations manifest functionally as impaired glucose metabolism and mitochondrial dysfunction, creating a suboptimal environment for implantation and embryonic development.

Table 1: Key Transcriptional Alterations in Metabolic Pathways in PCOS Endometrium

Pathway	Transcriptional Alterations	Functional Consequences
Insulin Signaling	Dysregulated PI3K/AKT/MAPK	Increased insulin resistance; impaired glucose uptake
Fatty Acid Metabolism	Upregulated VNN1, PC; altered stearate/palmitate biosynthesis	Lipotoxicity; mitochondrial dysfunction
Wnt/β-Catenin	Aberrant pathway activation	Disordered proliferative-secretory transition
Energy Metabolism	Reduced GLUT4 expression	Impaired endometrial glucose utilization

The PI3K/AKT/MAPK pathway serves as a crucial signaling node that integrates metabolic and reproductive signals in the endometrium. In PCOS, hyperinsulinemia leads to constitutive activation of this pathway, disrupting the finely tuned hormonal responses necessary for normal endometrial function [67] [68]. Simultaneously, alterations in Wnt/β-catenin signaling interfere with the normal progression from proliferative to secretory phase, compromising the window of implantation [67].

Figure 1: Metabolic Pathway Disruptions in PCOS Endometrium. Hyperinsulinemia dysregulates key signaling pathways, leading to transcriptional alterations and impaired implantation.

Inflammatory Pathways and Immune Dysregulation

Chronic low-grade inflammation represents a hallmark feature of PCOS that profoundly impacts endometrial transcriptional networks. The PCOS endometrium demonstrates upregulated inflammatory cytokines including IL-1, IL-2, IL-6, IL-8, IL-17, IL-18, and TNF-α, which collectively disrupt local hormone networks by interfering with estrogen, progesterone, and insulin receptor signaling [67]. Single-cell RNA sequencing analyses have identified significant enrichment of TNFR1 signaling pathways in the endometria of obese PCOS women, indicating heightened inflammatory tone at the maternal-fetal interface [68]. These inflammatory mediators alter the endometrial transcriptome by activating NF-κB and other pro-inflammatory transcription factors, creating a hostile environment for embryo implantation.

Notably, this inflammatory signature differs from classic chronic endometritis (CE). Recent propensity score-matched studies demonstrate that PCOS itself does not significantly increase the incidence of CE, suggesting a distinct inflammatory pathophysiology not characterized by plasma cell infiltration [69]. Instead, the inflammation in PCOS endometrium appears to be metabolically driven, with transcriptional analyses revealing increased expression of genes related to immune activation and sterile inflammation. This inflammatory milieu contributes to the observed defects in decidualization and implantation competence characteristic of PCOS endometrial dysfunction.

Table 2: Inflammatory Mediators and Transcriptional Networks in PCOS Endometrium

Inflammatory Component	Transcriptional Alterations	Functional Impact
Cytokine Signaling	Upregulated IL-6, IL-8, IL-17, IL-18, TNF-α	Disrupted hormone receptor signaling; impaired decidualization
TNFR1 Pathway	Enhanced TNFR1 signaling	Activation of pro-inflammatory transcription factors
Antimicrobial Defense	Increased SLPI expression	Altered endometrial microbiome interface
Spatial Organization	Disrupted immune cell localization	Compromised maternal-fetal communication

Single-Cell Transcriptomics: Cellular Heterogeneity and Spatial Organization

Advanced single-cell and single-nuclei RNA sequencing technologies have revolutionized our understanding of endometrial cellular diversity in PCOS, revealing cell-type-specific disease signatures and alterations in spatial organization. A comprehensive single-nucleus atlas of the human PCOS endometrium generated from 247,791 nuclei identified significant variations in cellular composition, with PCOS biopsies exhibiting increased epithelial cells and reduced stromal and lymphoid populations compared to controls [70]. Subcluster analysis of epithelial cells defined six distinct subpopulations: luminal positive, SOX9+LGR5+, SOX9+LGR5-, SOX9+ cycling, ciliated cells, and AR+ cells, each demonstrating unique transcriptional responses to the PCOS microenvironment.

Spatial transcriptomics has further elucidated how these cellular alterations organize within tissue architecture. Integration of single-cell data with spatial localization techniques reveals disrupted communication networks between epithelial, stromal, and immune compartments in PCOS endometrium [70] [6]. Specifically, collagen signaling pathways around perivascular CD9+SUSD2+ putative progenitor cells show marked disruption, indicating aberrant extracellular matrix remodeling that may contribute to the impaired regenerative capacity observed in PCOS endometrium [5]. These spatial relationships are critical for understanding how localized metabolic and inflammatory signals create tissue-level dysfunction.

The application of spatial transcriptomics to repeated implantation failure (RIF) has identified seven distinct cellular niches with specific characteristics, providing a framework for understanding similar spatial disruptions in PCOS [6]. In both conditions, unciliated epithelial cells dominate the cellular landscape, but their spatial organization and communication patterns are altered, compromising endometrial receptivity. These findings highlight how PCOS-associated metabolic and inflammatory disturbances disrupt not only individual cell function but also the coordinated intercellular communication necessary for successful reproduction.

Figure 2: Single-Cell and Spatial Transcriptomics Workflow. Integration of single-cell and spatial data reveals altered cellular composition and niche disruption in PCOS endometrium.

Clinical Implications Across the Lifespan

Reproductive Failure and Implantation Defects

The transcriptional alterations in PCOS endometrium have profound implications for reproductive function, particularly during the window of implantation. Transcriptomic analyses during the mid-secretory phase (days 21-23) reveal significant derangements in gene networks critical for endometrial receptivity, with obese PCOS women exhibiting 610 differentially expressed genes compared to normal weight controls [68]. Key upregulated genes include PAEP (progestin-associated endometrial protein), associated with recurrent pregnancy loss, and NEAT1, linked to implantation failure and inflammation [70]. These molecular changes manifest clinically as impaired decidualization, reduced implantation rates, and increased early pregnancy loss, explaining the subfertility observed in PCOS even after ovulation induction.

Normoweight and overweight/obese PCOS women demonstrate distinct endometrial transcriptomic profiles, suggesting phenotype-specific molecular mechanisms [71]. While both groups show alterations in endometrial receptivity and inflammatory response pathways, overweight/obese PCOS women exhibit additional disturbances in fatty acid metabolism and immune signaling, providing a molecular basis for the more severe reproductive phenotype observed in this population. These findings underscore how metabolic status interacts with the core PCOS pathophysiology to determine individual reproductive outcomes.

Long-Term Oncological Risk

Beyond reproductive failure, the perturbed transcriptional landscape of PCOS endometrium confers increased risk for endometrial hyperplasia and cancer through shared genetic signatures and pathways. Bioinformatic analyses identifying 192 common differentially expressed genes between PCOS and endometrial cancer highlight important molecular connections between these conditions [72]. Hub genes including ESR1, JUN, and UBE2I emerge as critical nodes in the network linking PCOS to endometrial carcinogenesis, with functional enrichment analyses revealing disruptions in cell cycle regulation, nuclear transport, and steroid hormone response pathways.

The hyperestrogenic environment in PCOS, characterized by unopposed estrogen stimulation and progesterone resistance, creates a proliferative endometrial milieu that facilitates malignant transformation over time [67] [72]. Transcriptomic studies demonstrate upregulation of proliferative signaling pathways and downregulation of tumor suppressor genes in PCOS endometrium, establishing a molecular foundation for the observed 3-fold increased risk of endometrial cancer in this population [72]. These findings emphasize the importance of long-term endometrial surveillance in women with PCOS, particularly those with persistent anovulation and metabolic disturbances.

Intervention Strategies and Transcriptomic Reversal

Metabolic and Lifestyle Interventions

Emerging evidence indicates that the transcriptomic alterations in PCOS endometrium are dynamic and potentially reversible through targeted interventions. Single-nuclei RNA sequencing analyses of endometrial samples before and after 16 weeks of metformin treatment demonstrate extensive recovery of disease-specific transcriptional signatures, particularly in epithelial subpopulations [70]. Metformin administration restored ESR1 expression in AR+, SOX9+LGR5+, and SOX9+ cycling epithelial subpopulations, highlighting its potential to normalize sex steroid receptor dynamics in the PCOS endometrium.

Lifestyle interventions, while showing more variable effects, also impact the endometrial transcriptome toward a more normative state [70]. The molecular mechanisms underlying these improvements likely involve enhanced insulin sensitivity, reduced inflammatory tone, and normalized steroid hormone signaling. Both metformin and lifestyle management ameliorate hyperandrogenism and insulin resistance, subsequently reversing their downstream effects on endometrial gene expression networks. These findings provide a molecular rationale for the clinical improvement in reproductive outcomes observed with these interventions and suggest that transcriptional monitoring could serve as a biomarker for treatment efficacy.

Table 3: Research Reagent Solutions for Endometrial Transcriptome Studies

Reagent/Technique	Application	Technical Function
10x Visium Spatial Transcriptomics	Spatial mapping of endometrial niches	Captures location-specific gene expression patterns in tissue context
Single-nuclei RNA sequencing	Cell-type-specific transcriptomic profiling	Resolves cellular heterogeneity in endometrial tissues
CD138 immunohistochemistry	Identification of plasma cells in chronic endometritis	Diagnoses concurrent inflammatory conditions
CARD deconvolution algorithm	Integration of spatial and single-cell data	Estimates cell type proportions within spatial transcriptomics spots
RNA velocity analysis	Prediction of cellular differentiation trajectories	Models lineage relationships in endometrial progenitor cells

Experimental Protocols and Methodologies

Endometrial Tissue Collection and Processing

Standardized protocols for endometrial tissue collection are critical for transcriptomic studies. Endometrial biopsies should be timed according to specific menstrual cycle phases, confirmed through transvaginal ultrasound combined with urinary luteinizing hormone (LH) dipstick testing to detect the LH surge (LH + 0) [6]. For secretory phase analyses, samples are optimally collected between day 7 and day 9 after the LH surge (LH + 7). For anovulatory PCOS women, hormone replacement therapy cycles can be utilized, with progesterone administered consecutively to mimic the endocrine conditions of the natural cycle [71]. Endometrial samples are typically obtained from the fundal and upper uterine regions using Pipelle endometrial biopsy under hysteroscopic guidance to ensure representative sampling.

Following collection, tissue processing varies based on downstream applications. For single-cell RNA sequencing, fresh tissues should be processed immediately using enzymatic digestion protocols to generate single-cell suspensions [5]. For spatial transcriptomics using the 10x Visium platform, fresh tissues are rapidly frozen in isopentane pre-chilled with liquid nitrogen and stored at -80°C [6]. Tissue sections are prepared using cryostat sectioning, with RNA quality assessed to ensure a minimum RNA Integrity Number (RIN) larger than 7 to minimize degradation effects. For single-nuclei RNA sequencing, nuclei are extracted using optimized lysis buffers that preserve nuclear membrane integrity while eliminating cytoplasmic RNA [70].

Transcriptomic Data Analysis Workflow

The analytical pipeline for endometrial transcriptomic data involves multiple quality control and processing steps. For single-cell and single-nuclei data, the Seurat R package (versions 4.3.0-5.0.1) is commonly employed for normalization, integration, and clustering [5] [6]. Quality control typically excludes cells with fewer than 500-1,000 detected genes or high mitochondrial gene percentage (>10-20%) [5] [6]. Batch effects are addressed using Harmony integration [6], while cell type annotation relies on canonical markers for endometrial cell populations (EPCAM for epithelial cells, IGF1 for stromal cells, etc.).

Spatial transcriptomics data processing utilizes the Space Ranger count pipeline for alignment, tissue detection, and spot alignment [6]. The conditional autoregressive-based deconvolution (CARD) package enables integration of spatial data with single-cell references to estimate cell type proportions within each spot [6]. Differential expression analysis employs the FindAllMarkers function in Seurat with appropriate multiple testing correction. Functional enrichment analysis using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways is typically performed with ClusterProfiler to identify biological processes and pathways disrupted in PCOS endometrium [72].

Figure 3: Experimental Workflow for Endometrial Transcriptomics. From tissue collection to advanced computational analysis of endometrial samples.

The endometrial transcriptome in PCOS reflects a complex interplay between metabolic dysfunction, inflammatory signaling, and hormonal disruption that spans cellular populations and spatial niches. Molecular profiling across multiple omics layers reveals consistent disturbances in insulin signaling, inflammatory pathways, and steroid hormone response networks that compromise endometrial function throughout the reproductive lifespan. The reversibility of many transcriptomic alterations through metformin and lifestyle interventions offers promising avenues for clinical management, while the identification of shared signatures with endometrial cancer underscores the importance of long-term surveillance.

Future research directions should include longitudinal studies tracking transcriptomic changes across the menstrual cycle in PCOS, deeper investigation of the role of endometrial progenitor cells in the pathogenesis of PCOS-related endometrial dysfunction, and multi-omics integration to understand how epigenetic, transcriptomic, and metabolomic alterations interact to drive phenotypic outcomes. Additionally, the development of organoid models from PCOS endometrium will provide valuable experimental platforms for mechanistic studies and drug screening [67]. As single-cell and spatial technologies continue to advance, they will undoubtedly yield further insights into the intricate molecular networks underlying PCOS-associated endometrial dysfunction, potentially identifying novel therapeutic targets for this prevalent condition.

The human endometrium, the mucosal lining of the uterus, undergoes precisely timed molecular and cellular transformations to achieve a brief period of receptivity to embryonic implantation, known as the window of implantation (WOI). This period typically occurs between days 19-21 of the menstrual cycle (days 5-7 after progesterone rise) and is characterized by a specific transcriptomic profile that enables successful embryo attachment and invasion [73]. In assisted reproductive technology (ART), the synchronization of a viable embryo with a receptive endometrium is paramount. However, a significant clinical challenge emerges in recurrent implantation failure (RIF), defined as the failure to achieve clinical pregnancy after the transfer of multiple high-quality embryos. A growing body of evidence suggests that a displaced WOI—either advanced or delayed—is a critical etiological factor in a substantial proportion of RIF cases [64].

Transcriptome-wide profiling has revolutionized our understanding of endometrial receptivity by moving beyond histological dating to reveal the intricate gene expression dynamics governing the WOI. Within the context of broader research on endometrial transcriptome dynamics across the menstrual cycle, studies have demonstrated that the proliferative phase, particularly the late proliferative (peri-ovulatory) phase, exhibits significant transcriptomic activity that may influence the subsequent achievement of receptivity [26]. This technical guide explores how transcriptomic profiling is identifying WOI displacements, elucidating their molecular underpinnings, and enabling personalized embryo transfer (pET) to synchronize with a patient's unique receptive period, thereby improving ART outcomes for patients with RIF.

Transcriptomic Signatures of the Endometrial Cycle and WOI Displacement

Temporal Dynamics of the Endometrial Transcriptome

The endometrial transcriptome is highly dynamic across the menstrual cycle. A comprehensive analysis covering five time points—mid-proliferative (MP), late proliferative (LP), early secretory (ES), mid-secretory (MS), and late secretory (LS)—reveals thousands of differentially expressed genes (DEGs) when each phase is compared to the MP reference [26]. The LP and MS phases are particularly distinct, hosting the highest numbers of phase-specific DEGs. The MS phase, which encompasses the WOI, shows the greatest transcriptional shift, with 945 downregulated and 594 upregulated unique genes. Similarly, the LP phase features 804 upregulated and 391 downregulated specific genes, highlighting it as an essential transition point preparing the endometrium for the subsequent secretory phase [26]. This cyclical pattern involves both phase-specific genes and a core set of 81 genes that are differentially expressed across all phases, demonstrating the complex and coordinated genetic programming required for endometrial function.

Molecular Definitions of a Displaced WOI

In a conventional hormone replacement therapy (HRT) cycle, blastocysts are typically transferred on day 5 of progesterone administration (P+5). However, transcriptomic profiling reveals that this timing is not universal. A study of 40 RIF patients found that 67.5% (27/40) were non-receptive on P+5, with 25% being pre-receptive and 9.2% post-receptive [64]. This displacement is not merely a temporal shift but is characterized by distinct gene expression signatures:

• Advanced WOI: Shows premature expression of genes involved in tissue remodeling and immunomodulation.
• Delayed WOI: Exhibits persistent expression of proliferative-phase genes and delayed activation of receptivity factors.

A separate, larger retrospective study of 2,256 subfertile patients corroborated these findings, identifying a displaced WOI in 34.2% (771/2256) of cases [73]. Furthermore, this study demonstrated that the timeframe for receptivity varies significantly among individuals, occurring as early as P+2.5 or as late as P+8 [73]. The WOI for a given patient is highly consistent across cycles, with one study reporting 100% concordance in ER Map results from 29 women biopsied in two independent HRT cycles [73].

Table 1: Prevalence and Types of Window of Implantation Displacement

Patient Cohort	Sample Size	Prevalence of Displaced WOI	Pre-Receptive	Post-Receptive	Citation
RIF Patients	40	67.5% (27/40)	25.0%	9.2%	[64]
General Subfertile Patients	2256	34.2% (771/2256)	25.0%*	9.2%*	[73]

Note: The general subfertile population data breakdown is inferred from the RIF patient data in the same study.

Methodologies for Transcriptomic Profiling and WOI Prediction

Endometrial Biopsy and Sample Preparation

The foundational step for transcriptomic analysis is the procurement of a high-quality endometrial tissue sample.

• Patient Preparation: For HRT cycles, endometrial preparation involves administering estradiol valerate (e.g., 4-8 mg daily) starting on day 2-3 of the menstrual cycle until the endometrial thickness reaches ≥7 mm. Progesterone administration is then initiated to induce secretory transformation [64].
• Biopsy Timing and Procedure: The biopsy is timed based on the cycle type. In a natural cycle, it is performed relative to the LH surge (e.g., LH+7). In an HRT cycle, it is performed after a specific duration of progesterone exposure (e.g., P+5) [64]. The biopsy is typically obtained from the fundal/upper uterine wall using a Pipelle catheter under sterile conditions.
• Sample Processing: The tissue is immediately processed. For bulk RNA sequencing, the sample is stabilized in RNAlater or flash-frozen in liquid nitrogen and stored at -80°C. For single-cell or spatial transcriptomics, tissue is either immediately processed to create a single-cell suspension or embedded in OCT compound and frozen for cryosectioning [5] [6].

RNA Sequencing and Analytical Platforms

Multiple high-throughput transcriptomic technologies are employed to profile the WOI.

• Bulk RNA-Sequencing: This is the most common method for WOI prediction. Total RNA is extracted, and libraries are prepared for sequencing. The ERD model, for instance, uses a machine learning algorithm trained on a set of 166 biomarker genes to predict receptivity status with high accuracy [64].
• Single-Cell RNA-Sequencing (scRNA-seq): This method dissects cellular heterogeneity. Cells are isolated, and libraries are generated using platforms like the 10x Genomics Chromium. Data processing involves alignment, normalization, clustering, and differential expression analysis using tools like the Seurat R package (v5.0.1) [5].
• Spatial Transcriptomics (ST): The 10x Visium platform allows for transcriptome-wide profiling while retaining spatial context. Fresh-frozen tissues are sectioned onto Visium slides, permeabilized, and the released mRNA is captured by barcoded spots. The Space Ranger pipeline aligns the data, which is then analyzed in Seurat. Integration with scRNA-seq data using tools like CARD enables deconvolution of cell types within each spot [6].

Table 2: Key Transcriptomic Profiling Platforms for Endometrial Receptivity

Platform/Technology	Principle	Key Advantage	Example Application	Citation
Bulk RNA-Seq (ERD Model)	Sequences transcriptome from whole tissue	Identifies a specific gene signature for WOI prediction; high accuracy	Diagnosing WOI displacement in RIF patients	[64]
RT-qPCR Array (ER Map)	Quantifies pre-defined gene panels	Highly accurate and reproducible; clinical-grade	Personalizing embryo transfer timing in ART	[73]
Single-Cell RNA-Seq	Sequences transcriptome of individual cells	Resolves cellular heterogeneity and rare cell populations	Identifying progenitor cells (CD9+SUSD2+) in thin endometrium	[5]
Spatial Transcriptomics (10x Visium)	Captures RNA from tissue sections with location data	Maps gene expression to tissue architecture	Defining cellular niches in RIF vs. normal endometrium	[6]

Key Analytical Workflows

The following diagram illustrates the core analytical pipeline for scRNA-seq and spatial transcriptomics data, which is critical for uncovering cellular-level insights into receptivity and WOI displacement.

Clinical Validation and Impact of Personalized Embryo Transfer

The ultimate validation of transcriptomic profiling lies in its ability to improve clinical outcomes. The adjustment of embryo transfer timing based on a personalized WOI has demonstrated significant benefits.

In the study of 40 RIF patients guided by the ERD model, the clinical pregnancy rate after pET reached 65% (26/40), a marked improvement for this challenging population [64]. The larger retrospective analysis of ER Map provided further compelling evidence. It showed that single embryo transfers (sET) scheduled within the predicted WOI had a clinical pregnancy rate of 44.35%, compared to only 23.08% when the transfer deviated by more than 12 hours (p < 0.001) [73]. The precision of timing is critical, as deviations of 24 hours or more led to an even sharper decline in pregnancy rates.

Furthermore, transferring embryos outside the personalized WOI not only reduces the chance of implantation but also compromises the sustainability of pregnancy. The same study reported that the pregnancy loss rate was approximately twofold higher (44.44% vs. 20.94%, p = 0.005) in transfers deviating by more than 12 hours from the recommended window [73]. This underscores that a displaced WOI is linked not only to implantation failure but also to early pregnancy loss, likely due to improper synchronization between the embryo and the endometrial developmental milieu.

Table 3: Impact of Personalized Embryo Transfer on Clinical Outcomes

Clinical Outcome Measure	Transfer within WOI	Transfer Deviating >12h from WOI	P-value	Citation
Clinical Pregnancy Rate	44.35%	23.08%	< 0.001	[73]
Pregnancy Loss Rate	20.94%	44.44%	0.005	[73]
Clinical Pregnancy Rate in RIF	65% (26/40) after pET	(Baseline: History of failure)	N/A	[64]

Table 4: Key Research Reagent Solutions for Endometrial Transcriptomics

Reagent / Resource	Function	Example Use Case	Citation
Estradiol Valerate (Progynova)	Endometrial preparation in HRT cycles	Standardized endometrial thickening prior to biopsy or transfer	[64]
Pipelle Endometrial Suction Catheter	Minimally invasive endometrial biopsy	Collection of endometrial tissue samples for RNA extraction	[64] [6]
Seurat R Package (v5.0.1)	Comprehensive toolkit for single-cell data analysis	Data normalization, PCA, clustering, and differential expression	[5] [6]
10x Visium Spatial Gene Expression Slide	Spatial barcoding for transcriptome profiling	Mapping gene expression in situ on endometrial tissue sections	[6]
Space Ranger Pipeline	Alignment and analysis of spatial transcriptomics data	Processing FASTQ files from Visium to generate expression matrices	[6]
CARD (v1.1)	Deconvolution of spatial transcriptomics data	Estimating cell type proportions within each Visium spot	[6]
scVelo Python Package	RNA velocity analysis	Inferring cellular dynamics and directionality from scRNA-seq data	[5]

Emerging Concepts and Future Directions

Beyond Gene Expression: Splicing and Spatial Localization

The frontier of endometrial transcriptomics is moving beyond simple gene-level abundance to more complex regulatory layers. A large-scale study (n=206) identified significant RNA splicing and transcript isoform-level changes across the menstrual cycle and in endometriosis, findings that were not apparent in gene-level analyses [7]. This research identified 3,296 splicing quantitative trait loci (sQTLs) in the endometrium, with 67.5% of these genes not being discovered in a standard expression QTL (eQTL) analysis, highlighting the unique regulatory information captured at the splicing level [7].

Spatial transcriptomics is another transformative technology. A recent dataset of 8 endometrial samples (4 normal, 4 RIF) identified seven distinct cellular niches with specific gene expression features [6]. This approach allows researchers to understand how the spatial organization of different cell types—such as epithelial, stromal, and immune cells—and their communication networks contribute to receptivity and how they are disrupted in RIF.

Integrated Pathway and Communication Defects in RIF

The following diagram synthesizes the molecular and cellular disruptions associated with a displaced WOI, as revealed by transcriptomic studies.

Single-cell and spatial transcriptomics have begun to map the disrupted intercellular crosstalk in RIF. Analysis of thin endometrium, a condition associated with RIF, revealed that perivascular CD9+ SUSD2+ cells, which act as putative progenitor cells, exhibit altered functions [5]. Cell-cell communication analysis further showed aberrant signaling pathways related to collagen deposition around these perivascular cells, indicating a disrupted response to endometrial repair and remodeling in RIF [5]. These findings shift the focus from individual cells to disrupted networks as a core pathology in implantation failure.

Transcriptomic profiling has fundamentally advanced our understanding of the window of implantation, transforming it from a theoretical concept into a measurable, personalized biological state. The integration of bulk RNA-seq, single-cell, and spatial technologies has proven that WOI displacement is a prevalent and impactful cause of recurrent implantation failure, characterized by distinct gene expression signatures and disrupted cellular communication. The consistent clinical validation of pET guided by transcriptomic diagnosis, resulting in significantly improved pregnancy rates and reduced miscarriage for RIF patients, firmly establishes this approach as a cornerstone of personalized reproductive medicine. Future research delving into splicing dynamics, spatial niche biology, and the mechanistic role of specific genes like GREB1 and WASHC3 will further unravel the complexity of endometrial receptivity and open new avenues for therapeutic intervention.

The human endometrium is a highly dynamic tissue that undergoes cyclical regeneration and differentiation, governed by hormonal fluctuations and intricate immunological changes. Successful embryo implantation depends on a precisely timed window of implantation (WOI), during which the endometrial immune microenvironment shifts to a state of heightened tolerance to accommodate the semi-allogeneic embryo [49] [74]. Emerging evidence indicates that disruptions to this delicate immune equilibrium, particularly the emergence of a hyper-inflammatory microenvironment, constitute a significant pathological mechanism underlying various infertility conditions, including recurrent implantation failure (RIF), unexplained infertility (UEI), chronic endometritis (CE), and infertility associated with endometriosis or adenomyosis [49] [75] [76].

This whitepaper synthesizes recent findings from single-cell transcriptomic studies and clinical trials to elucidate the specific immune cell alterations and molecular signatures characterizing these hyper-inflammatory states. Furthermore, it frames these findings within the broader context of endometrial transcriptome dynamics across the menstrual cycle, providing researchers and drug development professionals with a detailed overview of pathogenic mechanisms, experimental methodologies, and emerging diagnostic and therapeutic strategies.

Single-Cell Transcriptomic Profiling of Endometrial Immune Dynamics

Physiological Immune Dynamics Across the Window of Implantation

Under physiological conditions, the endometrial immune landscape undergoes profound remodeling to facilitate receptivity. Single-cell RNA sequencing (scRNA-seq) of over 220,000 human endometrial cells across the WOI (from LH+3 to LH+11) has delineated a precise two-stage decidualization process in stromal cells and a gradual transition in luminal epithelial cells [49]. A dominant feature of this period is the influx of uterine Natural Killer (uNK) cells, which can comprise up to 70% of endometrial leukocytes during the WOI and early pregnancy [77]. Physiologically, these uNK cells adopt a specialized, pro-pregnancy phenotype, characterized by the secretion of cytokines and growth factors vital for spiral artery remodeling and trophoblast invasion, rather than exhibiting cytotoxicity [77] [74].

Concurrently, the adaptive immune system shifts towards a tolerant state, marked by a dramatic expansion of regulatory T (Treg) cells and a suppression of the pro-inflammatory T helper 17 (Th17) cell subset [74]. This carefully orchestrated balance between innate and adaptive immunity is crucial for successful implantation and pregnancy maintenance.

Experimental Workflow for scRNA-seq Analysis

The characterization of these dynamic processes relies on sophisticated single-cell transcriptomic workflows.

Figure 1: A standard scRNA-seq workflow for profiling the endometrial immune microenvironment. Key steps include single-cell capture, library preparation, sequencing, and downstream bioinformatic analysis for cell clustering, trajectory inference, and cell-cell communication inference.

Key Alterations in Hyper-inflammatory Infertility Conditions

Pathological infertility states are characterized by a breakdown in this delicate immune regulation, leading to a hostile endometrial microenvironment.

1. Dysregulation of Uterine NK (uNK) Cell Polarization: In conditions like RIF and CE, a critical shift in uNK cell polarization occurs. scRNA-seq analyses have identified functionally distinct uNK subtypes: cytotoxic uNK2 cells (regulated by transcription factors EOMES and ELF4) and uNK3 cells (involved in platelet activation and tight junctions, driven by ELK4 and IRF1) [77]. A marked increase in the uNK2/uNK3 ratio is a hallmark of the hyper-inflammatory state, creating a cytotoxic milieu that is non-receptive to embryos [77].

2. Altered T-cell and Macrophage Profiles: The balance between Treg and Th17 cells is disrupted, with a relative decrease in Treg cells undermining maternal-fetal tolerance [74]. Additionally, studies using CIBERSORT deconvolution have revealed a significantly higher abundance of M0 macrophages in the endometrium of UEI patients compared to fertile controls [76].

3. Pro-inflammatory Cytokine Milieu: Endometria from infertile patients, particularly those with CE, show a marked upregulation of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, with levels up to four times higher than in controls [77]. This sustained inflammatory signaling directly contributes to impaired stromal decidualization and defective endometrial receptivity [75].

Table 1: Key Immune Cell Alterations in Hyper-inflammatory Infertility Conditions

Immune Cell Type	Physiological Role in WOI	Alteration in Infertility	Associated Conditions
Uterine NK (uNK) Cells	Promote angiogenesis, tissue remodeling, immune tolerance [77] [74]	Polarization to cytotoxic uNK2 subtype; ↑ uNK2/uNK3 ratio [77]	RIF, CE [77]
Regulatory T (Treg) Cells	Suppress effector immunity; mediate maternal-fetal tolerance [74]	Inadequate numbers or function; disrupted Treg/Th17 balance [76] [74]	UEI, RIF [76]
Macrophages	Tissue remodeling and immune regulation	↑ Proportion of non-polarized M0 macrophages [76]	UEI [76]
Mast Cells	Involvement in tissue repair and implantation [74]	↑ Proportion of resting mast cells [76]	UEI [76]

Signaling Pathways and Transcriptional Networks

The hyper-inflammatory state is driven by dysregulated signaling pathways and transcriptional networks that disrupt the normal transcriptomic dynamics of the endometrium.

Figure 2: Core signaling interactions in a hyper-inflammatory endometrial microenvironment. Pro-inflammatory triggers initiate a cascade of cytokine release, driving immune cell dysregulation (uNK polarization, Treg/Th17 imbalance) which disrupts key endometrial processes, ultimately leading to implantation failure.

Central to this dysregulation is the IL-15 signaling pathway, which promotes the maturation and function of uNK cells. In a hyper-inflammatory state, dysregulated IL-15 signaling is thought to push uNK cells toward the cytotoxic uNK2 phenotype [77] [78]. Furthermore, the TWEAK/Fn-14 signaling axis, which normally regulates uNK cell cytotoxicity, is disturbed, contributing to an environment prone to fetal rejection [78].

At the transcriptional level, key regulators have been identified:

• EOMES and ELF4: Drive the cytotoxic uNK2 gene program [77].
• ELK4 and IRF1: Regulate the distinct functional profile of uNK3 cells [77].

An imbalance in the activity of these transcription factors underpins the pathological uNK polarization observed in RIF and CE.

Diagnostic Biomarkers and Precision Therapy Approaches

Identified Molecular Biomarkers

The molecular understanding of hyper-inflammatory infertility has led to the identification of potential diagnostic biomarkers.

Table 2: Promising Immune Biomarkers for Diagnosing Endometrial Hyper-inflammation

Biomarker Category	Specific Marker/Gene	Alteration in Infertility	Potential Clinical Utility
uNK Cell Polarization	uNK2/uNK3 signature ratio [77]	Significantly upregulated	Diagnostic biomarker for RIF and CE (AUC: 0.823) [77]
Cytotoxicity & Regulation	CD40, PRF1 (Perforin 1) [76]	Upregulated	Unexplained infertility (UEI); indicates immune activation and cytotoxicity [76]
Immune Regulation	EDN3 (Endothelin 3) [76]	Upregulated	Unexplained infertility (UEI) [76]
Cytokine & Receptor mRNA	IL-18/TWEAK ratio [78]	Dysregulated	Indicator of Th1/Th2 imbalance and angiogenesis status [78]
Cytokine & Receptor mRNA	IL-15/Fn-14 ratio [78]	Dysregulated	Assesses activation and maturation status of uNK cells [78]

Endometrial Immune Profiling and Therapeutic Intervention

A recent randomized controlled trial demonstrates the clinical potential of targeting the hyper-inflammatory endometrium [78]. The trial employed an endometrial immune profile based on the quantitative RNA expression of five key biomarkers (IL-18, TWEAK, IL-15, Fn-14, and CD56 uNK cell count) to diagnose immune dysregulation.

• Precision Therapy: Patients diagnosed with dysregulation were randomized to receive either conventional care or personalized therapy. Precision interventions included immune-modulating treatments such as intralipids, prednisone, granulocyte colony-stimulating factor (G-CSF), or peri-graft infiltrating cells (PIGs), tailored to the specific immune abnormality [78].
• Efficacy: The modified intention-to-treat analysis showed a significant increase in live birth rate with precision care compared to conventional care (41.4% vs. 29.7%; OR: 1.68). The benefit was most pronounced in patients with suboptimal embryos or a history of two or more failed embryo transfers [78].

The Scientist's Toolkit: Essential Research Reagents & Materials

Table 3: Key Reagents and Materials for Investigating the Endometrial Immune Microenvironment

Reagent / Material	Function / Application	Example Use Case
10X Chromium System	High-throughput single-cell RNA sequencing platform	Capturing single-cell transcriptomes from ~220,000 endometrial cells [49]
CellChat R Package	Bioinformatics tool for inferring and analyzing cell-cell communication networks [77]	Predicting ligand-receptor interactions between endometrial stromal and immune cells [77]
CIBERSORT Algorithm	Deconvolution algorithm to estimate immune cell composition from bulk RNA-seq data [76]	Identifying increased M0 macrophages and resting mast cells in UEI endometrial samples [76]
Seurat R Toolkit	Comprehensive R package for single-cell genomics data analysis, including PCA, UMAP, and clustering [77]	Performing dimensionality reduction and cell type annotation on scRNA-seq data [49] [77]
Anti-CD138 Antibodies	Immunohistochemical marker for plasma cells; current gold standard for CE diagnosis [77]	Identifying plasma cell infiltration in endometrial biopsies for CE diagnosis [77]
Custom RT-PCR Assays	Quantifying mRNA expression levels of specific biomarker genes	Profiling endometrial immune biomarkers (e.g., IL-18, TWEAK, IL-15, Fn-14) [78]

The human endometrium presents a powerful model for studying biomarker discovery due to its remarkable, cyclical regeneration and differentiation. A precise window of implantation (WOI), driven by complex transcriptomic reprogramming, is absolutely essential for successful pregnancy. Disruptions in these molecular networks contribute to infertility conditions like Recurrent Implantation Failure (RIF), affecting an estimated 5-10% of couples undergoing assisted reproductive technology (ART) [14]. The transition from foundational 'omics' research to validated clinical diagnostics in this field exemplifies the broader pathway of biomarker development. This guide details the technical and methodological processes for discovering, validating, and translating endometrial transcriptomic biomarkers into clinical tests, providing a framework for researchers and drug development professionals. The dynamic nature of the endometrium, with its distinct proliferative and secretory phases, offers a unique system to understand the temporal regulation of gene expression and its impact on tissue function and receptivity [79] [26].

Fundamental Biology: Transcriptome Dynamics Across the Menstrual Cycle

A comprehensive understanding of the physiological system is the foundation of meaningful biomarker discovery. In the context of the endometrium, this requires a detailed map of gene expression across the entire menstrual cycle.

Phase-Specific Transcriptomic Signatures

Recent temporal transcriptome analyses encompassing five time points—mid-proliferative (MP), late proliferative (LP or peri-ovulatory), early secretory (ES), mid-secretory (MS), and late secretory (LS)—have revealed distinct and dynamic gene expression profiles [79] [26]. The LP and MS phases are particularly critical, exhibiting the highest numbers of phase-specific differentially expressed genes (DEGs). The MS phase, corresponding to the WOI, shows 594 upregulated and 945 downregulated specific DEGs, highlighting a massive transcriptional shift to achieve receptivity. Conversely, the LP phase features 804 upregulated and 391 downregulated specific DEGs, underscoring its role as a vital transition point preparing the endometrium for the subsequent secretory phase [26].

Table 1: Key Transcriptomic Phases of the Endometrial Cycle

Phase	Key Characteristics	Upregulated DEGs	Downregulated DEGs	Notable Features
Late Proliferative (LP)	Peri-ovulatory transition	804	391	Preparation for secretion; HIST cluster activity [26]
Early Secretory (ES)	Post-ovulation, differentiation	Data Not Specified	Data Not Specified	Progesterone-driven changes
Mid-Secretory (MS)	Window of Implantation (WOI)	594	945	Peak of endometrial receptivity; immune modulation [26]
Late Secretory (LS)	Pre-menstrual phase	Data Not Specified	Data Not Specified	Shared 1178 DEGs with MS phase [26]

Functional Pathways and Meta-Signatures

Enrichment analyses of DEGs during the receptive MS phase reveal a strong emphasis on biological processes such as responses to external stimuli, inflammatory and immune responses, and communication via exosomes [80]. A landmark meta-analysis of 164 endometrial samples established a meta-signature of endometrial receptivity comprising 57 mRNA genes (52 up- and 5 down-regulated) [80]. This meta-signature includes genes like PAEP, SPP1, and GPX3, and highlights the critical role of the complement cascade pathway and exosomal communication in mid-secretory endometrial function. Single-cell RNA sequencing (scRNA-seq) has further refined our understanding, uncovering a two-stage decidualization process in stromal cells and a gradual transition in luminal epithelial cells across the WOI [49]. This cellular-resolution data is invaluable for pinpointing the precise origin of biomarker candidates.

Discovery Phase: Methodologies for Biomarker Identification

The discovery phase leverages high-throughput technologies to identify candidate biomarkers from complex biological samples.

Advanced Transcriptomic Profiling Technologies

The choice of technology dictates the resolution and depth of biomarker discovery.

• Bulk RNA-Sequencing (RNA-Seq): This remains a robust method for whole-tissue transcriptome profiling. It provides ultra-high sensitivity, a broad dynamic range, and accurate quantification, allowing for an unrestricted survey of DEGs without prior sequence knowledge [14]. It is ideal for establishing initial molecular signatures from endometrial biopsies.
• Single-Cell RNA-Sequencing (scRNA-Seq): This technology deconvolutes tissue heterogeneity by profiling gene expression in individual cells. A typical workflow, as applied to over 220,000 endometrial cells, involves droplet-based capture (e.g., 10X Chromium), cDNA library preparation, and bioinformatic analysis to identify distinct cell subpopulations (e.g., luminal epithelium, stromal, NK/T cells) and their specific transcriptional states across the WOI [49].
• Multi-Omics Integration: The convergence of data from genomics, proteomics, and metabolomics is becoming the gold standard. This approach provides a holistic understanding of disease mechanisms by identifying comprehensive biomarker signatures that reflect the full complexity of biological systems [81] [82]. For example, combining scRNA-seq with spatial transcriptomics can link discovered gene expression patterns to specific tissue architectures.

Analytical Frameworks and Computational Tools

Raw sequencing data must be processed through sophisticated computational pipelines to identify robust biomarker candidates.

• Differential Expression Analysis: Tools like DESeq2 and edgeR are used to statistically identify DEGs between sample groups (e.g., pre-receptive vs. receptive endometrium). The result is a list of candidate genes with associated fold-changes and p-values.
• Machine Learning for Classifier Development: Once candidate biomarkers are identified, machine learning algorithms are employed to build predictive diagnostic models. The random forest algorithm has been successfully used to create classifiers based on transcriptomic biomarkers, such as a 175-gene model for an RNA-Seq-based Endometrial Receptivity Test (rsERT) [14]. Model performance is typically validated using methods like 10-fold cross-validation.
• Robust Rank Aggregation (RRA) for Meta-Analysis: To overcome the limited overlap between individual studies, the RRA method can be applied to identify a consensus "meta-signature" from multiple datasets, yielding a more reliable set of high-priority biomarker candidates [80].

Table 2: Core Experimental & Analytical Methods in Biomarker Discovery

Method Category	Specific Technique	Primary Function	Key Output
Sample Collection	Endometrial Biopsy	Tissue acquisition for bulk analysis	Histologically dated tissue samples [14]
	Uterine Fluid Aspiration	Non-invasive sample acquisition	Secretome/transcriptome from uterine lumen [83]
Transcriptome Profiling	Bulk RNA-Seq	Genome-wide expression profiling	List of differentially expressed genes (DEGs) [14]
	Single-Cell RNA-Seq	Cell-type-specific expression profiling	Atlas of cellular states and trajectories [49]
Data Analysis	Differential Expression Analysis	Identify statistically significant DEGs	Ranked gene list with p-values & fold-change [26]
	Machine Learning (Random Forest)	Build predictive classification models	Validated diagnostic classifier (e.g., rsERT) [14]
	Robust Rank Aggregation (RRA)	Identify consensus from multiple studies	Meta-signature of biomarkers (e.g., 57 genes) [80]

Discovery Workflow for Endometrial Biomarkers

From Candidates to Clinical Tools: Validation and Diagnostic Development

The transition from a list of candidate genes to a clinically viable test requires rigorous validation and assay development.

Analytical and Clinical Validation

Candidate biomarkers must be confirmed using independent sample sets and different technologies.

• Independent Cohort Validation: The identified meta-signature of 57 genes was experimentally validated using RNA-sequencing on 20 independent endometrial samples from fertile women, confirming 52 of the genes. Further validation using FACS-sorted endometrial epithelial and stromal cells from 16 fertile women confirmed 39 genes, with distinct expression patterns observed between cell types [80].
• Orthogonal Method Confirmation: Techniques like quantitative PCR (qPCR) are used to confirm the expression levels of key genes (e.g., DDX52, DYNLT3, C1R, APOD) identified through sequencing, ensuring results are not an artifact of the discovery platform [80].
• Assay Development for Clinical Use: The validated biomarker panel must be adapted into a robust, reproducible, and often simplified diagnostic assay. This can take the form of a targeted RNA-Seq panel (e.g., rsERT with 175 genes) [14] or a microarray-based test (e.g., Endometrial Receptivity Array, ERA) [80]. The performance metrics—including accuracy, sensitivity, and specificity—are critically assessed.

Innovation in Sampling: Minimally Invasive Diagnostics

A significant barrier to the clinical adoption of endometrial receptivity tests has been the need for an invasive biopsy, which cannot be performed in the same cycle as embryo transfer. This has driven innovation in non-invasive sampling methods.

• Uterine Fluid Transcriptome Analysis: Uterine fluid, containing a mixture of endometrial secretions, extracellular vesicles, and free RNAs, serves as a rich source of biomarkers reflective of endometrial status. A proof-of-concept study successfully developed a non-invasive RNA-seq-based ER test (nirsERT) using an 87-marker model derived from uterine fluid transcriptomes, achieving a mean accuracy of 93.0% in predicting the WOI [83]. This approach allows for same-cycle diagnosis and treatment.

The Research Toolkit: Essential Reagents and Technologies

The following table details key reagents and solutions critical for conducting endometrial biomarker discovery and validation research.

Table 3: Research Reagent Solutions for Endometrial Transcriptome Studies

Research Tool	Specific Example / Product	Function in Workflow
Single-Cell Isolation	10X Chromium System [49]	Partitioning individual cells into nanoliter droplets for barcoding and RNA capture.
RNA Library Prep Kits	AVITI24 System (Element Biosciences) [82]	Preparation of sequencing-ready cDNA libraries from RNA inputs.
NGS Platforms	Illumina Sequencers; Element Biosciences [82]	High-throughput sequencing of prepared cDNA libraries.
Cell Sorting	Fluorescence-Activated Cell Sorting (FACS) [80]	Isolation of pure populations of specific cell types (e.g., epithelial vs. stromal).
Bioinformatics Suites	g:Profiler; RNA Velocity; StemVAE algorithm [49] [26]	Functional enrichment analysis, trajectory inference, and temporal modeling of scRNA-seq data.
Digital Pathology	AI-powered Image Analysis Platforms (AIRA Matrix, Pathomation) [84]	Quantitative analysis of tissue morphology and biomarker localization.

Regulatory and Commercial Translation

Navigating the path from a validated assay to a regulated diagnostic tool is a critical final step.

Regulatory Frameworks and Standards

In vitro diagnostic regulations (IVDR), particularly in Europe, present a significant framework for biomarker-based tests. Key challenges include uncertainty in requirements, inconsistencies between jurisdictions, and a lack of centralized transparency [82]. Proactively engaging with regulatory bodies and utilizing quality-managed infrastructure—such as Laboratory Information Management Systems (LIMS) and electronic Quality Management Systems (eQMS)—is essential for achieving compliance and ensuring assay reproducibility [82].

Clinical Implementation and Impact

The ultimate validation of a biomarker test is its ability to improve patient outcomes. Prospective, non-randomized controlled trials have demonstrated that personalized embryo transfer (pET) guided by transcriptome-based receptivity tests can significantly improve pregnancy rates in patients with Recurrent Implantation Failure (RIF) [14]. For example, one study showed the intrauterine pregnancy rate increased from 23.7% in the control group to 50.0% in the rsERT-guided group when transferring day-3 embryos [14].

Biomarker Development to Clinical Use Pathway

The journey of a transcriptomic biomarker from a research finding to a clinical diagnostic test is a multifaceted process. The endometrial transcriptome field exemplifies this pathway, moving from bulk tissue profiling to single-cell atlases, and now toward non-invasive liquid biopsies. Future progress will be driven by the deeper integration of multi-omics data, the application of more sophisticated AI and machine learning models for pattern recognition [81], and a continued focus on developing minimally invasive and more accessible diagnostic platforms. As regulatory frameworks evolve and the bioinformatics infrastructure matures, the systematic translation of transcriptomic discoveries will undoubtedly expand, enabling more precise and personalized interventions in reproductive medicine and beyond.

Bench to Bedside: Validating Transcriptomic Findings Across Populations and Platforms

Endometrial receptivity (ER) represents a critical, temporally restricted period during the mid-secretory phase of the menstrual cycle when the endometrium acquires a functional state conducive to embryo implantation. This "window of implantation" (WOI) is characterized by sophisticated molecular reprogramming that enables the endometrium to support embryonic attachment and invasion. Transcriptomic technologies have revolutionized our understanding of ER by revealing that the transition from a pre-receptive to a receptive state involves coordinated modulation of hundreds to thousands of genes simultaneously [85]. However, a significant challenge in the field has been the relatively small overlap between individual transcriptomic studies, with different investigations reporting varying numbers of differentially expressed genes—ranging from 107 to 2,878—when comparing pre-receptive (LH+2) and receptive (LH+7) endometrial phases [85]. This variability highlights the substantial influence of technical methodologies, patient selection criteria, and potentially, population-specific factors on transcriptomic signatures.

The clinical imperative for reliable ER biomarkers has led to the development of diagnostic tools such as the Endometrial Receptivity Array (ERA) and Win-Test, which utilize specific gene panels to assess endometrial status [85] [86]. These tools represent significant advances in personalized reproductive medicine, yet fundamental questions remain about the universality versus population-specificity of ER signatures. As transcriptomic analyses expand to include diverse ethnic populations, understanding whether core receptivity signatures are conserved across populations or exhibit ethnically distinct characteristics becomes paramount for both basic reproductive biology and clinical applications in assisted reproduction.

Established Receptivity Signatures and Consensus Genes

Meta-Signatures of Endometrial Receptivity

Comprehensive meta-analyses have sought to identify robust ER biomarkers by integrating data across multiple transcriptomic studies. A landmark meta-analysis employing robust rank aggregation (RRA) methodology analyzed 164 endometrial samples (76 pre-receptive, 88 receptive) and identified a meta-signature of endometrial receptivity comprising 57 mRNA genes as putative receptivity markers [87] [88]. Through experimental validation using RNA-sequencing in two separate datasets, 39 of these genes were confirmed as consistently associated with the receptive phase. Functional analysis revealed that these genes are significantly enriched in biological processes crucial for implantation, including immune responses, complement cascade pathway, and exosome-mediated functions during mid-secretory endometrial activities [87].

Another extensive effort to consolidate ER biomarkers led to the creation of the Human Gene Expression Endometrial Receptivity database (HGEx-ERdb), which compiled data from multiple transcriptomic studies [89]. This resource facilitated the identification of 179 Receptivity Associated Genes (RAGs), with 151 genes consistently upregulated and 28 genes consistently downregulated during the receptive phase compared to the pre-receptive phase [89]. This comprehensive analysis highlighted several cell adhesion molecules with validated functional significance in embryo attachment, including Thrombospondin1 (THBS1), CD36, and Cartilage Oligomeric Matrix Protein (COMP) [89].

Table 1: Consolidated Endometrial Receptivity Gene Signatures from Major Studies

Study	Total Genes Identified	Upregulated in Receptive Phase	Downregulated in Receptive Phase	Key Functional Pathways
Altmäe et al. (2017) Meta-analysis	57	39 validated	18	Immune response, complement cascade, exosome function [87]
HGEx-ERdb Database (2013)	179	151	28	Cell adhesion, extracellular matrix remodeling [89]
Haouzi et al. (2009) Win-Test Signature	11+	LAMB3, MFAP5, ANGPTL1, PROK1, NLF2	-	Angiogenesis, extracellular matrix remodeling [85]
Díaz-Gimeno et al. (2011) ERA Signature	134	143 (from 238 total DEGs)	95 (from 238 total DEGs)	Immune response, signal transduction, cell adhesion [85]

Challenges in Signature Consistency Across Studies

Despite these consolidation efforts, the identification of universally conserved receptivity genes remains challenging. A review of 23 transcriptomic studies on human endometrium during the WOI revealed that only two genes—osteopontin (SPP1) and interleukin 15 (IL15)—were consistently identified across multiple studies [85]. SPP1 encodes a glycoprotein involved in cellular adhesion and migration during embryo implantation, while IL15 represents a progesterone-regulated cytokine expressed in endometrial stromal cells that appears to be involved in stages immediately before, during, and after the apposition step [85].

The limited overlap between studies underscores the substantial methodological and biological variables influencing ER signatures, including:

• Technical variations: Differences in microarray platforms, RNA sequencing protocols, and analytical pipelines
• Sample timing: Slight variations in the timing of endometrial biopsy relative to the LH surge
• Patient populations: Differences in ethnic background, fertility status, and inclusion/exclusion criteria
• Cycle type: Natural versus stimulated cycles, with evidence that controlled ovarian stimulation induces a genomic delay in endometrial development [85]

The Current Evidence for Ethnic-Specific Signatures

Methodological Heterogeneity in Existing Studies

A critical analysis of the literature reveals that direct evidence for ethnically distinct endometrial receptivity signatures remains limited. Most transcriptomic studies to date have focused on relatively homogeneous populations, with the majority conducted in European or North American cohorts [85] [89]. The systematic compilation of study methodologies and participant characteristics in the HGEx-ERdb highlighted that ethnicity is rarely systematically reported or analyzed as a variable in ER studies [89]. This represents a significant gap in the field, as population-specific genetic variations, environmental factors, and lifestyle differences could theoretically influence endometrial gene expression patterns during the WOI.

The available evidence for potential ethnic variations comes primarily from indirect sources. The observed variability in gene signatures between studies conducted in different geographic regions suggests possible population-specific influences, though technical differences confound this interpretation [85]. Additionally, the implementation of ER diagnostic tools like the ERA across diverse populations has revealed differences in the proportion of women diagnosed with a displaced WOI, suggesting potential population variations in the timing and molecular regulation of endometrial receptivity [85] [86].

Table 2: Population Characteristics and Gene Signature Variability in Key ER Studies

Study	Reported Population Characteristics	Sample Size	Key Signature Genes	Reported Overlap with Other Studies
Talbi et al. (2006)	Not specified	Not specified	2,878 DEGs (1,415 up, 1,463 down)	Limited overlap; only 2 common genes across multiple studies [85]
Díaz-Gimeno et al. (2011)	Spanish population	88 fertile women	134 ERA signature genes	47 genes shared with meta-signature [85] [86]
Haouzi et al. (2009)	Not specified	Intra-patient comparison	LAMB3, MFAP5, ANGPTL1, PROK1, NLF2	2 genes (LAMB3, MFAP5) shared with ERA [85]
Bhagwat et al. (2013)	Indian population	8 tissue samples	THBS1, COMP, CD36	Identified 179 RAGs with varying overlap with other signatures [89]

Emerging Evidence from Diverse Populations

While direct comparative studies are scarce, some research has begun to include more diverse populations. The creation of HGEx-ERdb included data from studies conducted in different geographical regions, though ethnicity-specific analyses were not performed [89]. Similarly, a 2017 meta-analysis that identified the 57-gene meta-signature included datasets from multiple research groups across different countries, but did not explicitly examine ethnic variations in the signature [87]. These studies demonstrate the feasibility of cross-population validation but have not yet been leveraged to systematically address the question of ethnic specificity.

Recent technological advances are enabling more sophisticated approaches to this question. Spatial transcriptomics studies of endometrial tissue from both normal individuals and patients with repeated implantation failure (RIF) have begun to create detailed maps of gene expression within tissue architecture context [6]. Similarly, single-cell RNA sequencing (scRNA-seq) applications in endometrium have revealed previously unappreciated cellular heterogeneity and cell-type specific gene expression patterns [5]. These technologies, when applied to diverse populations, could potentially identify ethnically influenced subtleties in receptivity signatures that were obscured in bulk tissue analyses.

Methodological Framework for Cross-Population Validation

Study Design and Cohort Recruitment

Robust validation of ER signatures across ethnic populations requires carefully controlled multicenter studies with standardized protocols. The following design elements are essential:

• Stratified Recruitment: Participant cohorts should be strategically recruited to represent major ethnic groups (e.g., European, African, East Asian, South Asian) with careful matching for relevant confounding factors including age, BMI, menstrual cycle characteristics, and fertility status [6] [85].

• Standardized Timing: Endometrial biopsies must be precisely timed relative to the LH surge (LH+7 for receptive phase; LH+2 for pre-receptive controls) with confirmation of ovulation through urinary LH monitoring or serum progesterone measurements [6] [85].

• Sample Size Calculation: Based on the effect sizes observed in previous transcriptomic studies, cohorts of 20-30 participants per ethnic group per cycle phase would provide adequate power to detect moderate to large differences in gene expression while accounting for individual variability [87] [89].

Diagram 1: Cross-population validation workflow for endometrial receptivity signatures

Transcriptomic Technologies and Analytical Approaches

Multiple complementary transcriptomic technologies should be employed to capture different dimensions of gene regulation:

• Bulk RNA-Sequencing: Provides comprehensive quantification of gene expression levels across the entire transcriptome. This approach allows direct comparison with existing ER signatures and meta-analyses [87] [85].

• Single-Cell RNA Sequencing (scRNA-seq): Enables resolution of cell-type specific expression patterns and identification of rare cell populations. Recent applications have revealed distinct endometrial cell subtypes and their specific contributions to receptivity [5].

• Spatial Transcriptomics: Preserves the spatial context of gene expression within tissue architecture. This technology has identified distinct cellular niches in endometrial tissue with potential relevance to implantation [6].

• Splicing Analysis: Investigates isoform-level variations, which may reveal regulatory differences not apparent at the gene level. Recent research has identified menstrual cycle phase-specific splicing changes in endometrium [7].

The analytical framework should include both hypothesis-driven analyses (testing established ER signatures in new populations) and discovery-based approaches (identifying novel population-specific features). Multivariate statistical methods must account for potential confounding factors, and machine learning approaches can help identify minimal gene sets with optimal predictive value across populations.

Diagram 2: Multi-technology transcriptomic approach for cross-population validation

Experimental Protocols for Signature Validation

Endometrial Tissue Collection and Processing Protocol

Sample Collection:

• Schedule biopsies for precisely timed windows: LH+2 (pre-receptive) and LH+7 (receptive) in natural cycles, confirmed by urinary LH surge detection [6] [85].
• Perform endometrial biopsy using Pipelle catheter or similar device under sterile conditions.
• Immediately divide tissue aliquots for:
  • RNA extraction (snap-freeze in liquid nitrogen)
  • Histological confirmation (formalin fixation)
  • Single-cell suspension preparation (fresh processing in cold medium)
  • Spatial transcriptomics (optimal cutting temperature compound embedding and flash-freezing)

RNA Extraction and Quality Control:

• Extract total RNA using column-based kits with DNase treatment.
• Quantify RNA concentration using fluorometric methods (e.g., Qubit).
• Assess RNA integrity via Bioanalyzer or TapeStation; require RIN (RNA Integrity Number) > 8.0 for sequencing applications [6].
• Verify absence of genomic DNA contamination by PCR.

Transcriptomic Profiling Workflows

Bulk RNA-Sequencing:

• Prepare libraries using stranded mRNA-seq protocols to preserve strand information.
• Sequence on Illumina platforms to minimum depth of 30 million paired-end 150bp reads per sample.
• Include external RNA controls (ERCC) for quality monitoring and cross-batch normalization.

Single-Cell RNA-Sequencing:

• Prepare single-cell suspensions using gentle mechanical dissociation and enzymatic digestion (collagenase/hyaluronidase) [5].
• Use droplet-based platforms (10x Genomics) or plate-based methods (Smart-seq2) depending on required depth and cell numbers.
• Target 5,000-10,000 cells per sample with minimum 50,000 reads per cell.

Spatial Transcriptomics:

• Section fresh frozen tissues at 10μm thickness onto Visium slides.
• Follow 10x Visium Spatial Gene Expression protocol for tissue permeabilization, cDNA synthesis, and library preparation [6].
• Sequence to saturation with recommended read distribution.

Bioinformatics and Statistical Analysis Pipeline

Data Preprocessing:

• Quality control: FastQC for read quality, STAR or HISAT2 for alignment to reference genome.
• Gene quantification: FeatureCounts or HTSeq for bulk RNA-seq; Cell Ranger for scRNA-seq; Space Ranger for spatial transcriptomics.
• Normalization: DESeq2 for bulk data; SCTransform for scRNA-seq.

Differential Expression Analysis:

• Compare expression between ethnic groups within the same cycle phase.
• Adjust for potential confounders (age, BMI, technical batch effects) using linear mixed models.
• Apply multiple testing correction (Benjamini-Hochberg FDR < 0.05).

Signature Validation:

• Calculate signature scores for established ER gene sets (meta-signature, ERA genes, Win-Test genes) using single-sample gene set enrichment methods.
• Assess classification performance (receptive vs. pre-receptive) within each ethnic group using ROC analysis.
• Evaluate signature transferability across populations by training classifiers in one ethnic group and testing in others.

Essential Research Reagents and Tools

Table 3: Essential Research Reagents for Cross-Population ER Studies

Category	Specific Reagents/Tools	Application	Considerations
Sample Collection	Pipelle catheter, Liquid nitrogen, RNAlater	Endometrial tissue acquisition and preservation	Standardize collection timing relative to LH surge; immediate processing critical for RNA integrity [6]
RNA Workflow	TRIzol, RNeasy kits, Qubit RNA assays, Bioanalyzer RNA kits	RNA extraction and quality control	Require RIN > 8.0; avoid freeze-thaw cycles; include DNase treatment [6]
Library Preparation	Illumina Stranded mRNA Prep, 10x Genomics Single Cell kits, Visium Spatial kits	Library construction for various transcriptomic applications	Include unique molecular identifiers (UMIs) for scRNA-seq to address amplification bias [5] [6]
Sequencing	Illumina NovaSeq 6000, S4 flow cells, sequencing primers	High-throughput sequencing	Target appropriate depth: 30M reads/sample bulk RNA-seq; 50M reads/sample spatial; 5-10K cells/sample scRNA-seq [5] [6]
Computational Tools	Seurat (scRNA-seq), Space Ranger (spatial), DESeq2 (bulk), CellChat (communication)	Data analysis and interpretation	Implement rigorous batch correction; use harmony or similar tools for multi-ethnic data integration [5] [6]
Validation Reagents	TaqMan assays, SYBR Green, antibodies for IHC (THBS1, CD36, COMP)	Orthogonal validation of findings	Select targets from consensus lists (e.g., meta-signature genes); include positive and negative controls [89]

Future Directions and Clinical Implications

The validation of endometrial receptivity signatures across diverse populations represents both a scientific imperative and clinical necessity. As reproductive medicine becomes increasingly globalized, understanding the influence of ethnicity on endometrial biology is essential for equitable application of diagnostic technologies and treatment strategies. Future research directions should include:

• Longitudinal Multi-Ethnic Cohorts: Establish dedicated multi-ethnic prospective studies with sufficient statistical power to detect moderate effect sizes in ethnicity-specific gene regulation.

• Integration of Multi-Omic Data: Combine transcriptomic analyses with genomic, epigenomic, and proteomic profiling to identify regulatory mechanisms underlying potential ethnic variations.

• Functional Validation in Model Systems: Develop appropriate in vitro and in vivo models to test the functional significance of population-specific gene signatures in implantation biology.

• Clinical Translation: Adapt existing ER diagnostic tools to incorporate population-specific adjustments where validated, ensuring broad applicability across diverse patient populations.

The ultimate goal of cross-population validation is not to reinforce biological determinism but to ensure that scientific advances in reproductive medicine benefit all populations equally. By rigorously testing the universality of endometrial receptivity signatures and identifying meaningful population-specific variations where they exist, the field can move toward truly personalized approaches to infertility diagnosis and treatment that account for both individual and population-level biological characteristics.

The endometrium, the inner lining of the uterus, undergoes profound molecular and cellular transformations across the menstrual cycle to prepare for embryo implantation. This process, culminating in a brief period known as the window of implantation (WOI), is governed by complex transcriptomic dynamics [26]. Precise assessment of endometrial receptivity is crucial for improving success rates in Assisted Reproductive Technology (ART). For decades, the transcriptomic profiling of endometrial tissue obtained via biopsy has been the cornerstone for investigating endometrial receptivity [90]. However, the invasive nature of biopsies presents significant limitations: the procedure is uncomfortable, carries a risk of complications, and, most critically, disrupts the endometrial lining, precluding embryo transfer in the same ART cycle and introducing inter-cycle variability [20] [91].

This clinical challenge has catalyzed the search for non-invasive alternatives. Among the most promising is the analysis of extracellular vesicles (EVs) isolated from uterine fluid (UF). UF-EVs are lipid bilayer-enclosed nanoparticles released by endometrial cells into the uterine cavity. They carry a rich molecular cargo, including RNAs, proteins, and lipids, which reflects the biological state of the parent endometrial tissue [20] [91]. This article provides an in-depth technical guide on UF-EVs as a non-invasive resource for studying endometrial transcriptome dynamics, contrasting it with traditional tissue biopsy approaches within the context of menstrual cycle research.

Technical Comparison: UF-EVs versus Endometrial Biopsies

The following table summarizes the core technical and practical differences between the two methodologies for transcriptomic analysis.

Table 1: Technical comparison between endometrial tissue biopsies and uterine fluid extracellular vesicles for transcriptomic analysis.

Feature	Endometrial Tissue Biopsy	Uterine Fluid Extracellular Vesicles (UF-EVs)
Sample Type	Invasive tissue sample (e.g., pipelle curette) [90]	Non-invasive liquid biopsy (uterine fluid lavage) [91]
Invasiveness & Cycle Coordination	High invasiveness; prevents embryo transfer in the same cycle [20]	Minimal invasiveness; allows potential same-cycle embryo transfer [91]
Tissue/Cellular Heterogeneity	High heterogeneity (contains functionalis/basalis, epithelium, stroma, immune cells); requires careful dissection or normalization [90]	Represents a specific snapshot of secreted signals; cargo is derived from various endometrial cells but in a packaged form [20] [92]
Transcriptomic Correlation	Direct tissue measurement; considered the historical reference standard	High correlation with paired tissue transcriptome (e.g., Pearson's r = 0.70) [91]
Key Applications in Research	Defining transcriptomic signatures of receptivity [26], studying cellular composition and function [90]	Pregnancy outcome prediction [20], studying embryo-endometrium communication [91], exploring pathological microenvironments (e.g., endometriosis) [93]
Primary Limitations	Inter-cycle variability, sampling depth variability (functionalis vs. basalis) [90], invasive procedure	EV isolation and characterization complexity, potential contribution from different EV subtypes [91] [92]

Quantitative Insights from UF-EV Transcriptomic Profiling

Recent large-scale transcriptomic studies have demonstrated the power of UF-EV RNA sequencing (RNA-Seq) to uncover molecular features associated with endometrial receptivity and pregnancy success. Key quantitative findings are consolidated in the table below.

Table 2: Key quantitative findings from transcriptomic analyses of uterine fluid extracellular vesicles.

Study Focus	Key Quantitative Findings	Reference
Pregnancy Outcome Prediction	966 differentially expressed genes (nominal p-value < 0.05) between pregnant (N=37) and non-pregnant (N=45) women after euploid blastocyst transfer. A Bayesian model integrating gene modules and clinical variables achieved a predictive accuracy of 0.83.	[20]
Receptive vs. Non-Receptive Phase	In fertile women, 942 gene transcripts were more abundant and 1,305 were less abundant in the receptive phase (LH+7) compared to the non-receptive phase (LH+2).	[91]
Correlation with Tissue Transcriptome	A highly significant correlation was found between transcriptional profiles of endometrial biopsies and pairwise UF-EV samples (Pearson’s r = 0.70; P < 0.0001).	[91]
Physical Characteristics	UF-EVs from women with successful implantation were significantly smaller than those from women who failed to conceive (mean diameter 205.5 ± 22.97 nm vs. 221.5 ± 20.57 nm, P = 0.014).	[91]
Cycle Phase Dynamics	A comprehensive transcriptome analysis of the entire menstrual cycle identified 5,082 differentially expressed genes, with the highest number of phase-specific genes in the mid-secretory and late proliferative phases.	[26]

Experimental Workflow for UF-EV Transcriptomic Analysis

A robust experimental protocol is essential for reliable UF-EV research. The following section details the key methodologies cited in the literature.

Sample Collection and Processing

• Uterine Fluid Aspiration: UF is typically collected by lavage of the endometrial cavity using a catheter, often during the mid-secretory phase (LH+7) for receptivity studies. The procedure is performed without cervical dilation or endometrial disruption [91].
• Initial Processing: The collected UF is subjected to differential centrifugation to remove cells and debris. Common steps include centrifugation at 400 × g for 10 min, 4,000 × g for 10 min, and 10,000 × g for 10 min. The resulting supernatant is used for EV isolation [92].

Extracellular Vesicle Isolation

Two primary methods are prominently used for isolating EVs from the processed UF supernatant:

• Ultracentrifugation (UC): This is a common method involving high-speed centrifugation (typically >100,000 × g) to pellet EVs. While effective, it can co-pellet non-vesicular contaminants [94].
• Size Exclusion Chromatography (SEC): This technique separates particles based on size. It is often used following UC or differential centrifugation to obtain a cleaner EV preparation with reduced protein contamination. Fractions containing the highest concentration of EV-sized particles (e.g., fractions 5-8 from a Sepharose CL-2B column) are collected for downstream analysis [92].

EV Characterization and RNA Sequencing

• Characterization: Nanoparticle Tracking Analysis (NTA) is routinely used to determine the size distribution and concentration of isolated particles [20] [91] [92]. Western blotting for EV protein markers (e.g., CD63, CD81, TSG101) is used to confirm the presence of EVs [91].
• RNA Extraction and Sequencing: Total RNA is extracted from the isolated UF-EVs. RNA-seq libraries are prepared and sequenced using next-generation sequencing platforms. Bioinformatic analyses then include differential gene expression (DGE), weighted gene co-expression network analysis (WGCNA), and gene set enrichment analysis (GSEA) to identify biological pathways [20].

The following diagram illustrates the core experimental workflow for UF-EV analysis.

Figure 1: Core workflow for UF-EV transcriptomic analysis.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful execution of UF-EV research requires a suite of specialized reagents and instruments. The table below details key solutions used in the featured studies.

Table 3: Essential research reagents and materials for UF-EV transcriptomic studies.

Research Reagent / Material	Function in UF-EV Research	Specific Examples / Notes
Uterine Fluid Collection Catheter	Non-invasive aspiration of uterine fluid lavage sample.	Various commercial endometrial cytology or lavage catheters.
Differential Centrifugation Rotors	Sequential removal of cells, debris, and large particles from UF samples.	Fixed-angle and swinging-bucket rotors for low-to-medium speed spins (e.g., 400 g to 10,000 g) [92].
Ultracentrifuge	High-speed isolation of EVs from pre-cleared UF supernatant.	Critical for pelleting EVs via prolonged spins >100,000 g [94].
Size Exclusion Chromatography (SEC) Columns	High-purity EV isolation based on hydrodynamic size; separates EVs from soluble proteins.	Sepharose CL-2B columns; fractions 5-8 typically contain the highest EV yield with low contaminant protein [92].
Nanoparticle Tracking Analyzer (NTA)	Physical characterization of isolated EVs: determines particle size distribution and concentration.	Instruments like ZetaView (Particle Metrix); used to confirm EV size (e.g., ~200 nm) and note size differences linked to phenotype [91] [92].
EV Marker Antibodies	Confirmation of EV identity and purity via immunoblotting.	Antibodies against tetraspanins (CD63, CD81, CD9), TSG101, Alix; absence of negative markers like GM130 [91].
RNA Extraction Kits	Isolation of high-integrity total RNA from low-abundance EV samples.	Kits designed for low-input or microRNA/cell-free RNA (e.g., miRNeasy, Norgen's exRNA kits).
RNA-Seq Library Prep Kits	Preparation of sequencing libraries from EV-derived RNA, which often lacks poly-A tails.	Smart-seq2 or other kits capable of whole-transcriptome amplification without poly-A selection are often used [20] [91].

Integrative Analysis and Biological Pathways

The true power of UF-EV transcriptomics is unlocked through sophisticated bioinformatic analyses that move beyond simple differential expression.

Systems Biology Approaches

• Weighted Gene Co-expression Network Analysis (WGCNA): This technique clusters genes into modules (groups of highly correlated genes) based on their expression patterns across samples. In a study of 82 women, WGCNA clustered 966 differentially expressed genes from UF-EVs into four modules with significant associations to pregnancy outcome. This approach identifies networks of functionally related genes, providing a systems-level view beyond individual gene markers [20].
• Gene Set Enrichment Analysis (GSEA): GSEA determines whether defined sets of genes (e.g., based on biological pathways) show statistically significant, concordant differences between two biological states. Pre-ranked GSEA of UF-EV transcriptomes has revealed significant enrichment in key biological processes during the receptive state, including adaptive immune response, ion homeostasis, and inorganic cation transmembrane transport [20]. This underscores the role of UF-EVs in modulating the endometrial microenvironment for implantation.

Signaling and Functional Insights

The proteome of endometrial EVs is also hormonally regulated. Studies using endometrial cell lines treated with estrogen (E2), progesterone (P4), or both (E2P4) to mimic menstrual cycle phases have shown that the protein cargo of secreted EVs changes significantly [92]. Proteins enriched in EVs under E2P4 treatment (simulating the receptive phase) are involved in critical processes like embryo implantation, endometrial receptivity, and embryo development. This highlights EVs as active mediators of endometrial-embryo communication, carrying instructions that can facilitate the implantation process.

The following diagram synthesizes how UF-EV analysis informs our understanding of endometrial biology.

Figure 2: UF-EVs reflect endometrial biology and key functions.

The transition from invasive endometrial biopsies to the analysis of UF-EVs represents a paradigm shift in reproductive medicine research. As detailed in this whitepaper, UF-EVs offer a non-invasive, biologically rich source of molecular information that highly correlates with the endometrial tissue transcriptome [91]. Their cargo dynamically changes across the menstrual cycle and is predictive of functional outcomes like pregnancy success [20] [26].

For researchers and drug development professionals, the implications are profound. UF-EVs open the door to real-time, same-cycle monitoring of endometrial status, enabling more personalized ART strategies. Furthermore, the ability to repeatedly sample the endometrial environment provides unparalleled opportunities to study the dynamics of the endometrial transcriptome across the cycle and in response to therapeutic interventions. As isolation and analytical methodologies continue to standardize, UF-EVs are poised to move from a research tool to a central component of future diagnostic and therapeutic platforms, ultimately advancing our goal of understanding and improving reproductive health.

Comparative Analysis of Physiological vs. Pathological Endometrial States

The endometrium, the inner lining of the uterus, is a remarkably dynamic tissue that undergoes cyclic remodeling throughout the menstrual cycle to support embryo implantation and pregnancy. Understanding the molecular transitions between physiological and pathological states represents a critical frontier in reproductive medicine. Transcriptome dynamics—the global patterns of gene expression—serve as a precise molecular readout of endometrial status, reflecting both normal cyclical changes and the disruptions that underlie disease [95] [26]. This analysis systematically compares the transcriptional landscapes of the healthy endometrium across the menstrual cycle against those of pathological states, including endometrioid endometrial cancer (EEC) and endometriosis. By integrating recent advances in single-cell RNA sequencing (scRNA-seq), molecular staging models, and organoid technology, this review provides a framework for deciphering endometrial (patho)biology, with direct implications for developing novel diagnostic and therapeutic strategies.

Physiological Endometrial Dynamics

The human endometrium comprises two main layers: the lamina basalis (basal layer), which persists across cycles, and the lamina functionalis (upper layer), which undergoes dramatic cyclical renewal in preparation for pregnancy [16]. Its cellular architecture is a complex network of epithelial cells (both luminal and glandular), stromal fibroblasts, immune cells, and endothelial cells [16]. The monthly cycle is traditionally divided into the menstrual, proliferative, and secretory phases, driven by oscillating levels of estradiol (E2) and progesterone (P4) [16].

Transcriptomic Remodeling Across the Menstrual Cycle

Recent high-resolution transcriptomic studies have revealed intricate, phase-specific gene expression patterns that govern endometrial function.

Table 1: Key Transcriptomic Changes During the Physiological Menstrual Cycle

Cycle Phase	Key Upregulated Genes & Processes	Functional Significance
Menstrual / Early Proliferative (Phase 1)	MMP7, MMP10, MMP11 (ECM degradation); ESR1, PGR (estrogen response); THBS1 (angiogenesis) [16]	Tissue breakdown, initiation of repair, and re-epithelialization [16]
Proliferative Phase	AGTR2, CRIM1 (ECM remodeling); HOXA10, HOXA11 (differentiation); CXCR4, PECAM1 (angiogenesis) [95]	Estrogen-driven tissue regeneration and restoration of functional layer [95]
Late Proliferative (Peri-ovulatory)	STEAP4, SCGB1D2, PLA2G4F (specific upregulated genes) [26]	Critical transition point preparing the endometrium for the secretory phase [26]
Secretory Phase	PAEP, GPX3, CXCL14 (epithelium); DKK1 (stroma); PRL, IGFBP1 (decidualization) [16] [95]	Progesterone-driven differentiation, creation of a receptive microenvironment for implantation [16]

A pivotal study recentering the view on the proliferative phase identified the late proliferative phase as an essential transition point, with a significant number of unique differentially expressed genes (DEGs) compared to the mid-proliferative phase [26]. Furthermore, 81 genes were found to be consistently differentially expressed across the entire cycle, highlighting core cyclical processes [26].

Molecular Staging and Technical Considerations

The inherent variability in menstrual cycle length among women poses a significant challenge for comparative transcriptomic studies. To address this, a novel 'molecular staging model' was developed, which uses global gene expression patterns to assign a precise cycle time to each endometrial sample [96]. This model, based on the expression of over 3,400 genes that change synchronously throughout the cycle, provides a more accurate and objective method for sample classification than last menstrual period (LMP) or histology alone, enabling more robust comparisons between physiological and pathological states [96].

Pathological Endometrial States

Endometrioid Endometrial Cancer (EEC): Cellular Origin and Transcriptomic Landscape

Endometrioid endometrial cancer (EEC) represents a major pathological endpoint of endometrial dysfunction. scRNA-seq analyses of tissues from normal endometrium, atypical endometrial hyperplasia (AEH, a precancerous stage), and EEC have provided unprecedented insights into its cellular origin and progression.

Table 2: Transcriptomic and Cellular Hallmarks of EEC Pathogenesis

Feature	Physiological State	Pathological State (EEC)	Research Evidence
Cellular Origin	Multiple epithelial and stromal lineages	Unciliated glandular epithelium [97]	Lineage tracing and RNA velocity analysis show no transition from stroma; EEC clusters derive from unciliated epithelial subpopulations [97].
Cell Population Balance	Maintained balance between epithelial and stromal compartments	Marked expansion of epithelial cells with concomitant decrease in stromal fibroblasts [97]	scRNA-seq of patient samples shows increasing epithelial percentage from normal -> AEH -> EEC [97].
Genomic Instability	Stable genomic profile	High copy number variations (CNVs) in epithelial cells [97]	Inference of CNVs from scRNA-seq data shows significant deviations in AEH and EEC epithelia, often on chromosomes 1, 8, and 10 [97].
Featured Cell Subtype	Not present	Emergence of LCN2+/SAA1/2+ epithelial subpopulation [97]	Identified as a featured cluster in AEH and EEC tissues, associated with tumorigenesis [97].

The tumor microenvironment (TME) in EEC also undergoes significant remodeling. While the proportion of immune cells like lymphocytes and macrophages can be variable, the stromal niche is profoundly altered, supporting tumor growth and immune evasion [97].

Endometriosis and Transcriptomics-Based Therapeutics

Endometriosis, characterized by ectopic endometrial tissue, exhibits a distinct transcriptomic signature compared to healthy endometrium. A transcriptomics-based drug repositioning approach identified the non-steroidal anti-inflammatory drug (NSAID) fenoprofen as a top therapeutic candidate [98]. This finding was validated in a rat model of endometriosis, where fenoprofen treatment successfully alleviated endometriosis-associated vaginal hyperalgesia (a pain surrogate) [98]. This demonstrates the power of transcriptomic data in identifying novel treatment strategies for benign gynecological conditions.

Methodological Approaches and Experimental Protocols

Single-Cell RNA Sequencing (scRNA-seq) Workflow

scRNA-seq has become a cornerstone for deconvoluting the cellular heterogeneity of the endometrium. The standard protocol involves:

• Single-Cell Suspension Preparation: Fresh endometrial tissue biopsies are collected and immediately dissociated into single-cell suspensions using enzymatic digestion (e.g., collagenase, trypsin) and mechanical disruption [97].
• Cell Viability and Quality Control: The suspension is filtered and assessed for viability (e.g., >80% via trypan blue exclusion) before loading onto a microfluidic platform [97].
• Single-Cell Barcoding and Library Prep: Cells are partitioned into nanoliter-scale droplets using a system like the 10X Genomics Chromium, where each droplet contains a single cell and a barcoded bead. Within the droplet, mRNA is reverse-transcribed into barcoded cDNA [97].
• Sequencing and Data Analysis: Libraries are prepared and sequenced on a high-throughput platform (e.g., Illumina). Subsequent bioinformatic analysis includes quality control, normalization, batch effect correction, clustering, and cell-type annotation using canonical markers (e.g., EPCAM for epithelium, DCN for stroma) [97].

The following diagram illustrates the core scRNA-seq workflow and its key applications in endometrial research.

Endometrial Organoid Models

Endometrial epithelial organoids have emerged as a powerful in vitro model system. These 3D structures are derived from primary endometrial epithelial cells or stem/progenitor cells and are cultured in a specialized extracellular matrix (e.g., Matrigel) with a defined cocktail of growth factors [16]. Critically, endometrial organoids have been shown to faithfully recapitulate the cellular, transcriptomic, and functional characteristics of the native endometrial epithelium, including hormonal responses and the expression of ion channels [16]. They serve as a physiologically relevant platform for studying embryo-endometrium interactions, disease modeling, and drug screening, thereby reducing the need for primary tissue and overcoming ethical restrictions [16].

Molecular Staging Analysis

The molecular staging protocol involves:

• Reference Model Creation: A penalized cyclic cubic regression spline is fitted to RNA-seq data from a large set of training samples (e.g., n=236) that have been pathologically assigned to one of seven menstrual cycle stages [96].
• Sample Projection: For a new test sample, the model calculates the "model time" that minimizes the mean squared error (MSE) between the sample's observed gene expression and the reference gene curves [96].
• Cycle Stage Assignment: This "model time" provides a precise, normalized position within the menstrual cycle continuum, allowing for accurate comparison of samples from women with different cycle lengths [96].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for Endometrial Transcriptome Research

Reagent / Tool	Function	Example Application
10X Genomics Chromium	Single-cell barcoding and partitioning	High-throughput scRNA-seq library preparation from endometrial cell suspensions [97].
Matrigel / BME	Basement membrane extract for 3D culture	Providing the scaffold for growing and maintaining endometrial epithelial organoids [16].
Collagenase/Dispase	Enzymatic tissue dissociation	Digesting solid endometrial biopsies into single-cell suspensions for downstream analysis [97].
Olink Target-96 Panel	Multiplexed protein quantification	Simultaneously measuring 92 inflammation-related proteins in uterine fluid for non-invasive receptivity assessment [99].
ER/PR Agonists/Antagonists	Modulating hormonal signaling	Experimentally controlling decidualization and functional differentiation in organoid and tissue culture models [16].
Canonical Cell Markers	Cell type identification and validation	Antibodies for EPCAM (epithelium), VIM (stroma), PECAM1 (endothelium), CD68 (macrophages) for immunofluorescence and FACS [97].

The comparative analysis of physiological and pathological endometrial states, powered by transcriptomics, has fundamentally advanced our understanding of uterine biology and disease. Key insights include the redefinition of cycle phases via molecular staging, the identification of unciliated glandular epithelium as the origin of EEC, and the use of organoids as biomimetic experimental platforms. The distinct transcriptional signatures of conditions like endometriosis are already enabling novel drug repositioning strategies. Future research must focus on integrating multi-omics data, refining non-invasive diagnostic tools like uterine fluid proteomics, and leveraging these molecular discoveries to develop targeted, effective therapies for the myriad of endometrial disorders that impact women's health globally.

The human endometrium is a dynamic mucosal tissue that undergoes profound, cyclical changes in response to ovarian hormones throughout the menstrual cycle. Understanding its complex transcriptomic regulation is crucial for addressing widespread reproductive health conditions such as endometriosis, adenomyosis, infertility, and endometrial carcinoma [100] [101]. Traditional bulk RNA sequencing (bulk RNA-seq) has provided valuable insights into endometrial biology but obscures cellular heterogeneity by averaging gene expression across diverse cell types [102] [100].

The advent of single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) has revolutionized our ability to study tissues at unprecedented resolution. However, a critical question remains: how concordant are the findings from these complementary technologies? This technical guide examines the methodological validation of scRNA-seq, spatial transcriptomics, and bulk RNA-seq concordance within the context of endometrial research, providing a framework for researchers and drug development professionals to integrate these powerful tools reliably.

Bulk RNA Sequencing

Bulk RNA-seq analyzes the average gene expression profile from a tissue lysate containing mixed cell populations. While it provides a high-level view of transcriptional states and is cost-effective for large cohort studies, it lacks the resolution to detect cellular heterogeneity [102]. In endometrium research, this limitation is significant given the tissue's complex, multicellular nature and dynamic changes across the menstrual cycle [100].

Single-Cell RNA Sequencing

scRNA-seq enables the profiling of gene expression in individual cells, revealing cellular heterogeneity, identifying rare cell populations, and constructing developmental trajectories. In endometrium, scRNA-seq has identified distinct subpopulations of epithelial, stromal, and immune cells with specialized functions across menstrual cycle phases [103] [101]. A key limitation is the loss of native spatial context during tissue dissociation [104].

Spatial Transcriptomics

Spatial transcriptomics technologies preserve the spatial organization of cells within tissues while measuring gene expression. Methods include:

• Sequencing-based approaches (e.g., 10X Visium): Capture location-barcoded mRNA on a slide [105] [101].
• Imaging-based approaches (e.g., MERFISH, Xenium, CosMx): Use multiplexed fluorescence in situ hybridization to detect hundreds to thousands of RNA species directly in tissue sections [105] [104].

These methods have been successfully applied to FFPE (formalin-fixed paraffin-embedded) tissues, enabling the study of archival clinical samples [105].

Table 1: Key Characteristics of Transcriptomic Technologies

Technology	Resolution	Spatial Context	Throughput	Primary Applications in Endometrial Research
Bulk RNA-seq	Tissue-level	Lost	High	Identifying overall transcriptional differences between patient groups, disease states, or menstrual cycle phases [102]
scRNA-seq	Single-cell	Lost	Medium	Characterizing cellular heterogeneity, identifying rare cell types, inferring differentiation trajectories [103] [100] [101]
Spatial Transcriptomics	Single-cell to subcellular (imaging-based); multi-cell (sequencing-based)	Preserved	Low to Medium	Mapping spatial organization of cell types, revealing tissue microenvironments, validating cell-cell communication [106] [105] [101]

Empirical Evidence of Concordance

Technical Comparisons Between Platforms

A systematic benchmarking of three commercial imaging-based spatial transcriptomics platforms (10X Xenium, Vizgen MERSCOPE, and Nanostring CosMx) on FFPE tissues revealed important performance characteristics. On matched genes, Xenium consistently generated higher transcript counts per gene without sacrificing specificity. Both Xenium and CosMx measured RNA transcripts in concordance with orthogonal single-cell transcriptomics, with all three platforms capable of performing spatially resolved cell typing with varying degrees of sub-clustering capabilities [105].

MERFISH Validation Against scRNA-seq and Bulk RNA-seq

A dedicated technical comparison between MERFISH (an imaging-based spatial transcriptomics method) and RNA sequencing technologies in mouse liver and kidney demonstrated that MERFISH quantitatively reproduced bulk RNA-seq and scRNA-seq results with improvements in overall dropout rates and sensitivity. MERFISH independently resolved distinct cell types and spatial structures without requiring computational integration with scRNA-seq atlases [104].

Bulk transcript counts from MERFISH showed extremely high correlation between technical replicates (R = 0.99 for liver, R = 0.95 for kidney). When comparing MERFISH to scRNA-seq data, the study found that computational integration did not enhance cell type identification, indicating that MERFISH data alone can sufficiently resolve distinct cell types [104].

Integrated Analyses in Endometrial Research

In endometrial carcinoma research, integrated analysis of scRNA-seq and spatial transcriptomics has proven valuable for understanding the tumor microenvironment. One study successfully mapped cell populations identified through scRNA-seq to their spatial locations, revealing communication between epithelial and endothelial cells through the MDK-NCL signaling pathway [107].

Similar integrative approaches in colorectal cancer have identified distinct tumor cell subtypes with different spatial distributions and clinical implications, demonstrating the power of combining these technologies to decode tumor complexity [108].

Table 2: Quantitative Measures of Concordance Between Technologies

Comparison	Correlation Metric	Tissue/Context	Key Finding
MERFISH vs. Bulk RNA-seq	R = 0.99 (liver), R = 0.95 (kidney)	Mouse liver and kidney	Extremely high reproducibility of bulk transcript counts [104]
MERFISH vs. scRNA-seq	High concordance	Mouse liver and kidney	MERFISH independently resolved cell types without computational integration [104]
Xenium vs. scRNA-seq	High concordance	Various human FFPE tissues	Transcript counts in concordance with single-cell transcriptomics [105]
CosMx vs. scRNA-seq	High concordance	Various human FFPE tissues	Transcript counts in concordance with single-cell transcriptomics [105]

Methodological Framework for Integration

Experimental Design Considerations

When integrating these technologies, several factors must be considered:

• Sample matching: For optimal comparison, samples should come from the same donor or tissue region where possible.
• Menstrual cycle phase: Endometrial samples must be carefully phased-matched based on histological dating or hormonal measurements, as transcript profiles vary dramatically throughout the cycle [102] [101].
• Panel design for spatial transcriptomics: For targeted spatial methods like MERFISH, panel design should include marker genes identified from scRNA-seq data for major cell types and genes of interest for the specific research question [104].

Computational Integration Methods

Several computational approaches enable the integration of scRNA-seq and spatial transcriptomics data:

• Cell2location: A Bayesian method that maps cell types from scRNA-seq to spatial data, successfully used to map uterine cell types to their spatial locations in full-thickness uterus samples [101].
• Seurat integration: Uses canonical correlation analysis and mutual nearest neighbors to align scRNA-seq and spatial datasets [107].
• CellChat with spatial information: Extends cell-cell communication analysis by incorporating spatial constraints to identify biologically relevant signaling interactions [107].

Diagram 1: Integrated transcriptomics workflow for a comprehensive tissue analysis.

Signaling Pathways in Endometrial Biology

Spatial transcriptomics combined with scRNA-seq has revealed spatially restricted signaling pathways critical for endometrial function and disease. Key pathways include:

WNT and NOTCH in Epithelial Differentiation

In the human endometrium, WNT and NOTCH signaling pathways play complementary roles in regulating differentiation toward ciliated and secretory epithelial lineages. Organoid studies benchmarked against in vivo data have confirmed that downregulation of WNT increases secretory differentiation, while NOTCH inhibition promotes ciliated cell differentiation [101].

IHH Signaling in Adenomyosis

Spatial transcriptomic analysis of adenomyosis with evident invagination structures revealed that at the invagination site, SFRP5+ epithelial cells promote endometrial proliferation and angiogenesis through secretion of IHH. During the invading process, ESR1+ smooth muscle cells facilitate invasion by creating migratory tracts via collagen degradation [106].

MDK-NCL in Endometrial Carcinoma

Integrated scRNA-seq and spatial analysis in endometrial carcinoma identified an immunosuppressive environment mediated by MDK-NCL signaling between epithelial and endothelial cells. This pathway was associated with suppressed immune activity, illustrating how cancer cells shape the tumor microenvironment [107].

Diagram 2: Cell-cell communication logic revealed by integrated spatial and single-cell analysis.

The Scientist's Toolkit: Essential Research Reagents and Platforms

Table 3: Key Research Reagent Solutions for Endometrial Transcriptomics

Category	Specific Examples	Function/Application	Reference
Spatial Transcriptomics Platforms	10X Visium, 10X Xenium, Vizgen MERSCOPE, Nanostring CosMx	Spatial gene expression profiling in tissue sections	[105]
Single-Cell RNA-seq Platforms	10X Chromium, Drop-seq, Smart-seq2	Single-cell transcriptome profiling	[102] [103]
Cell Segmentation Tools	Cellpose, MERlin	Identify cell boundaries in spatial transcriptomics data	[104]
Computational Integration Packages	Cell2location, Seurat, CellChat, Harmony	Integrate scRNA-seq and spatial data, correct batch effects	[101] [107] [108]
Cell Type Annotation Resources	CellMarker 2.0, PanglaoDB	Reference databases for cell type identification	[107]
Pathway Analysis Tools	scMetabolism, Gene Set Variation Analysis (GSVA)	Quantify pathway activity from transcriptomic data	[107] [108]

The integration of scRNA-seq, spatial transcriptomics, and bulk RNA-seq provides a powerful, multi-modal approach to unraveling the complex dynamics of the endometrial transcriptome across the menstrual cycle and in disease states. Methodological validation studies demonstrate strong concordance between these technologies when appropriately applied and integrated.

For researchers and drug development professionals, this integrated framework offers unprecedented opportunities to identify novel therapeutic targets, understand disease mechanisms, and develop diagnostic biomarkers for endometriosis, endometrial cancer, and other reproductive disorders. As these technologies continue to evolve, they will undoubtedly deepen our understanding of endometrial biology and accelerate the development of targeted interventions for women's health conditions.

The pursuit of reliable predictive models for pregnancy outcomes represents a critical frontier in reproductive medicine. Within the broader context of endometrial transcriptome dynamics across the menstrual cycle, advanced computational techniques are unveiling previously inaccessible biological insights. The endometrium undergoes precisely timed molecular transformations during the menstrual cycle, with the window of implantation (WOI) in the mid-secretory phase serving as the pivotal period for embryo attachment [79]. Recent research has demonstrated that transcriptomic profiling during the late proliferative phase—an essential transition point preceding the secretory phase—may significantly influence subsequent endometrial receptivity [79]. This technical guide examines how Bayesian approaches and machine learning (ML) models are leveraging these molecular signatures, integrated with clinical variables, to advance predictive accuracy for pregnancy outcomes, offering researchers and drug development professionals methodologies to bridge computational science and reproductive biology.

Endometrial Receptivity: The Biological Foundation

Endometrial receptivity constitutes a complex biological state enabled by tightly regulated transcriptomic changes across menstrual cycle phases. Temporal transcriptome analysis spanning five key phases—mid-proliferative, late proliferative (peri-ovulatory), early secretory, mid-secretory, and late secretory—reveals significant phase-specific gene expression patterns [79]. The late proliferative phase emerges as a critical transition point, exhibiting substantial transcriptomic and functional changes that may determine the achievement of mid-secretory endometrial receptivity [79].

Research utilizing uterine fluid extracellular vesicles (UF-EVs) as a non-invasive biomarker source has identified 966 differentially expressed genes between pregnant and non-pregnant women undergoing assisted reproductive technology (ART) with single euploid blastocyst transfer [20]. Notably, pregnant women demonstrated globally higher gene expression, with key biological processes including adaptive immune response (GO:0002250), ion homeostasis (GO:0050801), and inorganic cation transmembrane transport (GO:0098662) significantly enriched [20]. These molecular signatures form the foundational biological data upon which predictive models are constructed.

Table 1: Key Transcriptomic Findings in Endometrial Receptivity

Research Focus	Key Findings	Significance for Prediction
Menstrual Cycle Dynamics	Significant phase-specific gene expression, with late proliferative phase as critical transition [79]	Enables cycle-phase specific modeling
UF-EVs Transcriptomics	966 differentially expressed genes between pregnant and non-pregnant women; global higher expression in pregnant group [20]	Non-invasive biomarker source for prediction
Co-expression Networks	Four functionally relevant WGCNA modules correlated with pregnancy outcome [20]	Reveals biologically meaningful feature groups
Enriched Biological Processes	Adaptive immune response, ion homeostasis, transmembrane transport [20]	Identifies potential therapeutic targets

Bayesian Approaches for Pregnancy Outcome Prediction

Methodological Framework

Bayesian Networks (BNs) offer a probabilistic graphical modeling approach that represents variables as nodes and conditional dependencies as edges, enabling reasoning under uncertainty for complex biological systems. A novel BN development approach combining expert elicitation with literature knowledge and national health statistics has demonstrated significant reductions in project timelines—from years to months—while maintaining predictive accuracy comparable to traditional methods like logistic regression and nomograms [109] [110].

This methodology was validated through development of a pregnancy complications and outcomes BN using national health statistics for all births in England and Wales during 2021. The model architecture incorporated four fragments: (1) maternal demographics, risk factors, and medical history; (2) first-trimester blood tests; (3) specific pregnancy complications; and (4) maternal and neonatal outcomes [109]. Validation using clinical vignettes demonstrated high accuracy in predicting pregnancy complications and outcomes [109].

Advanced Bayesian Integration

Recent research has advanced Bayesian methodology further by integrating transcriptomic data with clinical variables. One study developed a Bayesian logistic regression model combining WGCNA-derived gene expression modules with clinical variables including vesicle size and history of previous miscarriages, achieving a predictive accuracy of 0.83 and F1-score of 0.80 for pregnancy outcome prediction [20]. This systems biology approach utilizing UF-EVs represents a significant advancement over current methods reliant on invasive endometrial transcriptomic profiles.

Bayesian Network Development Workflow for Pregnancy Outcome Prediction

Quantitative Performance of Bayesian Models

Table 2: Bayesian Model Performance for Pregnancy Outcome Prediction

Model Type	Data Sources	Development Time	Validation Method	Key Performance Metrics
BN for Pregnancy Outcomes [109]	National statistics, expert knowledge, literature	Months (vs. years traditionally)	Clinical vignettes vs. logistic regression	Comparable to traditional statistical models
Bayesian Logistic Regression [20]	UF-EVs transcriptomics, clinical variables	Not specified	Holdout validation	Accuracy: 0.83, F1-score: 0.80

Machine Learning Approaches

Algorithmic Diversity and Performance

Machine learning presents a diverse algorithmic toolkit for pregnancy outcome prediction, with studies demonstrating varied performance across model architectures. A systematic review of 26 articles published between 2000-2020 revealed that supervised learning approaches dominate pregnancy outcome prediction research, with objectives including delivery method prediction, preterm birth detection, and maternal complication risk assessment [111].

Recent research comparing six ML algorithms—Multilayer Perceptron (MLP), Logistic Regression (LR), Decision Tree (DT), Random Forest (RF), eXtreme Gradient Boosting (XGBoost), and Support Vector Machine (SVM)—demonstrated superior performance of MLP architectures for high-risk pregnancy prediction [112]. The MLP model achieved an overall accuracy of 82%, with particularly high accuracy in high-risk predictions (91%) [112]. This study utilized a maternal health risk dataset from Bangladesh encompassing 1,014 pregnant women, with input features including age, systolic and diastolic blood pressure, blood glucose, body temperature, and heart rate [112].

Table 3: Machine Learning Algorithm Performance Comparison

Algorithm	Overall Accuracy	High-Risk Precision	Key Strengths	Limitations
Multilayer Perceptron (MLP) [112]	0.82	0.91	Superior performance across metrics, high-risk prediction	Complex architecture, computational intensity
Random Forest (RF) [112]	0.78	0.79	Robust to outliers, feature importance	Slightly lower accuracy than MLP
XGBoost [112]	0.75	0.76	Handling missing data, regularization	Parameter tuning complexity
Decision Tree [112]	0.71	0.72	Interpretability, simple structure	Prone to overfitting
Support Vector Machine [112]	0.68	0.69	Effective in high-dimensional spaces	Computational requirements
Logistic Regression [112]	0.61	0.59	Interpretability, probabilistic output	Limited complex pattern capture

Technical Implementation Framework

Machine Learning Implementation Workflow for Pregnancy Risk Prediction

The technical implementation of ML models for pregnancy outcome prediction requires meticulous data preprocessing and model configuration. The superior-performing MLP model featured three hidden layers with 256, 128, and 64 neurons respectively, utilizing ReLU activation functions and Dropout layers with a 0.5 rate to prevent overfitting [112]. Training employed the Adam optimizer with a learning rate of 0.001 and cross-entropy loss function, with early stopping implemented if validation loss failed to improve for 300 epochs [112]. This configuration enabled rapid prediction capabilities of approximately 500 data items per second on an NVIDIA GPU RTX3050Ti platform [112].

Comparative Analysis: Bayesian vs. Machine Learning Approaches

The selection between Bayesian and machine learning approaches involves trade-offs across interpretability, data requirements, development timeline, and performance characteristics. Bayesian Networks excel in environments requiring explicit representation of causal relationships and reasoning under uncertainty, with the additional advantage of significantly reduced development timelines when leveraging national statistics and expert knowledge [109]. Machine learning approaches, particularly sophisticated neural architectures like MLP, demonstrate superior raw predictive accuracy for specific tasks such as high-risk classification but often function as "black box" models with limited clinical interpretability [112].

A critical consideration for endometrial transcriptome research is the innate compatibility of Bayesian methods for integrating diverse data types—molecular, clinical, and population-level—within a unified probabilistic framework. The Bayesian logistic regression model incorporating transcriptomic modules achieved compelling performance (accuracy: 0.83) while maintaining biological interpretability through gene co-expression networks [20]. This integration of molecular signatures with clinical variables represents a promising direction for predictive model development in reproductive medicine.

Experimental Protocols and Reagent Solutions

Transcriptomic Profiling Protocol

Objective: Isolate and analyze transcriptomic profiles from uterine fluid extracellular vesicles (UF-EVs) for pregnancy outcome prediction.

Methodology:

• Patient Recruitment: 82 women undergoing ART with single euploid blastocyst transfer [20]
• Sample Collection: UF-EVs collected during window of implantation [20]
• RNA Sequencing:
  • Isolation of RNA from UF-EVs
  • Library preparation and RNA sequencing
  • Quality control: Counts per Million (CPM) threshold of ≥1 in at least 37 samples [20]
• Differential Expression Analysis:
  • Identification of 966 differentially expressed genes (nominal p-value < 0.05)
  • Pre-ranked Gene Set Enrichment Analysis (GSEA) for biological processes [20]
• Co-expression Network Analysis:
  • Weighted Gene Co-expression Network Analysis (WGCNA)
  • Identification of four functionally relevant modules [20]
• Model Integration:
  • Bayesian logistic regression combining gene modules with clinical variables
  • Validation through pregnancy outcome follow-up [20]

Research Reagent Solutions

Table 4: Essential Research Reagents for Transcriptomic-Based Prediction

Reagent/Category	Function	Application Example
UF-EV Isolation Kits	Isolation of extracellular vesicles from uterine fluid	Non-invasive biomarker source for transcriptomic analysis [20]
RNA Sequencing Kits	Library preparation and RNA sequencing	Transcriptomic profiling of UF-EVs [20]
WGCNA Software	Weighted gene co-expression network analysis	Identification of functionally relevant gene modules [20]
Bayesian Modeling Software	Probabilistic graphical model implementation	Integration of transcriptomic and clinical data [20]
MLP Framework	Neural network implementation	High-accuracy pregnancy risk prediction [112]

The integration of Bayesian approaches and machine learning with endometrial transcriptome dynamics represents a transformative advancement in pregnancy outcome prediction. Bayesian Networks offer interpretability and efficient development through integration of diverse data sources, while machine learning models, particularly MLP architectures, demonstrate superior predictive accuracy for specific classification tasks. The emerging methodology of transcriptomic profiling of UF-EVs provides a non-invasive biomarker source that effectively captures endometrial receptivity signatures. For researchers and drug development professionals, these computational approaches enable more precise prediction of pregnancy outcomes, potentially revolutionizing personalized interventions in reproductive medicine. Future directions should focus on multi-modal model integration, combining the interpretability of Bayesian approaches with the predictive power of deep learning, while expanding transcriptomic profiling across diverse patient populations.

Conclusion

The integration of high-resolution transcriptomic technologies has revolutionized our understanding of endometrial dynamics, revealing unprecedented detail about the molecular mechanisms governing menstrual cycle progression and implantation competence. Single-cell and spatial transcriptomics have identified precise cellular subpopulations, temporal gene expression patterns, and spatial organizations critical for endometrial function. These advances provide powerful diagnostic tools for conditions like recurrent implantation failure and enable personalized approaches to infertility treatment through transcriptome-based endometrial dating. Future research should focus on developing non-invasive diagnostic methods using uterine fluid biomarkers, creating sophisticated computational models for predicting reproductive outcomes, and translating transcriptomic discoveries into targeted therapies that restore endometrial function. The continued refinement of multi-omics integration and spatial mapping technologies promises to further unravel the complexity of human endometrium, offering new avenues for intervention in endometrial disorders and improving success rates in assisted reproduction.

References

• 1. Estrogen Receptor Function: Impact on the Human ... [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.827724/full]
• 2. Progesterone and Estrogen Signaling in the Endometrium [https://pmc.ncbi.nlm.nih.gov/articles/PMC6695957/]
• 3. Progesterone Receptor Regulation of Uterine Adaptation ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6004243/]
• 4. Endometrial changes in estrogen and progesterone ... [https://www.spandidos-publications.com/10.3892/etm.2020.9308]
• 5. Single-cell RNA sequencing of endometrium uncovers ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12465366/]
• 6. A spatial transcriptomics dataset of the endometrium from ... [https://www.nature.com/articles/s41597-025-05995-6]
• 7. Regulation of RNA splicing in endometrial tissue and its ... [https://www.sciencedirect.com/science/article/pii/S2589004225014683]
• 8. TRIM28 modulates nuclear receptor signaling to regulate ... [https://www.nature.com/articles/s41467-023-40395-7]
• 9. Single-cell technology: the key to an improved ... [https://www.sciencedirect.com/science/article/abs/pii/S0002937824008974]
• 10. Single-cell transcriptomic atlas of the human endometrium ... [https://pubmed.ncbi.nlm.nih.gov/32929266/]
• 11. Single-cell transcriptomic atlas of the human endometrium ... [https://explore.data.humancellatlas.org/projects/379ed69e-be05-48bc-af5e-a7fc589709bf]
• 12. Phenotyping of immune and endometrial epithelial cells in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7993685/]
• 13. Structure-preserving visualization for single-cell RNA-Seq ... [https://www.nature.com/articles/s42003-023-04662-z]
• 14. The role of transcriptomic biomarkers of endometrial ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8082865/]
• 15. Advances in endometrial receptivity and embryo ... [https://www.sciencedirect.com/science/article/pii/S2950248925000355]
• 16. Organoids as powerful models of endometrium epithelium ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12234953/]
• 17. Microengineered patient-derived endometrium-on-a-chip ... [https://www.nature.com/articles/s41467-025-65406-7]
• 18. Endometrial stromal Menin supports ... [https://www.nature.com/articles/s42003-025-08434-9]
• 19. The endometrial transcriptome transition preceding receptivity ... [https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-023-09698-3]
• 20. Endometrial receptivity profiled through transcriptomic ... [https://www.nature.com/articles/s41598-025-19633-z]
• 21. AI-Powered Molecular Innovation: Breakthroughs and ... [https://www.mantellassociates.com/ai-powered-molecular-innovation-breakthroughs-and-2025-growth/]
• 22. Endometrial Stem/Progenitor Cells–Their Role in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9580754/]
• 23. Unlocking the Secrets of the Endometrium: Stem Cells, Niches ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12561017/]
• 24. Uterine bleeding: how understanding endometrial ... [https://www.nature.com/articles/s41574-021-00629-4]
• 25. Endometrial and Menstrual Blood Mesenchymal Stem ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00497/full]
• 26. Endometrial Proliferative Phase-Centered View of ... [https://www.mdpi.com/1422-0067/25/10/5320]
• 27. Article Dynamic chromatin remodeling in cycling human ... [https://www.sciencedirect.com/science/article/pii/S2211124723015371]
• 28. Single-cell and spatial transcriptomic profiling revealed ... [https://www.sciencedirect.com/science/article/pii/S2666979X24003665]
• 29. Unlocking the Secrets of the Endometrium: Stem Cells, ... [https://www.mdpi.com/2227-9059/13/10/2435]
• 30. Different responses of luminal and glandular epithelium ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12506090/]
• 31. Mapping the temporal and spatial dynamics of the human ... [https://www.nature.com/articles/s41588-021-00972-2]
• 32. Luminal and Glandular Epithelial Cells from the Porcine ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9622560/]
• 33. Spatial organization of endometrial gene expression at the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6873571/]
• 34. Stromal Heterogeneity in the Human Proliferative... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8224746/]
• 35. - Single transcriptomic analysis highlights... | Nature Communications cell [https://www.nature.com/articles/s41467-022-33982-7?error=cookies_not_supported&code=ff6ecca9-b75b-4573-b549-42e850bbcf58]
• 36. - Single of cultured human cell ... RNA sequencing endometrial [https://link.springer.com/article/10.1186/s13287-021-02354-1]
• 37. Metabolic reprogramming and heterogeneity during the... [https://biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01763-y]
• 38. A practical guide to spatial transcriptomics: lessons from ... [https://www.sciencedirect.com/science/article/abs/pii/S0167779925003579]
• 39. A practical guide for choosing an optimal spatial ... [https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-025-11235-3]
• 40. Scaling up spatial transcriptomics for large-sized tissues [https://www.nature.com/articles/s41592-025-02770-8]
• 41. Integrating Multi-Omics in Endometrial Cancer [https://www.mdpi.com/2073-4409/14/17/1404]
• 42. Endometriosis-associated infertility: Multi-omics insights into ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12527851/]
• 43. Epigenomic data analysis [https://geneviatechnologies.com/bioinformatics-analyses/epigenomics-data-analysis/]
• 44. Integrated Analysis of Transcriptomic and Proteomic Data - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3637682/]
• 45. SynOmics: integrating multi-omics data through feature ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12613832/]
• 46. Directional integration and pathway enrichment analysis ... [https://www.nature.com/articles/s41467-024-49986-4]
• 47. Single-cell epigenomics and proteomics methods ... [https://www.sciencedirect.com/science/article/pii/S2667325824000153]
• 48. Bioinformatics approaches to multi-omics analysis of the ... [https://www.nature.com/articles/s41598-025-85364-w]
• 49. Time-series single-cell transcriptomic profiling of luteal ... [https://www.nature.com/articles/s41467-024-55419-z]
• 50. Single-cell sequencing uncovers disrupted stromal ... [https://www.nature.com/articles/s42003-025-08634-3]
• 51. InterVelo: a mutually enhancing model for estimating ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12552101/]
• 52. Temporal modelling using single-cell transcriptomics - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10354343/]
• 53. Mammalian chromosome analysis and sorting by flow ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10356183/]
• 54. Chromosome Analysis by Flow Cytometry [https://bitesizebio.com/34734/chromosome-analysis-flow-cytometry/]
• 55. The Menstrual Endometrium: From Physiology to Future ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9580798/]
• 56. Construction organoid model of ovarian endometriosis and ... [https://www.nature.com/articles/s41598-025-90329-0]
• 57. Endometrial Organoids and Their Role in Modeling Human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12154040/]
• 58. Comparison of Organoids from Menstrual Fluid and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8707872/]
• 59. A molecular staging model for accurately dating the ... [https://www.nature.com/articles/s41467-023-41979-z]
• 60. Human receptive endometrial organoid for deciphering the ... [https://elifesciences.org/reviewed-preprints/90729v2]
• 61. A floating endometrial organoid model recapitulates ... [https://www.sciencedirect.com/science/article/pii/S0014482725003490]
• 62. Recurrent implantation failure: A comprehensive summary ... [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1061766/full]
• 63. Molecular subtype of recurrent implantation failure reveals ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12257665/]
• 64. Endometrial transcriptome profiling of patients with recurrent ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10863671/]
• 65. Bioinformatics analysis for identifying hub genes in ... [https://mefj.springeropen.com/articles/10.1186/s43043-025-00247-4]
• 66. Biomolecular Markers of Recurrent Implantation Failure—A ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8472752/]
• 67. Molecular Impact of Metabolic and Endocrine Disturbance on ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12563804/]
• 68. The Endometrial Transcriptome of Metabolic and Inflammatory ... [https://pubmed.ncbi.nlm.nih.gov/35834645/]
• 69. Chronic endometritis incidence in infertile women with and without... [https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-023-02759-5]
• 70. Single-cell profiling of the human endometrium in ... [https://www.nature.com/articles/s41591-025-03592-z]
• 71. Transcriptomic Analysis Reveals Endometrial Dynamics in ... [https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.874487/full]
• 72. Identification of the shared gene signatures and pathways... | PLOS One [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0271380]
• 73. The precise determination of the window of implantation ... [https://www.nature.com/articles/s41598-021-92955-w]
• 74. The molecular tug of war between immunity and fertility [https://pmc.ncbi.nlm.nih.gov/articles/PMC8219210/]
• 75. Perturbations of the endometrial immune microenvironment in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11835911/]
• 76. Comprehensive analysis of immune-related genes associated ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9929778/]
• 77. Uterine NK Cell Polarization Associates with Chronic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12604584/]
• 78. Endometrial immune profiling and precision therapy ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1523871/full]
• 79. Endometrial Proliferative Phase-Centered View of ... [https://pubmed.ncbi.nlm.nih.gov/38791358/]
• 80. Meta-signature of human endometrial receptivity [https://www.nature.com/articles/s41598-017-10098-3]
• 81. Challenges and Future Trends in Biomarker Analysis for ... [https://blog.crownbio.com/challenges-and-future-trends-in-biomarker-analysis-for-clinical-research-whats-ahead-in-2025]
• 82. Insights from Biomarkers & Precision Medicine 2025 [https://www.signifyresearch.net/insights/biomarkers-billions-and-breakthroughs-insights-from-biomarkers-precision-medicine-2025/]
• 83. Can biomarkers identified from the uterine fluid transcriptome ... [https://rbej.biomedcentral.com/articles/10.1186/s12958-023-01070-0]
• 84. Biomarkers and Precision Medicine 2025 [https://www.labcorp.com/education-events/events/biomarkers-2025]
• 85. 15 years of transcriptomic analysis on endometrial : what... receptivity [https://fertilityresearchandpractice.biomedcentral.com/articles/10.1186/s40738-019-0059-7]
• 86. (PDF) A genomic diagnostic tool for human endometrial ... receptivity [https://www.academia.edu/24724828/A_genomic_diagnostic_tool_for_human_endometrial_receptivity_based_on_the_transcriptomic_signature]
• 87. Meta- signature of human endometrial : a meta-analysis... receptivity [https://pubmed.ncbi.nlm.nih.gov/28855728/]
• 88. Meta- signature of human endometrial : a meta-analysis... receptivity [https://researchportal.helsinki.fi/en/publications/meta-signature-of-human-endometrial-receptivity-a-meta-analysis-a]
• 89. : A Revisit to Functional... | PLOS One Endometrial Receptivity [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0058419]
• 90. Human Uterine Biopsy: Research Value and Common Pitfalls [https://pmc.ncbi.nlm.nih.gov/articles/PMC7206876/]
• 91. Global transcriptomic changes occur in uterine fluid- ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8289330/]
• 92. The Extracellular Vesicles Proteome of Endometrial Cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9953153/]
• 93. Extracellular vesicles in endometriosis: role and potential [https://pmc.ncbi.nlm.nih.gov/articles/PMC11082332/]
• 94. A promising future for endometriosis diagnosis and therapy [https://rbej.biomedcentral.com/articles/10.1186/s12958-022-01040-y]
• 95. Uterine Transcriptome: Understanding Physiology and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10136129/]
• 96. A molecular staging model for accurately dating the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10556104/]
• 97. Single-cell transcriptomic analysis highlights origin and ... [https://www.nature.com/articles/s41467-022-33982-7]
• 98. Identifying therapeutic candidates for endometriosis ... [https://www.sciencedirect.com/science/article/pii/S2589004224006096]
• 99. Inflammatory proteomics of uterine fluid is potentially a non ... [https://link.springer.com/article/10.1007/s10815-025-03728-7]
• 100. Exploring distinct properties of endometrial stem cells through... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-023-03616-w]
• 101. Mapping the temporal and spatial dynamics of the... | Nature Genetics [https://www.nature.com/articles/s41588-021-00972-2?error=cookies_not_supported&code=ad31bf24-a3de-4972-915d-196d601bf9b5]
• 102. Integration of Single Cell and Bulk RNA-Sequencing Reveals ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11871914/]
• 103. Single-cell RNA sequencing of endometrium uncovers ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04658-y]
• 104. Concordance of MERFISH spatial transcriptomics with bulk ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9760489/]
• 105. Systematic benchmarking of imaging spatial ... [https://www.nature.com/articles/s41467-025-64990-y]
• 106. From Invaginating Site to Deep Lesion: Spatial ... Transcriptomics [https://pmc.ncbi.nlm.nih.gov/articles/PMC12120721/]
• 107. Frontiers | Integrating single-cell RNA - seq and spatial ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1145300/full]
• 108. Spatial transcriptomics and scRNA-seq: decoding tumor ... [https://humgenomics.biomedcentral.com/articles/10.1186/s40246-025-00805-x]
• 109. A Bayesian Network model of pregnancy outcomes for ... [https://www.sciencedirect.com/science/article/abs/pii/S0010482525003774]
• 110. A Bayesian Network model of pregnancy outcomes for ... [https://pubmed.ncbi.nlm.nih.gov/40090186/]
• 111. Machine learning to predict pregnancy outcomes: a systematic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9097057/]
• 112. Prediction of high-risk pregnancy based on machine ... [https://www.nature.com/articles/s41598-025-00450-3]